<SEC-DOCUMENT>0001104659-25-088481.txt : 20250909
<SEC-HEADER>0001104659-25-088481.hdr.sgml : 20250909
<ACCEPTANCE-DATETIME>20250909090036
ACCESSION NUMBER:		0001104659-25-088481
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250908
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250909
DATE AS OF CHANGE:		20250909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ELUTIA INC.
		CENTRAL INDEX KEY:			0001708527
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				474790334
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39577
		FILM NUMBER:		251301812

	BUSINESS ADDRESS:	
		STREET 1:		12510 PROSPERITY DRIVE
		STREET 2:		SUITE 370
		CITY:			SILVER SPRING
		STATE:			MD
		ZIP:			20904
		BUSINESS PHONE:		240-247-1143

	MAIL ADDRESS:	
		STREET 1:		12510 PROSPERITY DRIVE
		STREET 2:		SUITE 370
		CITY:			SILVER SPRING
		STATE:			MD
		ZIP:			20904

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AZIYO BIOLOGICS, INC.
		DATE OF NAME CHANGE:	20170605
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2525591d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:elut="http://aziyo.com/20250908">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03D_elut_aziyo.com_20250908 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20250908_20250908 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0001708527 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000004" name="dei:EntityCentralIndexKey">0001708527</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="elut-20250908.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001708527</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-08</xbrli:startDate>
        <xbrli:endDate>2025-09-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">FORM&#160;<span id="xdx_909_edei--DocumentType_c20250908__20250908_z9HvaunDVB6f" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt">Pursuant to Section&#160;13 or 15(d) of
the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">Date
of Report (Date of earliest event reported): </span><span style="text-decoration: underline">September 9, 2025 (<span id="xdx_905_edei--DocumentPeriodEndDate_c20250908__20250908_zRKoX06Ob8J"><ix:nonNumeric contextRef="AsOf2025-09-08" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September 8, 2025</ix:nonNumeric></span>)</span><span style="text-decoration: underline"><span style="font-size: 10pt; font-style: normal; font-weight: normal"></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90F_edei--EntityRegistrantName_c20250908__20250908_zYaCjyZ9oTjj" style="font-size: 14pt"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000011" name="dei:EntityRegistrantName">ELUTIA INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt">
    <td style="font-size: 10pt; vertical-align: top; text-align: center; width: 32%"><b style="font-size: 10pt"><span style="text-decoration: underline; font-size: 10pt"><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250908__20250908_zZDjcROpXUj8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></td>
    <td style="font-size: 10pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font-size: 10pt; vertical-align: top; text-align: center; width: 32%"><b style="font-size: 10pt"><span style="text-decoration: underline; font-size: 10pt"><span id="xdx_90D_edei--EntityFileNumber_c20250908__20250908_z0qfxA7fVeV4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000013" name="dei:EntityFileNumber">001-39577</ix:nonNumeric></span></span></b></td>
    <td style="font-size: 10pt; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font-size: 10pt; vertical-align: top; text-align: center; width: 32%"><b style="font-size: 10pt"><span style="text-decoration: underline; font-size: 10pt"><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20250908__20250908_zGWaRsyMxHYd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000014" name="dei:EntityTaxIdentificationNumber">47-4790334</ix:nonNumeric></span></span></b></td></tr>
  <tr style="font-size: 10pt">
    <td style="font-size: 10pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(State
or other jurisdiction of</span></p>
                                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">incorporation)</span></p></td>
    <td style="font-size: 10pt; vertical-align: bottom"><span style="font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-size: 10pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">File
    Number)</span></p></td>
    <td style="font-size: 10pt; vertical-align: bottom"><span style="font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-size: 10pt; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(IRS
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90E_edei--EntityAddressAddressLine1_c20250908__20250908_zzkKXaFMl3j9" style="font-size: 10pt"><b><span style="text-decoration: underline"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000015" name="dei:EntityAddressAddressLine1">20
Firstfield Road</ix:nonNumeric></span></b></span><b><span style="text-decoration: underline"><span style="font-size: 10pt">, <span id="xdx_90D_edei--EntityAddressCityOrTown_c20250908__20250908_zWk4Vk3oqea7"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000016" name="dei:EntityAddressCityOrTown">Gaithersburg</ix:nonNumeric></span></span></span></b><b><span style="text-decoration: underline"><span style="font-size: 10pt">,
<span id="xdx_907_edei--EntityAddressStateOrProvince_c20250908__20250908_zzqvbrXamL8k"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000017" name="dei:EntityAddressStateOrProvince">MD</ix:nonNumeric> </span></span></span></b><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20250908__20250908_zwNub9YTb2bi" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000018" name="dei:EntityAddressPostalZipCode">20878</ix:nonNumeric></span></span></b><span style="text-decoration: underline"><span style="font-size: 10pt">&#160;</span></span></p>

<p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="font-size: 10pt"><span style="text-decoration: underline; font-size: 10pt">(<span id="xdx_907_edei--CityAreaCode_c20250908__20250908_zvhgWf2XqXf" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000019" name="dei:CityAreaCode">240</ix:nonNumeric></span></span></b><b style="font-size: 10pt"><span style="text-decoration: underline; font-size: 10pt">)
<span id="xdx_90C_edei--LocalPhoneNumber_c20250908__20250908_zxAL92R64tB9" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000020" name="dei:LocalPhoneNumber">247-1170</ix:nonNumeric></span></span></b><span style="text-decoration: underline; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">N/A</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; font-family: Wingdings"><span id="xdx_900_edei--WrittenCommunications_c20250908__20250908_zWXgNT8Jmo91" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-size: 10pt; width: 98%"><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425) </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; font-family: Wingdings"><span id="xdx_902_edei--SolicitingMaterial_c20250908__20250908_zeWAA9mMnCB8" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-size: 10pt; width: 98%"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; font-family: Wingdings"><span id="xdx_900_edei--PreCommencementTenderOffer_c20250908__20250908_zZwKkokrFDQl" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-size: 10pt; width: 98%"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; font-family: Wingdings"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20250908__20250908_zfZg6ksLvGN" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="font-size: 10pt; width: 98%"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; vertical-align: bottom; width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline; font-size: 10pt">Title
    of each class</span></span></td>
    <td style="font-size: 10pt; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-size: 10pt; width: 26%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline; font-size: 10pt">Trading
Symbol</span></span><span style="text-decoration: underline; font-size: 10pt">(s)</span></td>
    <td style="font-size: 10pt; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="font-size: 10pt; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline; font-size: 10pt">Name
    of each exchange on which registered</span></span></td></tr>
  <tr style="font-size: 10pt; vertical-align: top">
    <td style="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><b style="font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20250908__20250908_zL8ReGya7eqe" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000025" name="dei:Security12bTitle">Class&#160;A
    Common Stock, $0.001 par value per share</ix:nonNumeric></span></b></td>
    <td style="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b style="font-size: 10pt"><span id="xdx_901_edei--TradingSymbol_c20250908__20250908_zKoIqbKJmMma" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" id="Fact000026" name="dei:TradingSymbol">ELUT</ix:nonNumeric></span></b></span></td>
    <td style="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&#160;</td>
    <td style="font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b style="font-size: 10pt">The <span id="xdx_906_edei--SecurityExchangeName_c20250908__20250908_zzzISb4ipT66" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-size: 10pt">Emerging growth company </span><span style="font-size: 10pt; font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20250908__20250908_zysokox0QX0j" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" format="ixt:booleantrue" id="Fact000028" name="dei:EntityEmergingGrowthCompany">x</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="font-size: 10pt; font-family: Wingdings"><span id="xdx_909_edei--EntityExTransitionPeriod_c20250908__20250908_zTztwHSLSAw8" style="font-size: 10pt"><ix:nonNumeric contextRef="AsOf2025-09-08" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityExTransitionPeriod">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 1.01</b></td><td><b>Entry into a Material Definitive Agreement.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Agreement to Sell Cardiac Implantable Electronic
Device Business</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
September 8, 2025, Elutia Inc. and its direct wholly-owned subsidiary Elutia Med LLC (collectively the &#8220;Company&#8221; or &#8220;Elutia&#8221;)
executed an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Boston Scientific Corporation (&#8220;BSC&#8221;), a
Delaware corporation, and Cardiac Pacemakers Inc. (&#8220;CPI&#8221;), a Minnesota corporation (collectively with BSC, the &#8220;Buyers&#8221;).
Subject to the terms and conditions of the Purchase Agreement, at the closing (the &#8220;Closing&#8221;) of the transactions contemplated
by the Purchase Agreement (the &#8220;Asset Purchase&#8221;), the Buyers will purchase from the Company substantially all of the assets
that are related to the Company&#8217;s business of researching, developing, administering, operating, commercializing, manufacturing,
selling and marketing its cardiac implantable electronic device (&#8220;CIED&#8221;) products, including its CanGaroo&#174;, CanGaroo&#174;
RM, EluPro</span>&#8482; and CIED envelope products, including next generation CIED envelope products (collectively the &#8220;CIED Business&#8221;).
The assets of the CIED Business constitute substantially all of the assets currently held in Elutia&#8217;s Device Protection segment.
The Buyers are only assuming certain liabilities related to performance of the contracts transferred in the Asset Purchase. The Purchase
Agreement provides for an aggregate purchase price, subject to certain adjustments pursuant to the terms of the Purchase Agreement, of
up to $88 million in cash, with $80 million due at Closing and $8 million held in escrow for a period of twelve months as a customary
indemnity holdback.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Purchase Agreement, the
Company has also agreed, for a five-year period following the Closing, to be subject to certain non-competition restrictions in business
lines related to the current CIED Business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Purchase Agreement contains customary representations,
warranties and covenants of the parties. The Company, on the one hand, and the Buyers, on the other hand, have agreed to indemnify each
other from and against losses the respective parties may incur arising out of breaches of the other party&#8217;s representations, warranties
and covenants contained in the Purchase Agreement. The Buyers will indemnify the Company for losses relating to the Acquired Assets and
Assumed Liabilities (both as defined in the Purchase Agreement) on or after the Closing, and the Company will indemnify the Buyers for
losses relating to the Excluded Assets and Excluded Liabilities (both as defined in the Purchase Agreement). The Company will also indemnify
the Buyers for losses related to the operation of the CIED Business prior to Closing, actions initiated by current or former stockholders
of the Company relating to the Asset Purchase, non-compliance with any applicable bulk sales laws, and any third party action against
the Buyers if the facts alleged in the action would give the indemnified party a right to indemnification under the Purchase Agreement,
among other indemnification requirements. Certain of the indemnification obligations of the parties under the Purchase Agreement are subject
to specified survival limitations and other customary exceptions and limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Closing is subject to customary closing conditions,
including, among others, (i) obtaining certain material consents, (ii) the absence of any law or order prohibiting the Asset Purchase,
(iii) the accuracy of representations and warranties set forth in the Purchase Agreement (subject to customary materiality qualifiers)
and material compliance with covenants set forth in the Purchase Agreement, (iv) the execution and delivery of certain related ancillary
documents, (v) the absence of any material adverse effect with respect to the CIED Business, (vi) the transfer of employees of the CIED
Business and (vii) certain other conditions contained therein. Subject to the satisfaction or waiver of the conditions to Closing, the
Company expects the Closing to occur in the fourth quarter of 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> </p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and the Buyers are each permitted
under certain circumstances to terminate the Purchase Agreement, including in the event that (i) the Closing has not occurred within four
months of the Purchase Agreement signing date, (ii) any final and nonappealable order is issued and effective or a law is enacted that
prohibits or makes illegal the Asset Purchase, or (iii) if the other party to the Purchase Agreement has breached any representation,
warranty, covenant or other agreement such that the closing conditions relating to either the accuracy of representations or the satisfaction
of covenants by the other party are not met and cannot be cured as provided in the Purchase Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing description of the Purchase Agreement
and the Asset Purchase does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Purchase
Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Purchase Agreement
is not intended to provide any other factual information about the Company, BSC, CPI, or their respective owners, subsidiaries and affiliates.
The representations, warranties and covenants contained in the Purchase Agreement (i) were made solely for purposes of the Purchase Agreement
and as of the date of the Purchase Agreement, (ii) were solely for the benefit of the parties to the Purchase Agreement, (iii) may be
subject to qualifications and limitations agreed upon by the parties to the Purchase Agreement, including being qualified by confidential
disclosures made for the purposes of allocating contractual risk among the parties to the Purchase Agreement instead of establishing these
matters as facts and (iv) may be subject to standards of materiality applicable to the contracting parties that differ from those applicable
to security holders of the Company. Investors and security holders of the Company should not rely on the representations, warranties and
covenants or any description thereof as characterizations of the actual state of facts or condition of the Company. Moreover, information
concerning the subject matter of the representations, warranties and covenants may change after the date of the Purchase Agreement, which
subsequent information may or may not be fully reflected in public disclosures by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 1in"><b>Item 7.01</b></td><td><b>Regulation FD Disclosure.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 9, 2025, Elutia issued a press release
announcing the Purchase Agreement, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Item 7.01 (including Exhibit
99.1) of this Current Report on Form 8-K is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section,
nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report contains &#8220;forward-looking statements&#8221;
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements can be identified by words such as &#8220;projects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221;
&#8220;estimates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;promise&#8221; or similar references
to future periods. All statements contained in this report that do not relate to matters of historical fact should be considered forward-looking
statements, including any statements and information concerning the Company&#8217;s plans for the closing of the sale of the CIED Business,
which is subject to customary closing conditions. Forward-looking statements are based on management&#8217;s current assumptions and expectations
of future events and trends, which affect or may affect our business, strategy, operations or financial performance, and actual results
may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements
are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and other important factors that may
cause actual results, performance or achievements to differ materially from those contemplated or implied in this press release, including,
but not limited to: risks associated with shifting focus to our drug-eluting biomatrix solutions in the breast reconstruction area and
away from our CIED Business; risks regarding delays in completing the proposed disposition of the CIED Business, or to meet any of the
other closing conditions to the proposed transaction on a timely basis or at all; our ability to successfully execute or achieve expected
benefits from the divestiture of our CIED Business; our ability to continue as a going concern; our ability to achieve or sustain profitability;
risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against
the various lawsuits related to FiberCel and VBM and avoid a material adverse financial consequence; our ability to raise funds in the
future in the amounts and at the times needed; our ability to manage our significant indebtedness and other obligations, such as our Revenue
Interest Obligation to Ligand Pharmaceuticals Incorporated, including our ability to negotiate waivers and similar accommodations as needed;
the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product
indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent
sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers,
which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated
benefits of the previous sale of our Orthobiologics Business; physician awareness of the distinctive characteristics, benefits, safety,
clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating
histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of
our customers, purchasing groups, third-party payors and governmental organizations could adversely affect our sales and profitability;
our ability to obtain regulatory approval or other marketing authorizations by the U.S. Food and Drug Administration and comparable foreign
authorities for our products and product candidates; and our ability to obtain, maintain and adequately protect our intellectual property
rights, which can be found in the &#8220;Risk Factors&#8221; section of Elutia&#8217;s public filings with the Securities and Exchange
Commission (&#8220;SEC&#8221;), including Elutia&#8217;s Annual Report on Form 10-K for the year ended December 31, 2024, as such factors
may be updated from time to time in Elutia&#8217;s other filings with the SEC, including Elutia&#8217;s Quarterly Reports on Form 10-Q,
accessible on the SEC&#8217;s website at www.sec.gov and the Investor Relations page of Elutia&#8217;s website at https://investors.elutia.com.
Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements
as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently
available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations
to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 1in"><b>Item 9.01</b></td><td style="text-align: justify"><b>Financial Statements and Exhibits.</b></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in; text-align: left">(d)</td><td style="text-align: justify">Exhibits</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 10%"><b>Exhibit No.</b></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center; width: 88%"><b>Description</b></td></tr>
  <tr style="vertical-align: top">
    <td style="layout-grid-mode: line; text-align: justify"><a href="tm2525591d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*</span><span style="font-size: 10pt">&#8224; </span></a></td>
    <td>&#160;</td>
    <td style="layout-grid-mode: line; text-align: justify"><a href="tm2525591d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Asset Purchase Agreement, dated September 8, 2025, by and among Boston Scientific Corporation and Cardiac Pacemakers Inc. and Elutia Inc. and Elutia Med LLC</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="layout-grid-mode: line; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="layout-grid-mode: line; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="layout-grid-mode: line; text-align: justify"><a href="tm2525591d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td style="layout-grid-mode: line; text-align: justify"><a href="tm2525591d1_ex99-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release of Elutia Inc., dated September 9, 2025</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="layout-grid-mode: line; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="layout-grid-mode: line; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="layout-grid-mode: line; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td style="layout-grid-mode: line; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL document)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">*Certain confidential information contained in
this Exhibit, marked in brackets, has been omitted, because it is both not material and of the type of information that the registrant
treats as private or confidential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#8224; Schedules have been omitted pursuant to Item 601(a)(5) of Regulation
S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font-size: 10pt; border-collapse: collapse; width: 100%">
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">ELUTIA INC.</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: italic 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">(Registrant)</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt; width: 50%"><span style="font-size: 10pt">Date: September 9, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Matthew Ferguson</td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Matthew Ferguson</span></td></tr>
  <tr style="font-size: 10pt; vertical-align: bottom">
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>


<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0pt 0">&#160;&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwjAQRU/QOwxZi8ZoF3Zp0SJWkSLiNtpRgm2mTKLWI3lLY4s4DAzD/+9/IQYio6WpkOE4L3LYY91U2iMUeEFGe8bgSFfrBMIt8GqcZ2199/7AlAKDgYmHSp2C0FkfxmGZgIxHcjZSU5CTJFaw24joq6dkL6ZE642uQNsSdkwNG/SaX33CXrdkqX51VQdkZ8gmMB7KXn6DkmMFW3roJ/HNQZ6nIhp0E4mM6d4E16L1aL8kLCqsQ53r6f9GHwleSpE= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2525591d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT><B>Execution
Version</B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED
FROM THIS EXHIBIT&nbsp;BECAUSE IT IS BOTH (i)&nbsp;NOT MATERIAL AND (ii)&nbsp;THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH INFORMATION
AS CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH &ldquo;[***]&rdquo;<FONT STYLE="text-transform: uppercase">.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSET PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BY AND AMONG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BOSTON SCIENTIFIC CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CARDIAC PACEMAKERS INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS BUYERS,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ELUTIA INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ELUTIA MED LLC,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS SELLERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>_________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DATED AS OF SEPTEMBER 8, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>_________________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIS DOCUMENT AND ANY TRANSACTION DOCUMENTS THAT MAY&nbsp;BE DELIVERED IN CONNECTION HEREWITH ARE SUBJECT TO THE CONFIDENTIALITY AGREEMENT (AS DEFINED HEREIN).</B></FONT><B> <FONT STYLE="font-size: 10pt">THIS AGREEMENT IS FOR DISCUSSION PURPOSES ONLY,&nbsp;IS SUBJECT IN ALL RESPECT TO DUE DILIGENCE AND IS NOT BINDING ON THE PARTIES.&nbsp;NO TRANSACTION OR AGREEMENT TO ENTER INTO A TRANSACTION WILL EXIST OR BE DEEMED TO EXIST UNTIL A DEFINITIVE AGREEMENT IS EXECUTED BY ALL PARTIES INVOLVED.</FONT></B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE OF CONTENTS</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;I PURCHASE AND SALE OF ASSETS</FONT></TD>
    <TD STYLE="text-align: right">1</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.1</FONT></TD>
    <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired Assets</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;1.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excluded Assets</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;II ASSUMPTION AND EXCLUSION OF LIABILITIES</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">5</FONT></TD>
    <TD STYLE="text-align: right">5</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excluded Liabilities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;2.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed Liabilities</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;III PURCHASE PRICE</FONT></TD>
    <TD STYLE="text-align: right">7</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delivery of Closing Payment and Escrow Amount</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory Adjustment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.3</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation of Purchase Price</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;3.4</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;IV CLOSING</FONT></TD>
    <TD STYLE="text-align: right">11</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Closing Date</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;4.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deliveries at Closing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;V WARRANTIES OF THE SELLERS</FONT></TD>
    <TD STYLE="text-align: right">14</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization, Good Standing and Qualification; No Ownership Interests</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorization; Binding Obligations; Governmental Consents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.3</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agreements; Actions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.4</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title to Assets; Conveyance; Sufficiency</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.5</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.6</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Benefit Plans.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.7</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance with Other Instruments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.8</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.9</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.10</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance With Laws; Permits</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.11</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.12</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical and Regulatory Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.13</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers; Expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.14</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.15</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing and Marketing Rights</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.16</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government Grants and Incentives</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.17</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personal Property</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.18</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Privacy and Data Security</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.19</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Business Practices</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.20</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products Liability</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.21</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Absence of Changes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.22</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related-Party Transactions</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.23</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.24</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.25</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.26</FONT></TD>
    <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customers and Suppliers</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.27</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanctions; Anti-Corruption</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.28</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.29</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solvency</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.30</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;5.31</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Other Warranties</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VI WARRANTIES OF THE BUYERS</FONT></TD>
    <TD STYLE="text-align: right">37</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Organization and Qualification</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authority Relative to this Agreement</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.3</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Conflict; Required Filings and Consents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;6.4</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brokers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VII CONDUCT OF BUSINESS PENDING THE CLOSING AND RELATED COVENANTS</FONT></TD>
    <TD STYLE="text-align: right">38</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conduct of Business Generally</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Trials</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.3</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA Approval Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.4</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice of Developments</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.5</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercially Reasonable Efforts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.6</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shared Contracts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.7</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Removal of Excluded Inventory</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.8</FONT></TD>
    <TD STYLE="text-align: justify">Ongoing Clinical Trial Agreements</TD>
    <TD STYLE="text-align: right">41</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;7.9</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive Dealing</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;VIII ADDITIONAL AGREEMENTS</FONT></TD>
    <TD STYLE="text-align: right">43</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consents</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Access to Information.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.3</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public Announcements; Form&nbsp;8-K Filings; Confidentiality.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.4</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Matters.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.5</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further Assurances.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.6</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insurance Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;8.7</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;IX Tax Matters</FONT></TD>
    <TD STYLE="text-align: right">49</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cooperation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Property Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;9.3</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer Taxes</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;X CLOSING CONDITIONS</FONT></TD>
    <TD STYLE="text-align: right">50</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions to the Obligations of Each Party</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions to the Obligations of the Buyers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;10.3</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conditions to the Obligations of the Sellers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;XI TERMINATION</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: right">51</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.1</FONT></TD>
    <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination</FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;11.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect of Termination</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;XII INDEMNIFICATION, LIMITATIONS OF LIABILITY AND CONDUCT OF CLAIMS</FONT></TD>
    <TD STYLE="text-align: right">53</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;12.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification by the Sellers</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;12.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indemnification by the Buyers.</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;12.3</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Claim Procedures</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;12.4</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment of Claims</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;12.5</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Limitations of Liability and Calculation</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;12.6</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax Treatment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;XIII GENERAL PROVISIONS</FONT></TD>
    <TD STYLE="text-align: right">57</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notices</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severability</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.3</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entire Agreement; Assignment</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.4</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties in Interest</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.5</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specific Performance</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.6</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governing Law</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.7</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WAIVER OF JURY TRIAL</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.8</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Headings</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.9</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Counterparts</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.10</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fees and Expenses</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.11</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment</FONT></TD>
    <TD STYLE="text-align: right">60</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.12</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waiver</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.13</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Construction</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.14</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actions; Privileged Matters</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&nbsp;13.15</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Tax Advice</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.375in; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Article&nbsp;XIV CERTAIN DEFINITIONS</FONT></TD>
    <TD STYLE="text-align: right">62</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBITS</U></B></FONT></TD>
    <TD STYLE="text-align: justify; width: 78%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 10%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;A</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Escrow Agreement</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;B</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Purchase Price Allocation Methodology</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;C</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Bill of Sale</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;D-1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Assignment of Trademarks</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;D-2</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Assignment of Patents and Patent Applications</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;E</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Seller Non-Competition Agreement</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit&nbsp;F</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;of Transition Services Agreement</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SCHEDULES</U></B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1(a)(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller Intellectual Property</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1(b)(iii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquired Equipment and Tools</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1(b)(iv)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permits</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1(b)(vi)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed Contracts</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1(b)(viii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed Lease Contracts</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1(b)(xvii)(A)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing Clinical Trial Agreements</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1(b)(xvii)(B)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ongoing Vendor Agreements</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2(h)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excluded Inventory</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2(j)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excluded Contracts</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2(m)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Excluded Patents</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2(o)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional Excluded Assets</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller Account</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2(a)(v)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-Closing Permits</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2(a)(vi)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Encumbrances</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2(a)(vii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Required Consents</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2(a)(viii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terminated Contracts</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2(a)(ix)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract Amendments</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Permitted Interim Business Operations</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shared Contracts</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Governmental Consents</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Closing Conditions</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2(f)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Buyer Contracts</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Known Claims</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operations Employees</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales Employees</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14(c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seller Marks</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Seller Disclosure Schedule</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ASSET PURCHASE AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
ASSET PURCHASE AGREEMENT (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of the 8<SUP>th</SUP> day of September, 2025 (the &ldquo;<U>Signing
Date</U>&rdquo;), by and among Boston Scientific Corporation, a Delaware corporation (&ldquo;<U>BSC</U>&rdquo;), and Cardiac Pacemakers
Inc., a Minnesota corporation (&ldquo;<U>CPI</U>&rdquo; and together with BSC, the &ldquo;<U>Buyers</U>&rdquo; and each, a &ldquo;<U>Buyer</U>&rdquo;),
on the one hand, and Elutia Inc., a Delaware corporation (&ldquo;<U>Elutia</U>&rdquo;), </FONT>and its direct wholly-owned subsidiary
Elutia Med LLC, a Delaware limited liability company (&ldquo;<U>Elutia Med</U>&rdquo; and together with Elutia, the &ldquo;<U>Sellers</U>&rdquo;
and each, a &ldquo;<U>Seller</U>&rdquo;). Certain capitalized terms used and not otherwise defined herein are defined in <U>Article&nbsp;XIV</U>
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>WHEREAS</B></FONT>,
the Sellers are, among other endeavors, engaged in the business of designing, researching, developing, testing, seeking regulatory approval
for, manufacturing, processing, packaging, labeling, marketing, using, promoting, storing, distributing, importing, exporting or selling
Products (as hereinafter defined) as well as line extensions, improvements and ongoing pipeline and development efforts relating to such
Products (the &ldquo;<U>CIED Business</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>WHEREAS</B></FONT>,
the Buyers or their designated Affiliates wish to purchase, and the Sellers wish to sell, all of the Acquired Assets, and the Buyers or
their designated Affiliates wish to assume the certain specified Assumed Liabilities, in each case, upon the terms and subject to the
conditions set forth in this Agreement (the &ldquo;<U>Acquisition</U>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>WHEREAS</B></FONT>,
in connection with the Acquisition, the Buyers, on the one hand, and the Sellers, on the other hand, each desire to make certain warranties,
covenants and other agreements as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE</B></FONT>, in consideration of the mutual promises and agreements set forth herein, the Buyers and the Sellers agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;I</B></FONT><B><BR>
PURCHASE AND SALE OF ASSETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;1.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Acquired
Assets</U>. At the Closing, subject to the terms and conditions set forth in this Agreement, the Sellers shall sell, assign, transfer,
convey and deliver, or shall cause to be sold, assigned, transferred, conveyed and delivered, to the applicable Buyers or their designated
Affiliates, free and clear of all Encumbrances (other than Permitted Encumbrances), and the Buyers or their designated Affiliates shall
purchase, acquire and take assignment and delivery of, good, marketable and valid title in, to and under all of the Sellers&rsquo; or
their respective Affiliates&rsquo; properties, rights, titles interests and other tangible and intangible assets of every type, condition
and description the extent owned, licensed, used or held for use by the Sellers in connection with, relating to or necessary for the ownership
or operation of the CIED Business or the Products, or otherwise used in or useful to the design, research, development, testing, seeking
regulatory approval for, manufacturing, processing, packaging, labeling marketing, using, promoting, storing, distributing, importing,
exporting or sale of the Products, in each case as the same exists as of the Signing Date and including any replacements of such assets
prior to Closing, and any such assets acquired by the Sellers or any of their respective Affiliates after the date hereof but prior to
the Closing, wherever located and whether or not all or any portion of said assets appear on or are reflected upon the Sellers&rsquo;
books, records or financial statements; <U>provided</U>, <U>however</U>, that the Acquired Assets shall not include any Excluded Assets
(all of such assets are hereinafter referred to collectively as the &ldquo;<U>Acquired Assets</U>&rdquo;). Without limiting the generality
of the foregoing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Acquired Assets shall include, other than the Seller Marks and Excluded Patents, all right, title and interest throughout the world in,
to and under all Intellectual Property owned or licensed by any Seller or any of their respective Affiliates in connection with or related
to the Products or the Acquired Assets or otherwise used in or useful to the design, development, manufacture, use, testing, marketing,
promotion, commercialization, sale, distribution or improvement of the Products or the Acquired Assets, all licenses and sublicenses
granted or obtained with respect thereto, and rights thereunder, and other agreements with respect to the foregoing, all remedies against
infringements thereof, rights to protection of interests therein, all income, royalties and payments receivable in respect thereof, and
all claims, causes of action, choses in action, rights of recovery and rights of set-off of any kind with respect thereto (including
all damages and payments for past, present or future infringement or misappropriation or dilution of Intellectual Property and the right
to sue and recover for past infringements or misappropriations or dilutions of Intellectual Property), including the Intellectual Property
described on <U>Schedule 1.1(a)</U>&nbsp;hereto, and any and all corresponding rights that have been or now or hereafter may be secured
throughout the world with respect to the foregoing (collectively, the &ldquo;<U>Seller Intellectual Property</U>&rdquo;), which will
be transferred, conveyed and delivered to CPI or its designated Affiliate (the &ldquo;<U>CPI Acquired Assets</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Acquired Assets shall also include the following, each of which will be transferred, conveyed and delivered to BSC or its designated Affiliate
(collectively, the &ldquo;<U>BSC Acquired Assets</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Products, and all information, documentation, reports, data, and other materials used by the Sellers or their respective Affiliates in
designing, researching, developing, testing, seeking regulatory approval for, manufacturing, processing, packaging, labeling marketing,
using, promoting, storing, distributing, importing, exporting or selling the Products, including, as applicable, all Design History Files,
Device Master Records, Technical Information, CAPA Documentation, design and manufacturing data and files, manufacturing processes and
procedures, prototypes, parts and assemblies, bills of material, drawings, specifications, schematics, inspection and audit documents,
procedures and test methods, production records, technical information, work instructions, processes, design and development verification
and validation protocols and other documentation or reports relating thereto, file histories, technical data, test data, nonclinical and
preclinical data, clinical data, pricing and cost information, and supplier lists and information, regulatory filings, correspondence,
approvals and records, and other documentation to the extent related to any of the Products;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
inventories relating to or held in connection with the Products, or otherwise used in or useful to the sale, use, manufacture, maintenance,
development or improvement of the Products, including raw materials, parts, work in process and finished goods (collectively, the &ldquo;<U>Acquired
Inventory</U>&rdquo;), including all Inventory set forth on the Estimated Inventory Statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all equipment, prototypes and tooling used for the CIED Business or the Acquired Assets, including for the product development, manufacturing
or commercialization of the Products as well as any and all equipment, prototypes and tooling located at the Sellers&rsquo; facilities
located in Roswell, Georgia, including the items described on <U>Schedule&nbsp;1.1(b)(iii)</U>&nbsp;hereto (the &ldquo;<U>Acquired Equipment
and Tools</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
Permits in connection with or related to the CIED Business or the Products, or otherwise used in or useful to the designing, researching,
developing, testing, seeking regulatory approval for, manufacturing, processing, packaging, labeling marketing, using, promoting, storing,
distributing, importing, exporting or selling of the Products, both governmental and private, and all rights under regulatory filings
with the FDA, all Notified Bodies, and all other regulatory bodies relating to the Products, including those described on <U>Schedule&nbsp;1.1(b)(iv)</U>&nbsp;hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
copy of the Books, Records and Files, and data stored on information systems, including Books, Records and Files relating to test data,
quality and manufacturing data and files, clinical and non-clinical data, adverse events and complaints, sales and marketing information,
training materials, medical affairs and information, materials related to billing, coding, coverage, and reimbursement matters, and information
on sales and distribution arrangements, including all policies, procedures, work instructions, manuals and training materials regarding
these topics, and all other documents and records relating to the CIED Business or the Acquired Assets, but excluding any accounting books,
records and ledgers and Books, Records and Files related to Taxes, in each case to the extent not primarily related to the CIED Business
or the Acquired Assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
Contracts (whether oral or written) that as of the Signing Date or as of the Closing relate to, or are used or held for use in connection
with, any of the Products or are necessary to run the CIED Business and (i)&nbsp;to which any Seller is a party; (ii)&nbsp;by which any
Seller or any of the Acquired Assets is or may become bound or subject; (iii)&nbsp;under which any Acquired Asset is leased or licensed,
including any real property lease or license agreements under which no Seller is the tenant; or (iv)&nbsp;under which any Seller has or
may acquire any right or interest in respect of the CIED Business, including, for the avoidance of doubt, the contracts described on <U>Schedule&nbsp;1.1(b)(vi)</U>&nbsp;hereto
but excluding any specifically scheduled Excluded Contracts (the &ldquo;<U>Assumed Contracts</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;all
of the rights of the applicable Seller or any of its Subsidiaries or Affiliates under each Shared Contract to the extent allocated to
a Buyer in accordance with <U>Section&nbsp;7.6</U><FONT STYLE="font-family: Times New Roman, Times, Serif">;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;all
rights under and to the real estate leases or occupancy agreements related to the Sellers&rsquo; facilities located in Roswell, Georgia,
including all contracts set forth on <U>Schedule 1.1(b)(viii)</U>&nbsp;(the &ldquo;<U>Assumed Lease Contracts</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
goodwill and other intangible assets related to or associated with the CIED Business or the Acquired Assets, excluding the goodwill associated
with the Seller Intellectual Property (which, for the avoidance of doubt, will be transferred, conveyed and delivered to CPI);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
amount of and all rights to any proceeds received by any Seller, including all insurance recoveries and recoveries from other third parties,
in respect of, in connection with, or arising from (i)&nbsp;the loss, destruction or condemnation of any Acquired Assets or otherwise
involving or relating to any Acquired Asset or the CIED Business, in each case, whether occurring prior to, on or after the Closing or
(ii)&nbsp;any Assumed Liabilities or the operation of such Acquired Assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;except
to the extent disclosure of such records would be prohibited by applicable privacy or data protection laws without the applicable individual&rsquo;s
consent, all personnel records and files of the Sellers with respect to the Transferred Employees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
confidentiality agreements and other restrictive covenant agreements (including noncompetition and nonsolicitation agreements) with the
Transferred Employees and Business Contingent Workers, in each case, which run in favor of the Sellers, and all rights and claims related
to any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;all
Forms I-9, E-Verify documentation (if applicable) and supporting work authorization documentation with respect to the Transferred Employees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;all
Contracts between any Seller and the Business Contingent Workers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Tax Return, Tax work paper, Tax information or Tax record relating solely to the CIED Business or the Acquired Assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;all
causes of action, claims, counterclaims, remedies, defenses, warranties, guarantees, refunds, covenants, indemnities, rights of recovery
and set-off of every kind and character related to the Acquired Assets or the Assumed Liabilities, in each case regardless of whether
such causes of action or rights are currently exercisable; <U>provided</U>, <U>however</U>, if any Losses associated with the foregoing
were actually incurred by a Seller pre-Closing, then such Losses shall constitute Excluded Assets and, if recovered by a Buyer after the
Closing, shall be paid over to the Sellers within thirty (30) Business Days of receipt by such Buyer (net of the cost of recovery by any
Buyer and their Affiliates) (the &ldquo;<U>Pre-Closing Claims</U>&rdquo;); <U>provided</U>, <U>further</U>, that in the event a Buyer
elects not to pursue or continue pursuing any such right or cause of action, the applicable Seller shall have the right, upon delivery
of written notice at least ten (10)&nbsp;Business Days in advance to, and with the consent of, BSC (such consent not to be unreasonably
withheld, conditioned or delayed), to pursue such right or cause of action (and in such event, the applicable Seller shall keep the Buyers
reasonably apprised of the status of such right or cause of action and allow the Buyers and their Representatives to participate in such
matter at their sole cost and expense); and <U>provided</U>, <U>further</U>, that, at a Buyer&rsquo;s request, the Sellers shall use their
respective reasonable efforts to enforce, for the benefit of such Buyer in relation to its ownership interests, at such Buyer&rsquo;s
cost and expense, any right, claim or cause of action that would otherwise be transferred hereunder but is not assignable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xvii)</FONT>&#8239;&#8239;&#8239;&#8239;all
clinical trial or study agreements set forth on <U>Schedule 1.1(b)(xvii)(A)</U>&nbsp;(the &ldquo;<U>Ongoing Clinical Trial Agreements</U>&rdquo;)
relating to ongoing clinical trials or studies relating to the CIED Business and the vendor contracts set forth on <U>Schedule 1.1(b)(xvii)(B)</U>&nbsp;relating
to the CIED Business (the &ldquo;<U>Ongoing Vendor Agreements</U>&rdquo;); provided that the assignment and transfer of such Ongoing Clinical
Trial Agreements and Ongoing Vendor Agreements shall be subject in each case to <U>Section&nbsp;7.8</U>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xviii)</FONT>&#8239;&#8239;&#8239;all
other Acquired Assets not constituting CPI Acquired Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;1.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Excluded
Assets</U>. Notwithstanding anything herein to the contrary, the Buyers and the Sellers acknowledge and agree that under the terms of
this Agreement the Buyers shall only acquire the Acquired Assets, and that the Buyers shall not acquire under the terms hereof, and shall
not be deemed to acquire under the terms hereof, any other assets of the Sellers, including any assets used or held for use exclusively
in the Retained Business (all such other assets of the Sellers not included in the definition of &ldquo;Acquired Assets&rdquo; are referred
to herein as the &ldquo;<U>Excluded Assets</U>&rdquo;). Without limiting the generality of the foregoing, the Excluded Assets shall include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
amounts (including the Purchase Price) paid or payable to any Seller pursuant to this Agreement or any other Transaction Document and
any other rights which accrue or will accrue to any Seller under the Transaction Documents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
Real Property Contracts (other than the Assumed Lease Contracts);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
distribution agreements to which any Seller is a party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
of the rights of any Seller under the Shared Contracts to the extent allocated to the Sellers in accordance with <U>Section&nbsp;7.6</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
services and personal records and files of the employees, independent contractors and other personnel of the Sellers or any of their Affiliates
who are not Transferred Employees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
assets of any Employee Benefit Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
accounts receivable of any Seller existing as of the Closing and arising out of the operation or conduct of the CIED Business prior to
the Closing for goods delivered or services provided prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
Inventory located at the Sellers&rsquo; facility in Roswell, Georgia used or held for use exclusively in the Retained Business (the &ldquo;<U>Excluded
Inventory</U>&rdquo;) as set forth on <U>Schedule 1.2(h)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
equipment, prototypes, and tooling, other than Acquired Equipment and Tools;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
Contracts listed on <U>Schedule 1.2(j)</U>&nbsp;(the &ldquo;<U>Excluded Contracts</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
taxpayer identification numbers, Tax Returns, Tax work papers, Tax information and Tax records of any Seller (except to the extent that
any such Tax documentation (excluding any taxpayer identification number) relates solely to the CIED Business or the Acquired Assets);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
rights to any Tax credit, Tax refund or similar Tax asset relating to any Tax of any Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
Intellectual Property of Sellers or their Affiliates (including the Seller Marks and the patents and patent applications set forth on
<U>Schedule&nbsp;1.2(m)</U>&nbsp;(the &ldquo;<U>Excluded Patents</U>&rdquo;)), other than the Seller Intellectual Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
assets of the Sellers or their Affiliates that relate solely to the Retained Business; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
assets, properties and rights described on <U>Schedule 1.2(o)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;II</B></FONT><B><BR>
ASSUMPTION AND EXCLUSION OF LIABILITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;2.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Excluded
Liabilities</U>. Except with respect to the Assumed Liabilities, the Sellers shall retain and remain solely responsible for, and the Buyers
shall not, and do not, assume or in any way become responsible for, any Liability of any Seller or any of their Affiliates whether existing
on the Closing Date or arising thereafter, and all such Liabilities shall be and remain the responsibility of the Sellers (collectively,
the &ldquo;<U>Excluded Liabilities</U>&rdquo;). Without limiting the generality of the foregoing, the Buyers are not assuming and the
Sellers shall not be deemed to have transferred to any Buyer the following Liabilities (each of which is an Excluded Liability):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Liability of any Seller arising out of or relating to the execution, delivery or performance of any of the Transaction Documents (including
the delivery of any of the closing deliverables described in <U>Section&nbsp;10.2(e)</U>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Liability of any Seller or their Affiliates arising from or relating to any action taken by any Seller or their Affiliates, or any failure
on the part of any Seller or their Affiliates to take any action, at any time after the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;except
as expressly provided in <U>Section&nbsp;8.4(c)</U>&nbsp;of this Agreement, the Transition Services Agreement or Employee Lease Agreement
(if applicable), any and all Liabilities directly or indirectly arising out of or related to any of the current or former employees (including
all Applicants, Offered Employees, Transferred Employees and Non-Transferred Employees), directors, consultants, independent contractors
or other service providers (including all Business Contingent Workers) of any Seller or any of their Affiliates (the &ldquo;<U>Service
Providers</U>&rdquo;), or any spouse, dependent or beneficiary thereof, including, for the avoidance of doubt, any such Liabilities that
may arise at any time, from and against all or any direct or indirect actions, proceedings, claims, demands, costs, losses, expenses,
damages, liabilities and penalties whatsoever (whether arising before, on or after the Closing Date) as a result of or in connection with
the consummation of the transactions contemplated hereby, the employment or engagement or the termination of employment or engagement
of any Service Provider by any Seller, including any Liabilities with respect to the Employee Benefits Plans, COBRA Liabilities, severance
payments, salaries or wages, fees, bonuses, allowances, compensation, premiums, costs, expenses, benefits or incentives of any kind, vacation
and paid time off obligations, social security contributions, fines, surcharges, delay interests and related employment taxes claims,
Liability under the United States Workers Adjustment and retraining Notification Act or any similar state of local Law (together, the
 &ldquo;<U>WARN Act</U>&rdquo;) and any other statutory, contractual or other common law Liability (the &ldquo;<U>Excluded Employee Liabilities</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all Liabilities arising from any Applicant or other Service Provider of the Sellers who is offered the opportunity to apply for employment
or engagement by any Buyer or any of their Affiliates, including by completing the Application Requirements, but does not complete the
Application Requirements or is not offered an opportunity for employment or engagement by such Buyer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
and all Liabilities arising from any Offered Employee, Business Contingent Worker, or other Service Provider of the Sellers who is offered
employment or engagement by any Buyer or any of their Affiliates but does not accept such employment or engagement on the terms, and within
the time period, required by such Buyer, including any Liabilities associated with the termination of any Contract with a Business Contingent
Worker who does not sign an Assignment Consent prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Taxes of a Seller or any of its Affiliates, including any Liability of such Seller or any of its Affiliates for the Taxes of any other
Person under applicable Law, as a transferee or successor, by contract or otherwise, including any Transfer Tax for which Sellers are
responsible pursuant to <U>Section&nbsp;9.3</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Liability for any Tax imposed with respect to the ownership or operation of the Acquired Assets, the Products or the CIED Business attributable
to a Tax period (or portion of a Tax period) ending on or before the Closing Date, including any Property Taxes to the extent specifically
allocated to Sellers pursuant to <U>Section&nbsp;9.2</U>, but excluding any Property Taxes to the extent specifically allocated to Buyers
pursuant to <U>Section&nbsp;9.2</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Liability (whether absolute, accrued, contingent or otherwise) imposed on, arising out of or that relates to the Products or any other
products of the CIED Business sold prior to the Closing Date (including returns and rejection and billing errors); <U>provided</U>, <U>however</U>,
that nothing in this Agreement shall absolve BSC from any Liability it would otherwise have under that certain Sales Agent Agreement dated
March&nbsp;6, 2025 by and between BSC and Elutia or any predecessor agreement governing the sales agency relationship between BSC and
Elutia (such agreements, the &ldquo;<U>Sales Agency Contracts</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Liability for recalls (either voluntary or involuntary), removals, field notifications, field corrections, field alerts, market withdrawals
or replacements, warnings, &ldquo;dear doctor&rdquo; letters, investigator notices, safety alerts or other notices of action relating
to an alleged lack of quality, safety, efficacy, or regulatory compliance of any Product or Acquired Assets, or seizures ordered or adverse
regulatory actions taken (or threatened) by a Governmental Authority with respect to any of the Products or any facilities involved in
the research, design, development, manufacture, processing, packaging, labeling, testing, storage, distribution, import, export or sale
of the Products or any other products of the CIED Business sold or manufactured prior to the Closing, including based on any actions occurring
or arising prior to the Closing Date; <U>provided</U>, <U>however</U>, that nothing in this Agreement shall absolve BSC from any Liability
it would otherwise have under the Sales Agency Contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Liability for Product Liability Claims or warranty claims for the Products or any other products of the CIED Business sold prior to the
Closing, including based on any actions occurring or arising prior to the Closing Date (&ldquo;<U>Excluded Product Liabilities</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Liability under any Assumed Contract for any breach or violation by the applicable Seller of any provision of any such Assumed Contract
at or prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Liability of any Seller or any of its Affiliates arising from or relating to any claim or Action initiated against any Seller or any of
its Affiliates on or prior to the Closing Date with respect to the CIED Business or with respect to any acts or occurrences occurring
on or prior to the Closing Date with respect to the CIED Business or the Acquired Assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
accounts payable of any Seller or its Affiliates existing as of the Closing or arising out of the operation or conduct of the CIED Business
prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
royalty payment obligations and comparable arrangements of any Seller, including royalty payment obligations in connection with any Excluded
Contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(o)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Liabilities relating to or arising out of the Excluded Assets; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(p)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
other Liability of the Sellers or their Affiliates that is not an Assumed Liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;2.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Assumed
Liabilities</U>. The term &ldquo;<U>Assumed Liabilities</U>&rdquo; means only the obligations of the Sellers under the Assumed Contracts,
in each case, only to the extent (a)&nbsp;such obligations (i)&nbsp;first accrue for performance on or after the Closing Date, (ii)&nbsp;do
not arise from or relate to any breach or violation by any Seller or any of its Affiliates of any term or provision of any of such contracts,
(iii)&nbsp;do not arise from or relate to any action, omission, event, circumstance or condition occurring or existing prior to the Closing
Date that, with or without notice or lapse of time, would constitute or result in a breach or violation of any term or provision of such
contracts, and (iv)&nbsp;are not Excluded Product Liabilities, and (b)&nbsp;for which the full text of such Contract, including all exhibits,
schedules and appendices thereto, has been disclosed to the Buyers prior to the Closing Date; <U>provided</U>, that, for the avoidance
of doubt, such assumption of the Assumed Liabilities shall not be deemed to affect the warranties made by the Sellers hereunder (or the
rights of the Buyer Indemnified Parties in respect of inaccuracies therein or breaches thereof), to the extent such warranties relate
to such Assumed Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;III</B></FONT><B><BR>
PURCHASE PRICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;3.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Delivery
of Closing Payment and Escrow Amount</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">(a)</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payments
at Closing</U>. Upon and subject to the terms and conditions of this Agreement, at the Closing, as the aggregate purchase price for the
sale, transfer, assignment, conveyance and delivery of the Acquired Assets, the Buyers (or their designated Affiliates) shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;pay
to the Sellers by wire transfer of immediately available funds an aggregate amount equal to (A)&nbsp;$88,000,000 (the &ldquo;<U>Base Purchase
Price</U>&rdquo;) <U>plus</U> (B)&nbsp;the amount of any Estimated Inventory Excess, if any, up to a maximum aggregate amount equal to
the Inventory Adjustment Cap, <U>minus</U> (C)&nbsp;the amount of any Estimated Inventory Shortfall, if any, and <U>minus</U> (D)&nbsp;the
Escrow Amount (such amount, the &ldquo;<U>Closing Payment</U>&rdquo;), to the accounts of the Sellers identified on and allocated in the
amounts set forth on <U>Schedule&nbsp;3.1(a)</U>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;deposit
an amount equal to $8,000,000 (the &ldquo;<U>Escrow Amount</U>&rdquo;) in escrow with Western Alliance Bank (the &ldquo;<U>Escrow Agent</U>&rdquo;),
to be held by the Escrow Agent for a period of twelve (12) months beginning on the Closing Date pursuant to an Escrow Agreement substantially
in the form of the attached <U>Exhibit&nbsp;A</U> (the &ldquo;<U>Escrow Agreement</U>&rdquo;), and distributed in accordance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Closing Payment shall be subject to adjustment
subsequent to the Closing pursuant to <U>Section&nbsp;3.2</U> hereof. The Closing Payment, as adjusted pursuant to <U>Section&nbsp;3.2</U>,
shall be referred to herein as the &ldquo;<U>Purchase Price</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;3.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Inventory
Adjustment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Estimated
Inventory Statement</U>. At least two (2)&nbsp;Business Days (but no more than four&nbsp;(4)&nbsp;Business Days) prior to the Closing,
Elutia shall prepare and deliver to BSC a statement (the &ldquo;<U>Estimated Inventory Statement</U>&rdquo;) setting forth the Sellers&rsquo;
(i)&nbsp;good faith estimate of the Inventory Value as of the Effective Time (the &ldquo;<U>Estimated Inventory Value</U>&rdquo;) together
with a list of the Acquired Inventory as of the Effective Time and (ii)&nbsp;calculation of the Estimated Inventory Shortfall or Estimated
Inventory Excess, as applicable, based on such Estimated Inventory Value. The Estimated Inventory Statement shall be subject to reasonable
review and comment by BSC. Prior to the Closing, the Sellers shall provide BSC a reasonable opportunity to review and provide comments
on the Estimated Inventory Statement and the Sellers shall consider such comments and discuss the same with BSC in good faith prior to
Closing. In no event shall the Buyers be required to make, or cause to be made, any payments or deposits under this <U>Article&nbsp;III</U>
unless and until the Estimated Inventory Statement has been delivered by Elutia. Within five (5)&nbsp;Business Days following the Closing,
the Buyers shall cause to be conducted a physical count of the Acquired Inventory to determine Inventory Value (the &ldquo;<U>Inventory
Count</U>&rdquo;). The Sellers shall be entitled to observe the Inventory Count. The result of the Inventory Count, as adjusted for activity
occurring between the Effective Time and the date of the Inventory Count, shall be used in order to determine the Closing Inventory Value
as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Post-Closing
Inventory Adjustment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Closing
Inventory Statement</U>. Within ninety (90) days after the Closing Date, BSC shall prepare and deliver to Elutia a statement (the &ldquo;<U>Closing
Inventory Statement</U>&rdquo;) setting forth (A)&nbsp;its calculation of the actual Inventory Value as of the Effective Time (the &ldquo;<U>Closing
Inventory Value</U>&rdquo;) together with a list of Acquired Inventory as of the Effective Time, which shall be based, in part, on the
Inventory Count, and (B)&nbsp;its calculation of the Post-Closing Adjustment Amount based thereon. At any time during such ninety- (90-)
day period, at the Buyers&rsquo; reasonable request, the Sellers shall cooperate and assist, and shall cause their respective Representatives
to assist, the Buyers and their Representatives in the preparation of the Closing Inventory Statement, and shall provide the Buyers and
their Representatives with any information reasonably requested by them, including access to all relevant books and records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Post-Closing
Adjustment</U>. The post-Closing adjustment shall be an amount equal to the Closing Inventory Value, as finally determined pursuant to
this <U>Section&nbsp;3.2(b)</U>, <U>minus</U> the Estimated Inventory Value (the &ldquo;<U>Post-Closing Adjustment Amount</U>&rdquo;);
provided, however, that (A)&nbsp;if the absolute value of the Post-Closing Adjustment Amount is less than or equal to [***], then the
Post-Closing Adjustment Amount shall be deemed to equal [***] and (B)&nbsp;if the Post-Closing Adjustment Amount is a positive number
and an amount equal to the Inventory Adjustment Cap has previously been paid by the Buyers to the Sellers as part of the Closing Payment,
then the Post-Closing Adjustment Amount shall be deemed to equal [***]. Promptly, and in any event no later than the fifth (5th) Business
Day following the determination and final resolution thereof in accordance with the terms of this <U>Section&nbsp;3.2(b)</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
the Post-Closing Adjustment Amount is a positive number then the Buyers shall pay or cause to be paid to the Sellers an aggregate amount
equal to the Post-Closing Adjustment Amount, by wire transfer of immediately available funds to such account or accounts and allocated
among the Sellers in such amounts as designated in writing by Elutia to BSC; <U>provided</U>, that under no circumstances shall (A)&nbsp;the
Post-Closing Adjustment Amount <U>plus</U> (B)&nbsp;any Estimated Inventory Excess previously paid by the Buyers to the Sellers as part
of the Closing Payment exceed the Inventory Adjustment Cap;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
the Post-Closing Adjustment Amount is a negative number, the Buyers shall have the option in BSC&rsquo;s sole discretion to require (i)&nbsp;that
the Sellers shall, jointly and severally, pay or cause to be paid to the Buyers an amount equal to the absolute value of the Post-Closing
Adjustment Amount (or any portion thereof), by wire transfer of immediately available funds to such account or accounts and allocated
among the Buyers in such amounts as designated by BSC in writing, or (ii)&nbsp;that BSC and Elutia shall provide a joint written instruction
to the Escrow Agent to deliver an amount equal to the absolute value of the Post-Closing Adjustment Amount (or any portion thereof) out
of the Escrow Funds to the Buyers by wire transfer of immediately available funds in accordance with the Escrow Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;if
the Post-Closing Adjustment Amount is equal to [***], then neither the Buyers, on the one hand, nor the Sellers, on the other hand, shall
be obliged to make any payment to the other pursuant to this <U>Section&nbsp;3.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Dispute
Notice</U>. In the event that the Sellers do not agree with the Closing Inventory Value set forth in the Closing Inventory Statement,
Sellers shall be entitled, within thirty&nbsp;(30) calendar days of the delivery of the Closing Inventory Statement (the &ldquo;<U>Dispute
Period</U>&rdquo;), to give the Buyers written notice (a &ldquo;<U>Dispute Notice</U>&rdquo;) of such disagreement, which disagreement
must be based solely on the Buyers&rsquo; mathematical error, failure to calculate Inventory Value in accordance with this Agreement or
the Buyers not having followed the terms of this Agreement. The Dispute Notice shall set forth in reasonable detail the specific items
of Inventory with which the Sellers do not agree and the basis for such objection (the &ldquo;<U>Disputed Inventory Items</U>&rdquo;).
Any Inventory items not specifically identified as disputed in a Dispute Notice that is timely delivered shall be deemed accepted by the
Sellers and final and agreed for all purposes of this Agreement, absent Fraud or intentional misconduct. In the event that Sellers (A)&nbsp;do
not deliver a Dispute Notice during the Dispute Period or (B)&nbsp;confirm in writing that they accept the Closing Inventory Statement
delivered by the Buyers, the Closing Inventory Value set forth on such Closing Inventory Statement shall irrevocably be deemed accepted
by the Sellers and to be final and agreed for all purposes of this Agreement, absent Fraud or intentional misconduct, and the Purchase
Price will be finally determined at such time. In the event that Sellers deliver a Dispute Notice within the Dispute Period, Elutia (on
behalf of the Sellers) and BSC (on behalf of the Buyers) shall, for a period of not less than sixty (60) days (the &ldquo;<U>Negotiation
Period</U>&rdquo;) after delivery of the Dispute Notice, attempt in good faith to mutually determine the Inventory Value of the Disputed
Inventory Items and mutually determine any resulting adjustments to the Closing Inventory Value. In the event that BSC and Elutia mutually
determine in writing the Inventory Value of the Disputed Inventory Items and resulting Closing Inventory Value, then such adjusted Closing
Inventory Value shall irrevocably be deemed to be final for all purposes of this Agreement, absent Fraud or intentional misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Arbitration
of Disputes</U>. In the event that no agreement can be reached by Elutia and BSC as to all or any of the Disputed Inventory Items
within the Negotiation Period, then for a period of thirty (30) days following the end the Negotiation Period either party shall
have the right to cause the determination of the Inventory Value of the remaining Disputed Inventory Items to be submitted to
arbitration by the Boston, Massachusetts office of one of the following entities or their respective successors, so long as such
entity or its successors is not the current principal regularly engaged outside accountant to any Buyer or any Seller:
Deloitte&nbsp;&amp; Touche LLP or KPMG LLP, or any successor entity to any of the foregoing (collectively, the
 &ldquo;<U>Accountants</U>&rdquo;); <U>provided</U>, <U>however</U>, that the engagement and charge of the Accountants shall be
limited to determining the Inventory Value of any specified Disputed Inventory Items remaining in dispute following the Negotiation
Period, and, shall not be entitled to determine any other matter. Elutia and BSC shall jointly select which of the Accountants will
perform the calculation within thirty (30) days after Elutia and BSC determine that they are unable to settle the Disputed Inventory
Items independently. The Accountant selected in accordance with the foregoing sentence, who shall be mutually agreeable to BSC and
Elutia, shall be responsible for the determination of the Inventory Value of the applicable remaining Disputed Inventory Items and
shall be referred to herein as the &ldquo;<U>Appraiser</U>.&rdquo; The Appraiser shall determine the Inventory Value of each of the
remaining Disputed Inventory Items within the limitations set forth above within ninety (90) days after the date of such
Appraiser&rsquo;s engagement. Any Disputed Inventory Items determined by an Appraiser in accordance with this <U>Section&nbsp;3.2(b)(iv)</U>&nbsp;shall
be deemed to be the final Inventory Value for such Disputed Inventory Item for all purposes of this Agreement. The fees and expenses
of the Appraiser incurred in the resolution of such dispute shall be borne by the Buyers, on the one hand, and the Sellers, on the
other hand, in such proportion as is appropriate to reflect the relative benefits received by each party from the resolution of the
dispute. For example, if Sellers challenge the calculation of the Closing Inventory Value in the Closing Inventory Statement by an
amount of $100,000, but the Appraiser determines that the Sellers have a valid claim for only $40,000, the Buyers shall bear 40% of
the fees and expenses of the Appraiser and the Sellers, jointly and severally, shall bear the other 60% of such fees and
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Final
Calculation of Closing Inventory Value and Purchase Price</U>. The final determination of the Closing Inventory Value pursuant to <U>Section&nbsp;3.2(b)(ii)</U>&nbsp;shall,
in the absence of Fraud or intentional misconduct, be conclusive for all purposes of this Agreement, and the Buyers and the Sellers and
the Appraiser, if applicable, shall each be free from any and all Liability resultant from such determination (other than the obligation
of the Buyers and the Sellers to pay the applicable Post-Closing Adjustment Amount if required to be paid).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Access
to Information</U>. Each party shall provide reasonable access during normal business hours upon reasonable prior notice to the information
and accounting personnel of such party and including the relevant work papers of their independent accountants (as applicable) and other
supporting documents, to the other party and its accountants and other representatives to the extent reasonably necessary to complete
its review of the Closing Inventory Statement; <U>provided</U>, <U>however</U>, that the independent accountants of each party shall not
be obligated to make any working papers available to the other party or its accountants or other representatives unless and until such
other party or such accountants or other representatives have signed a customary confidentiality and hold harmless agreement relating
to such access to working papers in form and substance reasonably acceptable to such independent accountants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
payment made pursuant to this <U>Section&nbsp;3.2</U> shall be treated as an adjustment to the Purchase Price for U.S. federal (and applicable
state and local) income Tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;3.3</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Allocation
of Purchase Price</U>. Within thirty (30) days after the Closing, Elutia (on behalf of all of the Sellers) shall deliver to BSC (on behalf
of the Buyers), for BSC&rsquo;s approval, an allocation of the Purchase Price, plus any other items of consideration for U.S. federal
(and applicable state and local) income Tax purposes, among the Acquired Assets and the covenant not to compete contained in the Seller
Non-Competition Agreement in accordance with Section&nbsp;1060 of the Code and the Treasury Regulations promulgated thereunder (and any
similar provision of federal, state, local or non-U.S. Law, as appropriate) (the &ldquo;<U>Allocation</U>&rdquo;). The Allocation shall
be prepared in accordance with Section&nbsp;1060 of the Code and the Treasury Regulations promulgated thereunder (and any similar provision
of federal, state, local or non-U.S. Law, as appropriate) and in a manner consistent with the allocation methodology set forth on <U>Exhibit&nbsp;B</U>.
The Allocation shall be subject to BSC&rsquo;s review and comment, and if BSC has any objection to the Allocation, (i)&nbsp;BSC shall
deliver a detailed written statement describing its objections to Elutia within thirty (30) days after receiving the Allocation and (ii)&nbsp;Elutia
and BSC shall work in good faith to resolve BSC&rsquo;s objections relating to the Allocation within thirty (30) days after Elutia&rsquo;s
receipt of such detailed written statement describing such objections. If Elutia and BSC are unable to resolve any such dispute, such
dispute shall be resolved promptly by a nationally recognized independent accounting firm reasonably acceptable to the Buyers and Sellers,
the costs of which shall be borne equally by the Buyers and the Sellers (jointly and severally); provided, that any determination by such
nationally recognized independent accounting firm shall be made in a manner consistent with the methodology as set forth in <U>Exhibit&nbsp;B</U>.
If the amount payable pursuant to this Agreement is subsequently adjusted pursuant to the terms of this Agreement, or additional amounts
are or become payable, the Allocation shall be adjusted in a manner consistent with the procedures set forth in this <U>Section&nbsp;3.3</U>
and consistent with the methodology set forth in <U>Exhibit&nbsp;B</U>. Each Buyer and each Seller and each of their respective Affiliates
shall file all Tax Returns (including, but not limited to,&nbsp;Internal Revenue Service Form&nbsp;8594) consistent with the Allocation,
as finally determined. Neither any Buyer nor any Seller shall take any Tax position inconsistent with such Allocation unless otherwise
required by a final &ldquo;determination&rdquo; within the meaning of Section&nbsp;1313(a)&nbsp;of the Code (or any similar provision
of federal, state, local or non-U.S. Law, as appropriate) and neither any Buyer nor any Seller shall agree to any proposed adjustment
to the Allocation by any taxing authority without first giving the other party prior written notice; <U>provided</U>, <U>however</U>,
that nothing contained in this Section&nbsp;3.3 shall prevent any Buyer or any Seller from settling any proposed deficiency or adjustment
by any taxing authority based upon or arising out of the Allocation, and neither any Buyer nor any Seller shall be required to litigate
before any court any proposed deficiency or adjustment by any taxing authority challenging such Allocation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;3.4</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Withholding</U>.
Each of the Buyers and their Affiliates, the Escrow Agent and any other party required to make a payment under this Agreement shall be
entitled to deduct and withhold from any amounts otherwise payable pursuant to this Agreement, such amounts as it is required to deduct
and withhold in respect of any such payments under applicable Law. Other than with respect any compensatory payment or the failure by
a Seller to provide an IRS Form&nbsp;W-9 pursuant to <U>Section&nbsp;4.2(a)(x)</U>, the Buyers shall provide Sellers with written notice
at least five (5)&nbsp;days prior to the Closing Date of any intent to deduct and withhold any amount payable pursuant to this Agreement
and use commercially reasonable efforts to cooperate with Sellers to eliminate or reduce any such withholding in accordance with applicable
Law. To the extent that amounts are so withheld, such amounts shall be treated for all purposes of this Agreement as having been paid
to the Person in respect of whom such deduction and withholding was made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;IV</B></FONT><B><BR>
CLOSING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;4.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closing
Date</U>. Subject to the fulfillment or waiver of all of the conditions contained in <U>Article&nbsp;X</U>, as soon as is reasonably practicable
on or after the fourth (4<SUP>th</SUP>) Business Day following the satisfaction or waiver (to the extent permitted hereunder) of the last
to be satisfied or waived of the conditions set forth in <U>Article&nbsp;X</U> (other than those conditions that by their terms are to
be satisfied at the Closing, but subject to the satisfaction or waiver (to the extent permitted hereunder), of such conditions), a closing
(the &ldquo;<U>Closing</U>&rdquo;) will be deemed to have occurred at the offices of Goodwin Procter LLP, in Boston, Massachusetts and
shall be effected by the exchange of executed transaction documents by facsimile, electronic mail (including .PDF delivery) or other mutually
acceptable electronic means or at such other location, date and time as the Buyers and Sellers may mutually agree in writing. The date
on which the Closing is actually held is referred to herein as the &ldquo;<U>Closing Date</U>.&rdquo; Notwithstanding the foregoing, if
the Closing Date would otherwise occur during the last five (5)&nbsp;Business Days of any calendar month, or the last fifteen (15) business
days of any calendar quarter, then BSC (on behalf of the Buyers) may (in its sole discretion) elect that the Closing Date shall take place
on the first Business Day of the following month, subject to the fulfillment or waiver of all of the conditions contained in <U>Article&nbsp;X</U>.
Unless otherwise agreed by the Buyers and Sellers, the Acquisition shall be deemed effective as of 12:01 a.m.&nbsp;Eastern Time on the
Closing Date (the &ldquo;<U>Effective Time</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;4.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Deliveries
at Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Sellers&rsquo;
Closing Deliverables</U>. At the Closing, the Sellers shall deliver to the Buyers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Escrow Agreement, duly executed by each Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
Bill of Sale and Assignment and Assumption Agreement in the form attached hereto as <U>Exhibit&nbsp;C</U> (the &ldquo;<U>Bill of Sale</U>&rdquo;),
duly executed by each Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
Assignment of Trademarks in the form attached hereto as <U>Exhibit&nbsp;D-1</U> and an Assignment of Patents and Patent Applications in
the form attached hereto as <U>Exhibit&nbsp;D-2</U> (collectively, the &ldquo;<U>Intellectual Property Assignment</U>&rdquo;), in each
case, duly executed by each applicable Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
non-competition and non-solicitation agreement in the form attached hereto as <U>Exhibit&nbsp;E</U> (the &ldquo;<U>Seller Non-Competition
Agreement</U>&rdquo;), duly executed by each Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
Transition Services Agreement in the form attached hereto as <U>Exhibit&nbsp;F</U> (the &ldquo;<U>Transition Services Agreement</U>&rdquo;),
duly executed by each Seller; <U>provided</U>, <U>that</U>, with respect to the form of Transition Services Agreement attached as <U>Exhibit&nbsp;F</U>,
the parties hereto acknowledge and agree that (A)&nbsp;such Transition Services Agreement (with the exception of the Schedule of Seller
Services (as defined therein)) is in substantially final form as of the Signing Date, (B)&nbsp;the parties will reasonably cooperate with
one another between the Signing Date and the Closing Date to finalize the Transition Services Agreement (including the Schedule of Seller
Services), and (C)&nbsp;the Sellers shall agree to provide, with respect to such Schedule of Seller Services, any services requested by
the Buyers to the extent that such services have been provided by Sellers to the CIED Business prior to the Closing Date and such services
remain capable of being provided by the Sellers to the Buyers after giving effect to the transactions contemplated by this Agreement (in
each case on costs and terms as mutually agreed between the Buyers and the Sellers in good faith), including that the Sellers will provide
all service reasonably requested by the Buyers relating to obtaining Permits relating to the CIED Business and transferring such Permits
to Buyers, including the Permits set forth on <U>Schedule 4.2(a)(v)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;fully
executed payoff letters and evidence, in form and substance reasonably satisfactory to the Buyers, of releases of each Encumbrance (other
than Permitted Encumbrances) on the Acquired Assets and Excluded Patents, effective upon or concurrent with the Closing, including the
Encumbrances set forth in <U>Schedule&nbsp;4.2(a)(vi)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;all
notifications, consents and approvals, in form and substance reasonably satisfactory to the Buyers, (i)&nbsp;listed in <U>Schedule&nbsp;4.2(a)(vii)</U>&nbsp;or
(ii)&nbsp;required to be obtained or given from or to any third party under any contract or Permit in connection with the Acquisition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;evidence
that the Contracts listed in <U>Schedule&nbsp;4.2(a)(viii)</U>&nbsp;will be terminated contingent upon the occurrence of the Closing and
effective upon the earlier of (i)&nbsp;Closing or (ii)&nbsp;the expiration of any time period for such notices prescribed in the underlying
Contract, in form and substance reasonably satisfactory to the Buyers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;amendments
to the Contracts listed in <U>Schedule&nbsp;4.2(a)(ix)</U>&nbsp;in the form provided by Buyers to the Sellers and (ii)&nbsp;new Contracts
between a Buyer and the counterparty to any Shared Contracts listed in <U>Schedule&nbsp;4.2(a)(ix)</U>&nbsp;being retained by a Seller,
in each case, to be effective at and conditioned upon the occurrence of the Closing and in form and substance reasonably satisfactory
to the Buyers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
Employee Lease Agreement (the &ldquo;<U>Employee Lease Agreement</U>&rdquo;), if any, in form and substance reasonably satisfactory to
the Buyers and Sellers, duly executed by the Sellers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
duly and properly completed and executed IRS Form&nbsp;W-9 from each Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
certificate, dated not more than ten (10)&nbsp;days prior to the Closing Date, duly issued by the applicable governmental agency of each
jurisdiction where a Seller is formed or qualified to do business, confirming that such Seller is in good standing or similar status in
such jurisdiction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
certificate, dated as of the Closing Date, of the Secretary of each Seller certifying (i)&nbsp;that attached thereto is a complete and
correct copy of the Organizational Documents of such Seller, as amended to date, (ii)&nbsp;that attached thereto are complete and correct
copies of resolutions adopted by the board of directors (or similar governing body) of such Seller, authorizing the execution, delivery
and performance of each of this Agreement and all of the other Transaction Documents to be executed by such Seller, and the consummation
of the transactions contemplated hereunder and thereunder, and that such resolutions have not been amended or modified in any respect
and remain in full force and effect, and (iii)&nbsp;that the persons named therein are duly elected, qualified and acting officers of
such Seller, and that set forth therein is a genuine signature or true facsimile thereof for each such officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;a
certificate (in form and substance reasonably acceptable to the Buyers), dated as of the Closing Date, signed by the President and Chief
Executive Officer of each Seller certifying that (A)&nbsp;each of the warranties of the Sellers contained in this Agreement shall have
been true and accurate in all material respects at the time originally made (as qualified by the Seller Disclosure Schedule&nbsp;in accordance
with <U>Article&nbsp;V</U>), or an earlier date if such warranty refers expressly to an earlier date, and shall be true and accurate in
all material respects as of the Closing (as qualified by the Seller Disclosure Schedule), with the same force and effect as if such warranties
had been made at and as of the Closing, in each such case without giving effect to any qualifications as to materiality or lack of Seller
Material Adverse Effect contained therein and (B)&nbsp;as to the conditions set forth in <U>Section&nbsp;10.2(a)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;at
least five (5)&nbsp;flash drives each containing copies of all of the documents and other materials or information posted to the electronic
data room located at www.dfsvenue.com under the project name &ldquo;Project Outback&rdquo; or to the SharePoint page&nbsp;titled &ldquo;Elutia
Regulatory&rdquo; located at https://elutia.sharepoint.com/sites/ElutiaRegulatory (together, the &ldquo;<U>VDR</U>&rdquo;) as of three
days prior to the date hereof (the &ldquo;<U>Disclosure Cut Off Time</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;a
copy of all Books, Records and Files that are Acquired Assets hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xvii)</FONT>&#8239;&#8239;&#8239;&#8239;a
License Agreement relating to the Excluded Patents, in a form reasonably satisfactory to the Buyers and duly executed by each Seller (the
 &ldquo;<U>License Agreement</U>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xviii)</FONT>&#8239;&#8239;&#8239;such
other documents as the Buyers may reasonably request of the Sellers to effect the transactions contemplated hereby, including all instruments
of assignment and transfer with respect to the Acquired Assets as the Buyers may reasonably request and as may be necessary to vest in
the Buyers good and marketable title to all of the Acquired Assets, in each case free and clear of all Encumbrances other than Permitted
Encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Buyers&rsquo;
Closing Deliverables</U>. At the Closing, the Buyers or their designated Affiliates shall duly execute and deliver to the Sellers: (i)&nbsp;the
Escrow Agreement, (ii)&nbsp;the Bill of Sale, (iii)&nbsp;the Intellectual Property Assignment, (iv)&nbsp;the Seller Non-Competition Agreement,
(v)&nbsp;the Transition Services Agreement, (vi)&nbsp;the Employee Lease Agreement (if applicable), and (vii)&nbsp;a certificate of resale
relating to the future sale of Acquired Inventory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;V</B></FONT><B><BR>
WARRANTIES OF THE SELLERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Sellers warrant to and for the benefit of the Buyers that each of the following warranties of the Sellers is as of the Signing Date and
as of the Effective Time will be true and accurate; <U>provided</U>, that such warranties shall be qualified by the exceptions as are
specifically set forth in the attached Disclosure Schedule&nbsp;of the Sellers (the &ldquo;<U>Seller Disclosure Schedule</U>&rdquo;),
it being agreed that each statement or other item of information set forth in the Seller Disclosure Schedule&nbsp;shall be deemed to be
a part of the warranties made by the Sellers hereunder. Notwithstanding any other provision of this Agreement or the Seller Disclosure
Schedule, each exception set forth in the Seller Disclosure Schedule&nbsp;will be deemed to qualify only each representation and warranty
set forth in this Agreement (i)&nbsp;that is specifically identified (by cross-reference or otherwise) in the Seller Disclosure Schedule&nbsp;as
being qualified by such exception, (ii)&nbsp;with respect to which the relevance of such exception is readily apparent on its face without
reference to any other document or information, and (iii)&nbsp;in each case only to the extent the exceptions in the Seller Disclosure
Schedule are </FONT>fairly, fully and accurately disclosed (with sufficient detail to enable the Buyers to identify the nature and scope
of the matter disclosed and to form a reasonably informed view whether to exercise any rights in respect of such matter). Notwithstanding
anything in this Agreement to the contrary, for purposes of this <U>Article&nbsp;V</U>, the terms &ldquo;Acquired Assets&rdquo; and &ldquo;Seller
Intellectual Property&rdquo; shall be deemed to include the Excluded Patents. For the avoidance of doubt, the term &ldquo;Acquired Asset&rdquo;
shall be deemed to include any Ongoing Clinical Trial Agreement and Ongoing Vendor Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization,
Good Standing and Qualification; No Ownership Interests</U>. Elutia is a corporation, duly formed, validly existing and in good standing
under the Laws of Delaware and its Subsidiary, Elutia Med, is a limited liability company, duly formed, validity existing and in good
standing under the Laws of Delaware. Each Seller has all requisite corporate or other entity power and authority to own and operate the
Acquired Assets, to execute and deliver this Agreement, the Escrow Agreement, the Bill of Sale, the Intellectual Property Assignments,
the Seller Non-Competition Agreement, the Transition Services Agreement, the Employee Lease Agreement (if applicable), and any other documents,
instruments, certificates, and agreements contemplated hereby (collectively, the &ldquo;<U>Transaction Documents</U>&rdquo;), and to carry
out the provisions and transactions of this Agreement and the other Transaction Documents and to carry on its business as presently conducted.
<U>Section&nbsp;5.1</U> of the Seller Disclosure Schedule&nbsp;sets forth each jurisdiction where a Seller is qualified, licensed or admitted
to do business (on a Seller-by-Seller basis) and separately lists each other state, province or country in which a Seller owns, uses,
licenses or leases its assets or properties, conducts business, has employees or engages independent contractors, in each case relating
to the Acquired Assets. Except as set forth in <U>Section&nbsp;5.1</U> of the Seller Disclosure Schedule, no Seller owns or controls,
directly or indirectly, any interest in any other corporation, association, partnership, limited liability company or other business entity
that is engaged in, or owns, licenses or leases any properties or assets relating to, or used or held for use in, any Products or the
Acquired Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization;
Binding Obligations; Governmental Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
corporate and other entity actions on the part of the Sellers, their respective officers, directors, managers, members and equityholders
necessary for the authorization, execution and delivery of this Agreement and the other Transaction Documents to which any Seller is a
party and the performance of all obligations of each Seller hereunder and thereunder and the consummation of the transactions contemplated
hereby and thereby have been taken prior to the date hereof. This Agreement and, as of the Closing, each of the other Transaction Documents
to which any Seller is a party have been or (in the case of such other Transaction Documents) as of the Closing will be duly executed
and delivered by such Seller and are valid or (in the case of such other Transaction Documents) as of the Closing will be binding obligations
of any Seller enforceable in accordance with their terms, except as limited by (i)&nbsp;applicable bankruptcy, insolvency, reorganization,
moratorium, and other laws of general application affecting enforcement of creditors&rsquo; rights, and (ii)&nbsp;general principles of
equity that restrict the availability of equitable remedies (such exceptions, the &ldquo;<U>Enforceability Exceptions</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Permit or Order of, or declaration or filing with, any Governmental Authority on the part of any Seller is required in connection with
the execution and delivery of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated
hereby and thereby, except as are set forth on <U>Section&nbsp;5.2(b)</U>&nbsp;of the Seller Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.3</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Agreements;
Actions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.3(a)</U>&nbsp;of the Seller Disclosure Schedule, there are no agreements, understandings or proposed
transactions between any Seller and any of its officers, directors, managers, member, equityholders, Affiliates, or any Affiliate thereof
in connection with or relating to, or otherwise used in or useful to the development, manufacture or commercialization of the Acquired
Assets or Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.3(b)</U>&nbsp;of the Seller Disclosure Schedule, there are no contracts or Orders to which a Seller
is a party or by which a Seller, or a party acting on behalf of a Seller, is bound that relate to the Acquired Assets or Products and
involve (each such contract, proposed transaction or Order disclosed or required to be disclosed in <U>Section&nbsp;5.3(b)</U>&nbsp;of
the Seller Disclosure Schedule, together with each such contract or Order entered into after the date of this Agreement, is referred to
herein as a &ldquo;<U>Material Contract</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
obligations (contingent or otherwise) of, or payments by, the Sellers in excess of [***] over the term of such contract;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
contract related to Indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
contract relating to severance, termination, retention or change of control payment, benefit or incentive for any Service Provider;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;payments
to the Sellers in excess of [***] over the term of such agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
development, acquisition, sharing, license, assignment or transfer of any Intellectual Property or other proprietary right to or from
the Sellers (other than: (A)&nbsp;paid-up licenses to any Seller arising from the purchase or license of generally available &ldquo;off
the shelf&rdquo; software, and (B)&nbsp;non-disclosure and confidentiality agreements entered into pursuant to any Sellers&rsquo; standard
form of non-disclosure agreement that has been provided to the Buyers);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
restriction on the right or ability of the Sellers (or of the Buyers or any of their Affiliates, after giving effect to the Closing) to
do any of the following: (A)&nbsp;to compete with, or solicit any customer of, any other Person; (B)&nbsp;to acquire any product or other
asset or any services from any other Person; (C)&nbsp;to solicit, hire or retain any person as an employee, consultant or independent
contractor; (D)&nbsp;to develop, manufacture, sell, supply, distribute, offer, support or service any product (including Products) or
any technology or other asset to or for any other Person; (E)&nbsp;to perform services for any other Person; or (F)&nbsp;to transact business
or deal in any other manner with any other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
research, design, development, manufacture, processing, packaging, labeling, testing, storage, distribution, import or export of any Products,
or nonclinical, preclinical or clinical trials (including pre- and post-marketing trials) relating to any Products;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;the
marketing, advertising, promotion or sale of any Products in any jurisdiction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
restrictions on the Sellers&rsquo; (or the Buyers&rsquo;, after giving effect to the Closing) exclusive rights to research, design, develop,
manufacture, process, package, label, test, store, distribute, import, export, market, advertise, promote or sell its products (including
any Products);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;an
obligation by any Seller to indemnify a third party specifically for infringements of Intellectual Property rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
supply or quality agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
lease, sale, license or disposition of any Acquired Assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;granted
rights to research, design, develop, manufacture, process, package, label, test, store, distribute, import, export, market, advertise,
promote or sell any Product to any other Person;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;any
collective bargaining agreements or other contracts with any Union;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
confidentiality, noncompetition, nonsolicitation, invention assignment or other restrictive covenant with any Business Employee or Business
Contingent Worker;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xvi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;any
agreement providing for any severance or incentive compensation of any kind;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xvii)</FONT>&#8239;&#8239;&#8239;&#8239;any
agreement providing for any equity acceleration or extended exercise period of any kind;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xviii)</FONT>&#8239;&#8239;&#8239;any
settlement or release agreements with any current or former officer of the CIED Business, Business Employee or Business Contingent Worker
entered into during the last three (3)&nbsp;years; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
other rights or obligations that are otherwise material to the CIED Business, the Acquired Assets or any Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers have delivered or have caused to be delivered to the Buyers correct and complete (in all material respects) copies of each Material
Contract listed or required to be listed in <U>Section&nbsp;5.3</U> of the Seller Disclosure Schedule, as such Material Contracts are
amended and supplemented to date. None of the Material Contracts has been modified in any material respect, except to the extent that
such modifications are disclosed by the copies provided to the Buyers. Each such Material Contract is a valid, binding and enforceable
obligation of a Seller and, to Sellers&rsquo; Knowledge, of the other party or parties thereto, subject to the Enforceability Exceptions,
and is in full force and effect. No Seller nor, to Sellers&rsquo; Knowledge, any other party or parties thereto, is in breach or non-compliance
in any material respect of any material term of any such Material Contract, and no event has occurred which with or without notice or
lapse of time or both would constitute a breach thereof or default thereunder in any material respect by any Seller or, to the Sellers&rsquo;
Knowledge, any other party thereto. No Seller has received notice of any breach of or default under, or intention to terminate or not
renew, any such Material Contract and, to the Knowledge of the Sellers, there is no reasonable basis for believing that any of the foregoing
will be forthcoming. Except as set forth in <U>Section&nbsp;5.3(c)</U>&nbsp;of the Seller Disclosure Schedule, (i)&nbsp;no Material Contract
listed or required to be listed in <U>Section&nbsp;5.3(b)</U>&nbsp;of the Seller Disclosure Schedule&nbsp;includes or incorporates any
provision the effect of which would be to enlarge or accelerate any obligations of any Seller or give additional rights to any other party
thereto, or will in any other way be adversely affected by, or terminate or lapse by reason of, the transactions contemplated by this
Agreement or the other Transaction Documents; and (ii)&nbsp;no permit, approval, authorization or consent of, or notification to, any
Person (excluding Governmental Authorities) is required in connection with the execution, delivery and performance by the Sellers of this
Agreement or the other Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.4</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Title
to Assets; Conveyance; Sufficiency</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Elutia
and Elutia Med, as applicable, own, lease, or hold a license or sublicense to or otherwise has a right to use any Acquired Assets. The
Sellers are the lawful owners of and have good and valid record and marketable title to all of the Acquired Assets, none of which are
subject to any Encumbrances (other than Permitted Encumbrances). At and as of the Closing, the Sellers will convey the Acquired Assets
to the Buyers by deeds, bills of sale and other instruments of assignment and transfer effective in each case to vest in the Buyers, and
the Buyers will have, good and valid record and marketable title to all of the Acquired Assets, free and clear of all Encumbrances (other
than Permitted Encumbrances).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
item of personal or tangible property included in the Acquired Assets (i)&nbsp;is in the Sellers&rsquo; possession and control at the
Sellers&rsquo; facility located in Roswell, Georgia, and (ii)&nbsp;to the extent that such assets are used to manufacture the Products,
they are in operating condition and repair and are adequate for the purposes for which such assets are presently used, except for ordinary
wear and tear or immaterial defects which do not adversely affect use and operation in the ordinary course of business and none are in
need of maintenance or repairs except for ordinary, routine maintenance and repairs that are not material in nature or cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
for the Acquired Assets and the assets to be provided under the Transition Services Agreement as of the Closing Date, there are no assets,
properties or rights of the Sellers or their Affiliates that are used or held for use in or related to the CIED Business or the Products.
The Acquired Assets, together with the services and assets to be provided under the Transition Services Agreement as of the Closing Date,
comprise all of the material services, material assets and material rights of the Sellers or their Affiliates necessary to produce and
market the Products and operate the CIED Business after the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth on <U>Section&nbsp;5.4(d)</U>&nbsp;of the Seller Disclosure Schedule, there are no Shared Contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.5</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Seller
Intellectual Property</U>. <U>Section&nbsp;5.5(a)</U>&nbsp;of the Seller Disclosure Schedule&nbsp;sets forth a complete and accurate list
of (i)&nbsp;all Seller Intellectual Property which is registered or for which a Seller has applied for registration before any Governmental
Authority or Internet domain name registrar, indicating for each such item, as applicable, the application or registration number, date
and jurisdiction of filing or issuance, and the identity of the current applicant or registered owner, (ii)&nbsp;unregistered trademarks
and service marks included in the Seller Intellectual Property, and (iii)&nbsp;all licenses, assignments and other contracts relating
to Seller Intellectual Property, together with all amendments and supplements thereto and all waivers and modifications of any terms thereof,
including any of the foregoing relating to: (A)&nbsp;Seller Intellectual Property which a Seller or its Affiliates have licensed from
others or which a Seller or its Affiliates have licensed or authorized for use by others; (B)&nbsp;the transfer, development, maintenance
or use of the Seller Intellectual Property; and (C)&nbsp;consents, settlements, decrees, orders, injunctions, judgements or rulings governing
use, validity or enforceability of Seller Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Infringement of Third Parties</U>. Except as set forth in <U>Section&nbsp;5.5(b)</U>&nbsp;of the Seller Disclosure Schedule, the development,
manufacture, marketing, sale, distribution or use of the Products or the Acquired Assets does not and will not interfere with, conflict
with, infringe upon, misappropriate or otherwise violate the Intellectual Property rights of any third party, and no Action or claim has
been asserted, is pending or, to the Sellers&rsquo; Knowledge, has been threatened alleging that the development, manufacture, marketing,
sale, distribution or use of the Products interferes with, conflicts with, infringes upon, misappropriates or otherwise violates the Intellectual
Property rights of any third party and, to the Sellers&rsquo; Knowledge, there is no basis therefor. No Seller has agreed, and is not
otherwise obligated, to indemnify or to a covenant not to sue any third party for or against any infringement, misappropriation, or other
violation with respect to any Seller Intellectual Property or other Intellectual Property. No Seller is obligated to provide any consideration
(whether financial or otherwise) or account to any third-party with respect to any exercise of rights by such Seller, or any successor
to such Seller, in any Seller Intellectual Property or with respect to the manufacture, use or sale of the Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Ownership;
Sufficiency</U>. The Sellers are the sole owners of the entire right, title and interest in and to the Seller Intellectual Property and
have maintained all registrations, grants and certificates issued in any jurisdiction worldwide with respect thereto in full force and
effect. No Action or claim has been asserted, is pending or, to the Sellers&rsquo; Knowledge, has been threatened that challenges or seeks
to deny or restrict the exclusive ownership or use by a Seller of any Seller Intellectual Property and, to the Sellers&rsquo; Knowledge,
there is no basis therefor. All actions reasonably necessary to maintain and protect the Seller Intellectual Property have been taken,
including payment of applicable registration, maintenance and renewal fees, filing of applicable statements of use, timely response to
office actions and disclosure of any required information, and full execution and recording of all assignments (and licenses where required).
The Seller Intellectual Property, including the Intellectual Property listed in <U>Section&nbsp;5.5(a)</U>&nbsp;of the Seller Disclosure
Schedule, constitutes all of the Intellectual Property held in connection with or related to the Products and the Acquired Assets, or
otherwise used or useful to, the design, development, manufacture, use, testing, marketing, promotion, commercialization, sale and distribution
of the Products and the Acquired Assets, and there are no other items of Intellectual Property that are material to or necessary for the
design, development, manufacture, use, testing, marketing, promotion, commercialization, sale, and distribution of the Products and the
Acquired Assets. No Trade Secrets, confidential information or other confidential proprietary rights of any Seller relating to the Products
have been disclosed to any third party outside of valid and appropriate confidentiality provisions in place to protect disclosure of same.
<U>Section&nbsp;5.5(c)</U>&nbsp;of the Seller Disclosure Schedule&nbsp;sets forth all third-party Intellectual Property which is incorporated
into, integrated or bundled with, or used by any Seller or its Affiliates in the development, use, manufacture, import, marketing, sale
or compilation of the Products or the Acquired Assets and any contracts with such third parties. To the extent that any third-party Intellectual
Property is incorporated into, integrated or bundled with, or used by a Seller or its Affiliates in the development, use, manufacture,
import, marketing, sale or compilation of any of the Products or Acquired Assets, such Seller or such Affiliate has a written contract
with such third-party pursuant to which such Seller or such Affiliate either (i)&nbsp;has obtained complete, unencumbered and unrestricted
ownership of, and is the exclusive owner of, such Intellectual Property or (ii)&nbsp;has, except as set forth in <U>Section&nbsp;5.5(c)</U>&nbsp;of
the Seller Disclosure Schedule, obtained perpetual, non-terminable licenses without any obligation of consideration (financial or otherwise)
to such third-party Intellectual Property sufficient for the development, use, manufacture, import, marketing, sale or compilation of
the Products or Acquired Assets. Except as set forth in <U>Section&nbsp;5.5(c)</U>&nbsp;of the Seller Disclosure Schedule, no Seller or
Affiliate of any Seller uses under license any Intellectual Property of a third party in the development, manufacture, marketing, sale
or distribution of the Products or the Acquired Assets, other than paid-up licenses to standard, non-customized computer software used
in connection with such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Filing,
Prosecution and Recordation</U>. All documents, recordations and certificates in connection with the registration or application for registration
of the Seller Intellectual Property have been filed with the relevant patent, copyright, trademark or other authorities in the United
States and non-United States jurisdictions, as the case may be, for the purposes of prosecuting, maintaining and perfecting such Seller
Intellectual Property. The Sellers have complied with all applicable notice and marking requirements for, and none of the labels or other
packaging or marketing materials with respect to the Products contain any false, inaccurate or incorrect marking for, the Seller Intellectual
Property. No inequitable conduct, nor any on-sale bar or public use or improper disclosure activity or violation, has been engaged in
or committed with respect to any material Seller Intellectual Property or in the prosecution of any patent applications or patents in
any Seller Intellectual Property, and no material information was withheld from any entity requiring disclosure of such information during
prosecution of such patent applications or patents. Without limiting the generality of the foregoing, (i)&nbsp;each item of Seller Intellectual
Property is in compliance with applicable Law, and all filings, payments and other actions required to be made or taken to maintain each
item of registered Seller Intellectual Property in full force and effect have been made by the applicable deadline, and (ii)&nbsp;the
Sellers have delivered to the Buyers complete and accurate copies of all applications, material correspondence and other material documents
related to each such item of registered Seller Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Options</U>.
Except as set forth in <U>Section&nbsp;5.5(e)</U>&nbsp;of the Seller Disclosure Schedule, there are no outstanding options, licenses,
sublicenses, or contracts of any kind held by any other Person to the Seller Intellectual Property, nor is any Seller bound by or a party
to any options, licenses or contracts of any kind with respect to the Intellectual Property of any other Person that relates to the Seller
Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Validity</U>.
All Seller Intellectual Property that is owned or purported to be owned by the Sellers or that is exclusively licensed to a Seller is
valid, subsisting and enforceable and is not subject to any outstanding order, judgement, injunction, decree, ruling or agreement adversely
affecting the Sellers&rsquo; use thereof or rights thereto, or that would impair the validity or enforceability thereof. To the Sellers&rsquo;
Knowledge, there is no basis or argument in fact or law from which one might reasonably infer that any of the Seller Intellectual Property
is invalid or unenforceable (including by reason of misjoinder or nonjoinder of inventors), and the same have not been adjudged invalid
or unenforceable in whole or in part. No Action or claim is pending or, to the Sellers&rsquo; Knowledge, threatened alleging that any
Seller Intellectual Property is invalid or unenforceable in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Infringement by Third Parties</U>. To the Sellers&rsquo; Knowledge, no Person is engaging in any activity that infringes or misappropriates
Seller Intellectual Property, and no threat, notice, demand or other communication (oral or written) to that effect has been made by any
Seller against any Person. No Seller has granted any license or other right to any third party with respect to Seller Intellectual Property,
no such license or other right exists, and there is no basis for a claim by any third party to such a license or other right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Licenses</U>.
Other than paid-up licenses of commercial off-the-shelf computer software, the Sellers have delivered or made available to the Buyers
correct and complete copies of any licenses of the Intellectual Property (1)&nbsp;out-licensed by any Seller or its Affiliates or (2)&nbsp;in-licensed
by a third party to any Seller of its Affiliate, in each case of (1)&nbsp;and (2), included in the Seller Intellectual Property, together
with all amendments and supplements thereto and all waivers and modifications of any terms thereof. With respect to each such license:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
license is valid and binding and in full force and effect and represents the entire agreement between the respective licensor and licensee
with respect to the subject matter of such license;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;such
license will not cease to be valid and binding and in full force and effect on terms identical in all material respects to those currently
in effect as a result of the consummation of the transactions contemplated by this Agreement, nor will the consummation of the transactions
contemplated by this Agreement constitute a material breach or default under such license or otherwise so as to give the licensor or any
other Person a right to terminate such license;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Seller has (A)&nbsp;received any notice of termination or cancellation under such license, (B)&nbsp;received any notice of breach or default
under such license, which breach has not been cured, or (C)&nbsp;granted to any other third party any rights, adverse or otherwise, under
such license that would constitute a material breach of such license; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
the Sellers nor, to the Sellers&rsquo; Knowledge, any other party to such license is in material breach or default thereof, and, to the
Sellers&rsquo; Knowledge, no event has occurred that, with notice or lapse of time, would constitute such a material breach or default
or permit termination, modification or acceleration under such license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Confidential
Information</U>. Each Seller has taken reasonable steps in accordance with normal industry practice to maintain the confidentiality of
its Trade Secrets and other confidential Seller Intellectual Property. All current and former employee and third-party inventors of Seller
Intellectual Property are obligated to assign all right, title and interest in their inventions to one or more of Seller, and have executed
invention assignment agreements. To the Sellers&rsquo; Knowledge, (i)&nbsp;there has been no misappropriation, misuse or breach of confidentiality
of any material Trade Secrets or other confidential Seller Intellectual Property by any Person; (ii)&nbsp;no current or former employee,
consultant, independent contractor or agent of such Seller has misappropriated any Trade Secrets of any other Person (including any former
employer) in the course of such performance as an employee, independent contractor or agent; and (iii)&nbsp;no current or former employee,
consultant, independent contractor or agent of such Seller is in material default or breach of any term of any employment agreement, non-disclosure
agreement, assignment of invention agreement or similar contract relating in any way to the protection, ownership, development, use or
transfer of Seller Intellectual Property. Each Seller has taken all reasonable steps under any material confidential non-disclosure agreements
to which it is a party to cause the recipients of any confidential information of such Seller provided thereunder to cease using and to
return or destroy all such confidential information pursuant to the provisions thereof. The Sellers have complied with all of its obligations
of confidentiality in respect of the claimed Trade Secrets or proprietary information of others and knows of no violation of such obligations
of confidentiality as are owed to it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Effect
of Contemplated Transactions</U>. Neither the execution, delivery or performance of this Agreement nor any of the Transaction Documents
will, with or without notice or the lapse of time, result in or give any other Person the right or option to cause or assert: (i)&nbsp;a
breach or violation of or conflict with any contract concerning Seller Intellectual Property, (ii)&nbsp;a loss of, or Encumbrance on,
the Seller Intellectual Property, or the Seller Intellectual Property to cease to be valid and enforceable rights; (iii)&nbsp;the release,
disclosure or delivery of the Seller Intellectual Property by any escrow agent or to any other Person; (iv)&nbsp;the grant, assignment
or transfer to any other Person of any license or other material right or interest, such as an ownership interest or covenant-not-to-sue,
under, in or to the Seller Intellectual Property; (v)&nbsp;that such Person has obtained rights under the Seller Intellectual Property
or that any Buyer will be obligated to pay any royalties or other amounts to any third-party with respect to the Seller Intellectual Property,
Products or Acquired Assets; (vi)&nbsp;the forfeiture or termination of, or give rise to a right of forfeiture or termination, of the
Seller Intellectual Property; or (vii)&nbsp;any impairment of the right of any Buyer to use, operate, possess, sell or license, without
restriction, any Acquired Assets or the Seller Intellectual Property or portion thereof (including in connection with the design, development,
manufacture, use, testing, marketing, promotion, commercialization, sale and distribution of any Product) or to license or dispose of,
or to bring any Action for the infringement of, the Seller Intellectual Property. Following the Closing, the Buyers will be permitted
to exercise all of the rights of the Sellers, including under the Seller Intellectual Property, to the same extent the applicable Seller
would have been able had the transactions contemplated by this Agreement or the other Transaction Documents not occurred and without the
payment of any consideration. There are no royalties, honoraria, fees or other payments payable by any Seller to any Person as a result
of the ownership or use of Seller Intellectual Property and the use, possession, sale, marketing, advertising or disposition of the Products,
and the consummation of the transactions contemplated by this Agreement or the other Transaction Documents will not result in any such
royalties, honoraria, fees or other payments being payable by any Buyer. Following the Closing, all Seller Intellectual Property will
be fully transferable, alienable or licensable by the Buyers without restriction, consent or permission, and without payment of any kind
to any third-party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Governmental
Authorities</U>. Except as set forth in <U>Section&nbsp;5.5(k)</U>&nbsp;of the Seller Disclosure Schedule, no funding, facilities or personnel
of any Governmental Authority were used, directly or indirectly, to develop or create, in whole or in part, the Seller Intellectual Property.
No Seller is nor has ever been a member or promoter of, user of, or a contributor to, any industry standards body or similar organization
(including any &ldquo;open source&rdquo; software compendium or collaboration or other group or organization) that could compel any Seller
to grant or offer to any third party any license or right to the Seller Intellectual Property, Products or Acquired Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Open
Source</U>. No Seller has embedded, used, linked or distributed any open source, software, technologies or other materials that are licensed
or distributed under any license arrangement or other distribution model qualifying for the &ldquo;Open Source&rdquo; definition promulgated
by the Open Source Initiative at www.opensource.org/osd or any other public domain or &ldquo;community&rdquo; (or similar) materials (collectively
 &ldquo;<U>Open Source Software</U>&rdquo;) in connection with any Product or Acquired Asset in any manner that requires, or purports to
require, (i)&nbsp;any material software code owned or authored by or on behalf of any Seller (&ldquo;<U>Seller Code</U>&rdquo;) to be
disclosed or distributed in source code form or be licensed for the purpose of making derivative works; (ii)&nbsp;any restriction on the
consideration to be charged for the distribution of any such Seller Code; (iii)&nbsp;the grant to any Person of any rights or immunities
under Seller Intellectual Property; or (iv)&nbsp;any other material limitation, restriction or condition on the right of any Seller with
respect to its use or distribution of any Seller Intellectual Property. The Sellers are in material compliance with all licenses for Open
Source Software that they embed, link to, use or distribute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section&nbsp;5.6</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Employee
Benefit Plans.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Section&nbsp;5.6(a)</U>&nbsp;of
the Seller Disclosure Schedule sets forth a list of each material Employee Benefit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;None
of the Sellers nor any current or former ERISA Affiliate have at any time sponsored, adopted, maintained, participated in or made contributions
to (or been obligated to sponsor, maintain, participate in or make contributions to) or have had any Liability or potential Liability
with respect to a plan which is or was (i)&nbsp;a &ldquo;multiemployer plan&rdquo; within the meaning of ERISA Section&nbsp;3(37) or 4001(a)(3),
(ii)&nbsp;a &ldquo;multiple employer welfare arrangement&rdquo; within the meaning of ERISA Section&nbsp;3(40), (iii)&nbsp;subject to
Section&nbsp;302 or Title IV of ERISA or Code Section&nbsp;412, or (iv)&nbsp;a &ldquo;voluntary employees&rsquo; beneficiary association&rdquo;
within the meaning of subsection 501(c)(9)&nbsp;of the Code or a supplemental unemployment benefit plan within the meaning of Section&nbsp;501(c)(17)
of the Code. No Seller has at any time sponsored, adopted, maintained, participated in or made contributions to (or been obligated to
sponsor, maintain, participate in or make contributions to) or have any Liability or potential Liability with respect to a plan which
is or was an &ldquo;employee pension benefit plan&rdquo; within the meaning of ERISA Section&nbsp;3(2)&nbsp;that is subject to Title IV
of ERISA or any &ldquo;defined benefit plan&rdquo; as defined in Section&nbsp;3(35) of ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.6(c)</U>&nbsp;of the Seller Disclosure Schedule, no Employee Benefit Plan provides benefits for Business
Employees or Business Contingent Workers whose primary work location is outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Employee Benefit Plan provides post-retirement medical or life or other welfare benefits to any current or future retired or terminated
Business Employee (or any dependent thereof) (or to any other Person), other than as required by COBRA or pursuant to a similarly applicable
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Section&nbsp;5.6(e)</U>&nbsp;of
the Seller Disclosure Schedule lists each Business Employee and each former Business Employee currently eligible to elect or currently
utilizing group health continuation coverage pursuant to COBRA as of the date of this Agreement and through the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Employee Benefit Plan that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is so qualified and (i)&nbsp;has received
an unrevoked favorable determination letter from the Internal Revenue Service indicating that such Employee Benefit Plan is so qualified
and any trust related thereto is Tax exempt, or (ii)&nbsp;is entitled to rely upon an opinion letter from the Internal Revenue Service
issued to a volume submitter or prototype document providing that the plan document is qualified in form under Section&nbsp;401(a)&nbsp;of
the Code. To the Knowledge of the Sellers nothing has occurred since the date of such determination that would reasonably be expected
to result in disqualification or loss of Tax exemption of any such Employee Benefit Plan or trust intended to be qualified under Section&nbsp;401(a)&nbsp;of
the Code. No Employee Benefit Plan that is subject to ERISA has at any time held employer securities or employer real property as a plan
asset, in each case, within the meaning of ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the Employee Benefit Plans have been maintained, funded and administered in compliance with their terms, and in material compliance
with the applicable provisions of ERISA, the Code, and any other applicable Law. There is no material pending or, to the Knowledge of
Sellers, threatened Proceeding by or before any Governmental Authority by or on behalf of, or related to, any Employee Benefit Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;With
respect to each Employee Benefit Plan, Seller has made available to the Buyers correct and complete copies of (to the extent applicable):
(i)&nbsp;the plan and any trust documents and any amendments thereto, the summary plan descriptions and any summaries of material modifications;
(ii)&nbsp;the most recent annual reports (IRS Form&nbsp;5500 series) filed with the IRS; and (iii)&nbsp;the most recent determination,
advisory or opinion letter, if any, received from the Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Employee Benefit Plan that is a group health plan subject to Section&nbsp;4980B of the Code and Part&nbsp;6 of Subtitle B of Title I or
ERISA has been administered and operated in material compliance, with the continuation coverage requirements of Section&nbsp;4980B of
the Code and Part&nbsp;6 of Subtitle B of Title I or ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Seller has any material Liability by reason of at any time being treated as a single employer under Section&nbsp;414 of the Code with
any other Person (other than each other).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Business Employee is on a leave of absence of any kind as of the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.6(l)</U>&nbsp;of the Seller Disclosure Schedule, to the Knowledge of Sellers, no Business Employee of
the Sellers providing services to the Business is eligible to claim short-term or long-term disability benefits or workers&rsquo; compensation
insurance as of the date of this Agreement and the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.6(m)</U>&nbsp;of the Seller Disclosure Schedule, neither the execution and delivery of this Agreement
nor the consummation of the transactions contemplated hereby will, alone or in connection with any other event (including the termination
of employment or service with the Sellers or any Buyer following the Closing), (i)&nbsp;result in any compensatory payment becoming due
under any Employee Benefit Plan or similar such arrangement to any Business Employee or Business Contingent Worker, (ii)&nbsp;increase
any benefits (including severance, deferred compensation and equity benefits) otherwise payable under any Employee Benefit Plan or similar
such arrangement to any Business Employee or Business Contingent Worker, (iii)&nbsp;result in the acceleration of the time of payment,
funding or vesting of any such benefits to any extent, or (iv)&nbsp;result in the forgiveness in whole or in part of any outstanding loans
made by a Seller to any Business Employee or Business Contingent Worker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.7</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with Other Instruments</U>. No Seller is in violation or default of any term of its Organizational Documents, or in material violation
or default of any provision of any contract or Order to which it is party or by which it or any of the Acquired Assets is bound or any
provision of any statute, rule&nbsp;or regulation applicable to the Sellers and relating to any Product or Acquired Asset. The execution,
delivery, and performance of and compliance with this Agreement, and the other Transaction Documents, and the consummation of the Acquisition,
will not, with or without the passage of time or giving of notice, result in any such violation, or be in conflict with or constitute
a default under any such term or provision described in the immediately preceding sentence, or result in the creation of any Encumbrance
upon any of the Acquired Assets or the suspension, revocation, impairment, forfeiture or nonrenewal of any Permit applicable to any Product
or Acquired Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.8</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Litigation</U>.
There is no Action pending or, to Sellers&rsquo; Knowledge, currently threatened against any Seller or any of its Affiliates or any of
their respective officers, directors, members or managers relating to any Product or any Acquired Assets, nor is there any basis for any
of the foregoing. The foregoing includes, without limitation, Actions pending or threatened in writing involving the prior employment
or activities of any Sellers&rsquo; former or current employees, agents, contractors or consultants, related to their use in connection
with the Acquired Assets of any information or techniques allegedly proprietary to any of their former employers or other Person or their
obligations under any contracts with prior employers or other Person. No Seller is a party or subject to the provisions of any Order relating
to any Product or Acquired Asset. There is no Action by any Seller pending or that any Seller intends to initiate, in each case relating
to any Product or Acquired Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.9</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.9(a)</U>&nbsp;of the Seller Disclosure Schedule, each of the Sellers has (i)&nbsp;in respect of the
Acquired Assets, the Products, and the CIED Business, timely filed all Tax Returns required to be filed with the appropriate taxing authorities
in all jurisdictions in which such Tax Returns are required to be filed, and all such Tax Returns are true, accurate and complete in all
material respects and (ii)&nbsp;timely paid all Taxes due and owing in respect of the Acquired Assets, the Products, and the CIED Business
(whether or not shown as due and owing on a Tax Return).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;None
of the Acquired Assets, Products or the CIED Business constitute or include (i)&nbsp;any United States real property interests as defined
in Section&nbsp;897 of the Code or (ii)&nbsp;any equity interest in a corporation, partnership, trust, joint venture, limited liability
company, association or any other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the extent that a Seller has received notice from a taxing authority that such Seller is or may be subject to taxation in a jurisdiction
in which it did not previously pay taxes with respect to the Acquired Assets, the Products or the CIED Business, such Seller has since
made appropriate tax filings in that jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the Sellers has timely withheld and timely paid all Taxes that are required to have been withheld and paid by such Seller in connection
with the Acquired Assets, the Products and the CIED Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Seller has received notice of any claim for assessment or collection of Taxes that has not been fully resolved, and no such claim is pending
or is presently being asserted against any Seller with respect to any of the Acquired Assets, the Products or the CIED Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Seller is a party to any pending Action with any taxing authority that relates to any Product, the CIED Business or any of the Acquired
Assets, and to the Sellers&rsquo; Knowledge, no such Action is threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;With
respect to any Product, the CIED Business or any Acquired Asset, no Seller is liable for the Taxes of any other Person as a transferee
or successor, by contract or otherwise under applicable Law (other than any contract entered into in the Ordinary Course of Business the
primary purpose of which is not Tax).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Seller has waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or
deficiency, in each case, with respect to the Acquired Assets, the CIED Business or any Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
are no Encumbrances for Taxes on any of the Acquired Assets, the Products or the CIED Business other than Permitted Encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Seller has complied in all material respects with any applicable escheat obligation in accordance with applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
nonqualified deferred compensation plan (within the meaning of Section&nbsp;409A(d)(1)&nbsp;of the Code) of any Seller that benefits any
Business Employee has been maintained in compliance with Section&nbsp;409A of the Code and all applicable IRS and Treasury Department
guidance issued hereunder in both operation and documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
amount that could be received or provided (whether in cash, securities or property or the vesting of property) as a result of any of the
transactions contemplated by this Agreement by any current or former Business Employee who is a &ldquo;disqualified individual&rdquo;
(as such term is defined in Treasury Regulation Section&nbsp;1.280G-1), under any employment, severance or termination agreement, any
compensation arrangement, or Employee Benefit Plan is or would be characterized as an &ldquo;excess parachute payment&rdquo; (as such
term is defined in Section&nbsp;280G of the Code).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Seller has an obligation to gross-up, indemnify or otherwise reimburse any current or former Business Employee for any tax incurred by
such individual, including under Section&nbsp;409A or Section&nbsp;4999 of the Code, or any interest or penalty related thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.10</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
With Laws; Permits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
the Sellers nor any of their Affiliates are in violation of any applicable Law, Order, or restriction of any Governmental Authority in
respect of the operation of the CIED Business or ownership or use of the Acquired Assets, nor have the Sellers or any of their Affiliates
been in such violation, or received any written (or, to the Sellers&rsquo; Knowledge, oral) notice of any such violation, at any time
during the past five&nbsp;(5)&nbsp;years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
the Sellers nor any of their Affiliates (i)&nbsp;have or are committing any unfair labor practice with respect to any of the Business
Employees or Business Contingent Workers, and (ii)&nbsp;have, or have had, a charge pending against the Sellers or any of their Affiliates
before any court or agency alleging unlawful discrimination in employment practices with respect to any of the Business Employees or Business
Contingent Workers, and there is no charge of or proceeding with regard to any unfair labor practice with respect to any of the Business
Employees or Business Contingent Workers, pending against the Sellers or any of their Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers are, and have at all times been in possession of, all material Permits necessary to own, lease and operate the Acquired Assets.
A true and complete list of all such Permits is set forth in <U>Section&nbsp;5.10(b)</U>&nbsp;of the Seller Disclosure Schedule, and each
such Permit is valid and in full force and effect, and accurate and complete copies of such Permits have been delivered to the Buyers.
Except as would not unreasonably be expected to result in a material Liability, neither the Sellers nor any of their Affiliates nor, to
the Sellers&rsquo; Knowledge, any Person acting on their behalf, is or has been in breach or violation of any such Permit. No suspension
or cancellation of any such Permit is pending or, to the Sellers&rsquo; Knowledge, threatened. The Sellers have not received any written
notice from any Governmental Authority alleging any actual or possible: (i)&nbsp;violation of or failure to comply with any term or requirement
of any such Permit, or (ii)&nbsp;revocation, withdrawal, suspension, cancellation, termination or material modification of any such Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.11</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Environmental
Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers are, with respect to the ownership, operation and use of the Acquired Assets, in compliance in all material respects with, and
have no material Liability arising under, any applicable Environmental Laws. The Sellers hold and are in compliance with all Environmental
Permits required for the ownership, operation and use of the Acquired Assets, each of which is set forth in <U>Section&nbsp;5.11(a)</U>&nbsp;of
the Seller Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
the Sellers nor any of their Affiliates have received any notice from any Person that a Seller is subject to any pending or, to the Sellers&rsquo;
Knowledge, threatened claim, and neither the Sellers nor any of their Affiliates are subject to any Order, (i)&nbsp;based upon any provision
of any Environmental Law and arising out of any act or omission of a Seller or any of its equityholders or Representatives or (ii)&nbsp;arising
out of the ownership, use, control or operation by a Seller or its Affiliates of any facility, site, area or property from which there
was a Release of any Hazardous Materials, in each such case relating to the ownership, operation or use of the Acquired Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers have provided to the Buyers copies of all material environmental site assessments (including any Phase I or Phase II reports)
and any other material reports in the possession of the Sellers or their Affiliates that pertain to compliance with, or Liability under,
Environmental Laws, in each case in respect of any property currently or formerly owned, leased, operated or used by the Sellers or their
Affiliates in connection with the ownership, operation or use of the Acquired Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.12</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Clinical
and Regulatory Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers are, and have been, in compliance with all Healthcare Laws applicable to the CIED Business, or by which any Acquired Asset or
Product is bound or affected. The research, design, development, manufacture, processing, packaging, labeling, testing, storage, distribution,
import, export or sale of each Product by or on behalf of any Seller is being, and has been, conducted in compliance with all applicable
Healthcare Laws, including good laboratory practices, good clinical practices, good manufacturing practices and, to the extent applicable
to any Seller, Acquired Asset or Product, similar Laws in the European Union, and all other countries where compliance is required. Each
Seller is, and to the Sellers&rsquo; Knowledge, any suppliers or contract manufacturers of the Products are, and at all times have been,
in compliance with registration and listing requirements to the extent required by applicable Healthcare Laws, and the Products, if so
required, are in conformance in all material respects with all applicable CE Marking certifications and declarations of conformity. No
Seller, nor any shareholder, member, manager, officer, director, employee, agent, independent contractor of a Seller nor any person or
entity acting on behalf of a Seller, has received any communication or notification of any pending or threatened Action from any Governmental
Authority, including the FDA, the Centers for Medicare&nbsp;&amp; Medicaid Services, the U.S.&nbsp;Department of Health and Human Services
Office of Inspector General, any Notified Body, or any comparable state, federal or foreign Governmental Authority alleging potential
or actual non-compliance by, or Liability of, such Seller in connection with any Acquired Asset or Product under any Healthcare Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers hold all Permits required to permit the research, design, development, manufacture, processing, packaging, labeling, testing,
storage, distribution, import, export or sale of the Products in jurisdictions where any Seller currently conducts such activities (the
 &ldquo;<U>Activities to Date</U>&rdquo;) with respect to each Product (collectively, the &ldquo;<U>Seller Licenses</U>&rdquo;). The Sellers
have fulfilled and performed all of their material obligations with respect to the Seller Licenses and are in compliance in all material
respects with all terms and conditions of the Seller Licenses, and no event has occurred which allows, or after notice or lapse of time
would allow, revocation, termination or material modification thereof or results in any other impairment of the rights of the holder of
the Seller Licenses. No Seller has received any information or notification from the FDA or any similar Governmental Authority with jurisdiction
over the research, design, development, manufacture, processing, packaging, labeling, testing, storage, distribution, import or export
of Acquired Assets, Products or Business activities which would reasonably be expected to lead to the denial of any application for clinical
research or marketing authorization, approval or clearance currently planned or pending before the FDA or any other similar Governmental
Authority. To the extent that any Product is imported to or exported from the United States, the import to or export of the Product by
or on behalf of any Seller or its Affiliates complies in all material respects with applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
filings, reports, documents, claims, submissions and notices required to be filed, maintained, or furnished to the FDA or any state, other
federal or non-United States equivalent agencies by the Sellers have been so filed, maintained or furnished and were complete and correct
in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing), including adverse event reports
and medical device reports, in each case with regard to the Products or Acquired Assets. <U>Section&nbsp;5.12(c)</U>&nbsp;of the Seller
Disclosure Schedule&nbsp;sets forth a list of all adverse event reports related to the Products, including any medical device reports
required in accordance with 21 CFR Part&nbsp;803. Set forth in <U>Section&nbsp;5.12(c)</U>&nbsp;of the Seller Disclosure Schedule&nbsp;are
complaint review and analysis reports of the Sellers through the date hereof, including information regarding complaints by product, root
cause analysis of closed complaints and identification of any file numbers for associated CAPA Documentation, which listing and reports
are complete and correct in all material respects. All applications, notifications, submissions, information, claims, reports, and filings
utilized as the basis for or submitted in connection with any and all requests for the Seller Licenses from the FDA or similar Governmental
Authority relating to any Product or Acquired Assets, when submitted to the FDA or any similar Governmental Authority, were true, accurate
and complete as of the date of submission. Any necessary or required updates, changes, corrections or modifications to such applications,
notifications, submissions, information, claims, reports, filings, and other data have been submitted to the FDA or similar Governmental
Authority and as so updated, changed, corrected or modified remain true, accurate and complete, and do not materially misstate any of
the statements or information included therein, or omit to state a material fact necessary to make the statements therein not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
manufacturing site owned or operated by Sellers, or to the Sellers&rsquo; Knowledge, that of a supplier or contract manufacturer of the
Products, with respect to any Product, has been subject to a Governmental Authority (including FDA) shutdown, adverse regulatory action,
detention, seizure or import or export restriction or prohibition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.12(e)</U>&nbsp;of the Seller Disclosure Schedule, there have been no recalls (either voluntary or involuntary),
removals, field notifications, field corrections, field alerts, market withdrawals or replacements, warnings, &ldquo;dear doctor&rdquo;
letters, investigator notices, safety alerts or other notices of action relating to an alleged lack of quality, safety, efficacy, or regulatory
compliance of any Product or Acquired Assets, or seizures ordered or adverse regulatory actions taken (or threatened) by the FDA or any
similar Governmental Authority with respect to any of the Products or any facilities involved in the research, design, development, manufacture,
processing, packaging, labeling, testing, storage, distribution, import, export or sale of any such Products or facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
nonclinical, preclinical and clinical trials that have been or are being conducted by or on behalf of, or sponsored by, a Seller or in
which such Seller has participated, in each case to the extent relating to any Products or Acquired Assets, were and, if still pending,
are being or have been conducted in compliance in all material respects with standard medical and scientific research procedures and the
experimental protocols, procedures and controls pursuant to applicable Healthcare Laws, including the FDCA and its applicable implementing
regulations at 21 C.F.R. Parts 11, 50, 54, 56, 58, 312, 812, and 1271, the Medical Device Directives, and all applicable EEA Member State
Laws governing performance evaluations and clinical trials with medical devices. No Seller has received any notices, correspondence or
other communication from the FDA or any similar Governmental Authority requiring the termination, suspension or material modification
of any nonclinical or preclinical studies or clinical trials conducted by or on behalf of a Seller or in which a Seller has participated,
in each case to the extent relating to any Products or Acquired Assets, and there is no reason to believe that the FDA or any similar
Governmental Authority is considering such action. <U>Section&nbsp;5.12(f)</U>&nbsp;of the Seller Disclosure Schedule&nbsp;lists all material
observations identified during any preclinical or clinical site evaluations for the Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers have delivered to the Buyers true, correct and complete copies of all written communications with FDA and any similar Governmental
Authority regarding the Products in any jurisdiction where any Product is sold or any Acquired Assets are licensed or permitted, as well
as correct and complete written summaries of all material oral communications between any Seller or its Representatives, on the one hand,
and any Governmental Authority in any jurisdiction or its respective employees, agents or representatives, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Seller is the subject of any pending or threatened investigation regarding the Products or the Acquired Assets by the FDA pursuant to
its &ldquo;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&rdquo; Final Policy set forth in 56 Fed.&nbsp;Reg.
46,191 (September&nbsp;10, 1991) and any amendments thereto (&ldquo;<U>FDA Fraud Policy</U>&rdquo;), or any similar policy of a Governmental
Authority. None of the Sellers, nor, any officer, employee, agent or distributor of the Sellers has made an untrue statement of material
fact to the FDA or any similar Governmental Authority, failed to disclose a material fact required to be disclosed to the FDA or any similar
Governmental Authority, or committed an act, made a statement or failed to make a statement that, at the time such disclosure was made,
would reasonably be expected to provide a basis for the FDA or any similar Governmental Authority to invoke the FDA Fraud Policy or any
similar policy. No Seller, nor any of their shareholders, members, managers, officers, directors, agents, distributors, employees or independent
contractors, have been (i)&nbsp;excluded from participation in any Government Healthcare Programs pursuant to 42 U.S.C. &sect; 1320a-7
or related Laws, (ii)&nbsp;suspended, debarred, or otherwise ineligible to contract with or sell to the United States government or any
of its agencies under the Federal Acquisition Regulation or other applicable Laws; (iii)&nbsp;listed on the U.S. General Services Administration&rsquo;s
System for Award Management list of excluded or debarred parties; or (iv)&nbsp;engaged in conduct resulting in or convicted of any offense
that would reasonably be expected to serve as a basis for disqualification or any other restriction from participation in research, suspension,
exclusion or debarment under 21 U.S.C. &sect; 335a or any similar authority. No such disqualification, research limitation, suspension,
exclusion, debarment or similar ineligibility is currently pending or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Seller maintains a healthcare compliance program that is reasonably designed to ensure compliance with applicable Healthcare Laws and
is consistent in all material respects with the U.S. Department of Health and Human Services Office of Inspector General&rsquo;s Compliance
Program Guidance and relevant industry codes of ethics, including the AdvaMed Code of Ethics on Interactions with Health Care Professionals.
Each Seller has timely made all reports, submissions, and disclosures required under the Physician Payments Sunshine Act (42 U.S.C. &sect;
1320a-7h), and all such reports, submissions, and disclosures were true, complete, and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the Sellers&rsquo; Knowledge, there have been no allegations of or investigations into research misconduct (i.e., falsification or fabrication
of data or plagiarism) with respect to any preclinical or nonclinical research giving rise to the development of the Products, or any
clinical investigation or clinical trial involving the Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers are currently in compliance in all material respects with, and have at all times, complied in all material respects with HIPAA.
Except for those incidents disclosed in <U>Section&nbsp;5.12(k)</U>&nbsp;of the Seller Disclosure Schedule, the Sellers have not suffered
any Breach of Unsecured Protected Health Information or Security Incident (as such terms are defined at 45 C.F.R. &sect; 164.402). There
have not been any actual or alleged incidents of, or claims or actions related to, data security breaches, unauthorized access or use
of any of any of the Sellers information technology systems, or unauthorized acquisition, destruction, damage, disclosure, loss, corruption,
alteration or use of any Protected Health Information provided by the Sellers&rsquo; customers whether held by the Sellers or their subcontractors,
and there are no facts or circumstances which could reasonably serve as the basis for any such allegations or claims. The Sellers, have
not received any correspondence relating to, or notice of any actions, claims, investigations or alleged violations of, laws with respect
to Protected Health Information from any person, there is no such ongoing action, claim, investigation or allegation, and there are no
facts or circumstances which could form the basis for any such action, claim, investigation or allegation. Each Seller has taken commercially
reasonable steps, to the extent required by HIPAA, such that Protected Health Information is protected against unauthorized access, use,
modification or disclosure. The Sellers are and have been at all times in the past six years in compliance in all material respects with
all applicable contractual privacy obligations relating to the collection, storage, use and transfer of Protected Health Information.
The Sellers, as applicable, have entered into &ldquo;business associate agreements&rdquo; with all Covered Entities and Business Associates
as required by HIPAA, and all such agreements are in the form required by HIPAA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Section&nbsp;5.12(l)</U>&nbsp;of
the Seller Disclosure Schedule lists all (i)&nbsp;clinical trial or study agreements and (ii)&nbsp;vendor agreements, in each case, relating
to ongoing clinical trials or studies relating to the CIED Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Section&nbsp;5.12(m)</U>&nbsp;of
the Seller Disclosure Schedule lists all clinical trial or study agreements that remain in effect relating to completed clinical trials
or studies relating to the CIED Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(n)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
vendor contracts relating to the quality systems of the CIED Business constitute Ongoing Vendor Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.13</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Brokers;
Expenses</U>. Except as set forth in <U>Section&nbsp;5.13</U> of the Seller Disclosure Schedule, no finder, broker, agent or other intermediary
has acted for or on behalf of any Seller or its shareholders in connection with the negotiation of this Agreement or the other Transaction
Documents or the consummation of the transactions contemplated hereby or thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.14</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consents</U>.
Except as set forth in <U>Section&nbsp;5.14</U> of the Seller Disclosure Schedule, no permit, approval, authorization or consent of any
Person (excluding governmental authorities) is required in connection with the execution, delivery and performance by the Sellers of this
Agreement or the other Transaction Documents, or the consummation of the transactions contemplated hereby or thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.15</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Manufacturing
and Marketing Rights</U>. No Seller has granted rights to research, design, develop, manufacture, process, package, label, test, store,
distribute, import, export or sell any Product to any other Person and is not bound by any contract that affects the Sellers&rsquo; exclusive
right to research, design, develop, manufacture, process, package, label, test, store, distribute, import, export or sell any Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.16</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Government
Grants and Incentives</U>. Except as set forth in <U>Section&nbsp;5.16</U> of the Seller Disclosure Schedule, no Seller has at any time
applied for or received any grants, incentives, benefits, qualifications and subsidies from any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.17</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Personal
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Acquired Assets (other than Seller Intellectual Property which is covered by <U>Section&nbsp;5.5</U> hereof) belong to or may be lawfully
used by any Seller, free and clear of any Encumbrance (other than Permitted Encumbrances) or expiration of term of such use, and no Affiliate
of any Seller (other than another Seller) owns, leases, controls or holds a license to any Acquired Asset. The Acquired Assets taken as
a whole are sufficient to develop, sell, manufacture, distribute and market the Products and conduct the CIED Business after the Closing
Date in substantially the same manner as it is currently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
has been no termination of, or threat to terminate, the right of any Seller to use or possess any of its assets, whether tangible or intangible,
that are necessary to make, have made, use and sell the Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
Acquired Equipment and Tools at a location other than the property described in the Assumed Lease Contracts are set forth on <U>Section&nbsp;5.17(c)</U>&nbsp;of
the Seller Disclosure Schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.18</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Privacy
and Data Security</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers comply and have at all times complied in all respects with: (i)&nbsp;all applicable Privacy Laws; (ii)&nbsp;each Seller&rsquo;s
policies, statements, and contractual obligations relating to the receipt, collection, compilation, use, storage, processing, sharing,
safeguarding, security, disposal, destruction, disclosure, or transfer of Personal Information; and (iii)&nbsp;all applicable industry
standards including, without limitation, the Payment Card Industry Data Security Standard and all other applicable requirements of the
payment card brands ((i)-(iii)&nbsp;collectively, the &ldquo;<U>Privacy Requirements</U>&rdquo;). The Sellers display a privacy policy
on each website and mobile application owned, controlled or operated by the Sellers, and each such privacy policy incorporates all disclosures
to data subjects required by the Privacy Laws. None of the disclosures made or contained in any such privacy policy has been misleading,
deceptive, or in violation of the Privacy Laws (including containing any material omission).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers have taken all organizational, physical, administrative, and technical measures required by Privacy Requirements and consistent
with standards prudent in the industry in which the Sellers operate to protect: (i)&nbsp;the integrity, security, and operations of all
Seller IT Assets; and (ii)&nbsp;all Personal Information and all other data owned, controlled, or stored by the Sellers from and against
data security incidents or other misuse. The Sellers have implemented reasonable procedures, satisfying the requirements of applicable
Privacy Requirements, to detect data security incidents and to protect Personal Information against loss and against unauthorized access,
use, modification, disclosure, or other misuse.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers have: (i)&nbsp;reasonable measures to monitor and detect security incidents related to the Seller IT Assets (collectively, &ldquo;<U>Information
Security Measures</U>&rdquo;); (ii)&nbsp;timely corrected any material exceptions or vulnerabilities identified in such Information Security
Measures; (iii)&nbsp;made available true and accurate copies of all Information Security Measures; and (iv)&nbsp;timely installed software
security patches and other fixes to identified technical information security vulnerabilities. The Sellers provide their employees with
regular training on privacy and data security matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Seller IT Assets are adequate for, and operate and perform in all material respects in accordance with their documentation and functional
specifications and otherwise as required in connection with, the operation of the business of the Sellers as previously conducted and
as currently conducted. The Seller IT Assets have not malfunctioned or failed at any time since the Sellers' inception in a manner that
resulted in significant or chronic disruptions to the operation of the Sellers' business. The Sellers IT Assets do not contain any computer
code designed to disrupt, disable or harm in any manner the operation of any software or hardware. None of the Sellers IT Assets contain
any unauthorized feature (including any worm, bomb, backdoor, clock, timer or other disabling device, code, design or routine) that causes
the software or any portion thereof to be erased, inoperable or otherwise incapable of being used, either automatically, with the passage
of time, or upon command by any Person. The Sellers have implemented and complied with appropriate backup, security and disaster recovery
technology consistent with industry practices, and, no Person has gained unauthorized access to any of the Sellers IT Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
connection with each third-party servicing, outsourcing, processing, or otherwise using Personal Information collected, held, or processed
by or on behalf of the Sellers, the Sellers have in accordance with Privacy Laws entered into valid, binding and enforceable written data
processing agreements with any such third party to: (i)&nbsp;comply with applicable Privacy Laws with respect to Personal Information;
(ii)&nbsp;act only in accordance with the instructions of the Sellers; (iii)&nbsp;take appropriate steps to protect and secure Personal
Information from data security incidents; (iv)&nbsp;restrict use of Personal Information to those authorized or required under the servicing,
outsourcing, processing, or similar arrangement; and (v)&nbsp;certify or guarantee the return or adequate disposal or destruction of Personal
Information. The Sellers have disclosed all such data processing agreements to which they are parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;There
have been no data security incidents, personal data breaches, ransomware incidents, or other adverse events or incidents related to any
Seller IT Assets, Personal Information, or Sellers data in the custody or control of the Sellers or any service provider acting on behalf
of the Sellers; and (ii)&nbsp;no breach or violation of the security of any of Sellers IT Assets has occurred or is threatened in writing,
and there has been no unauthorized or illegal use of, or access to, any Personal Information. The Sellers have a data breach response
plan which has been tested on at least an annual basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
consummation of any of the transactions contemplated hereby, including the transfer of Personal Information to the Buyers, will not violate
any applicable Privacy Requirements as they currently exist or as they existed at any time during which any of the Personal Information
was collected or obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers have not supplied or provided access to Personal Information processed by them to a third party for remuneration or other consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;There
have not been any claims or proceedings related to any data security incidents, ransomware incidents, or any violations of any Privacy
Requirements, and there are no facts or circumstances which could reasonably serve as the basis for any such allegations or claims. The
Sellers have not received any correspondence relating to, or notice of any proceedings, claims, investigations or alleged violations of,
Privacy Requirements, or any subject access or other individual rights requests made pursuant to the Privacy Requirements, with respect
to Personal Information from any person or governmental authority, and there is no such ongoing proceeding, claim, investigation or allegation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.19</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Business Practices</U>. No Seller nor any of their respective directors, officers, managers, members or employees (in their capacity as
directors, officers, managers, members or employees) has: (a)&nbsp;used any funds for unlawful contributions, gifts, entertainment or
other unlawful expenses relating to political activity in respect of the CIED Business; (b)&nbsp;directly or indirectly, paid or delivered
any fee, commission or other sum of money or item of property, however characterized, to any finder, agent, or other party acting on behalf
of or under the auspices of a governmental official or Governmental Authority which is in any manner illegal under any Laws of the United
States or any other country having jurisdiction; or (c)&nbsp;made any payment to any customer or supplier of the Sellers, or given any
other consideration to any such customer or supplier in respect of the CIED Business that violates applicable Law in any material respect.
Without limiting the foregoing, none of the Sellers (including any of their respective officers, directors, managers, members, agents,
employees or other Persons associated with or acting on its behalf) have, directly or indirectly, taken any action which would cause it
to be in violation of the U.S.&nbsp;Foreign Corrupt Practices Act, as amended, or any rules&nbsp;or regulations thereunder, including
by offering or conveying, directly or indirectly (such as through an agent), anything of value to obtain or retain business or to obtain
any improper advantage, including any bribe, rebate, payoff, influence payment, kickback or other similar unlawful payment to a foreign
government official, candidate for office, or political party or official of a political party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.20</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Products
Liability</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
claim has been made or threatened in connection with the product liability of any Product and no Governmental Authority has commenced
or threatened to initiate any Action or requested the recall (either voluntary or involuntary), removal, field notification, field correction,
field alert, market withdrawal or replacement, warning, &ldquo;dear doctor&rdquo; letter, investigator notice, safety alert or other notice
of action of any Product, or commenced or threatened to initiate any Action or referenced activity to enjoin the production of any Product,
and there is no basis for any such claim, Action or referenced activity, nor any reason to believe that any Governmental Authority is
considering the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Products supplied by the Sellers have complied with all Laws and with all government, trade association and other mandatory and voluntary
requirements, specifications and other forms of guidance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Product researched, designed, developed, manufactured, processed, packaged, labeled, tested, stored, distributed, imported, exported or
sold by the Sellers prior to the Closing contained or will contain any quality, design, engineering, manufacturing or safety defect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.21</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Changes</U>. Except as set forth in <U>Section&nbsp;5.21</U> of the Seller Disclosure Schedule, since December&nbsp;31, 2023: (a)&nbsp;there
has been no Seller Material Adverse Effect; (b)&nbsp;each Seller has conducted the CIED Business in the ordinary course of business; and
(c)&nbsp;there has not been any material loss, damage or destruction to, or any material interruption in the use of, any of the Acquired
Assets (whether or not covered by insurance), other than ordinary wear and tear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.22</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Related-Party
Transactions</U>. Except as set forth in <U>Section&nbsp;5.22</U> of the Seller Disclosure Schedule, (a)&nbsp;no Affiliate, employee,
officer, director or consultant of or to any Seller (i)&nbsp;owns or has any interest in any property or asset of any type or description
that is included in the Acquired Assets, or (ii)&nbsp;is a party to any contract with any Seller by which any of the Acquired Assets are
bound; and (b)&nbsp;no Affiliate of any Seller (other than another Seller) performs any services for or on behalf of a Seller in connection
with any of the Acquired Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.23</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Insurance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Section&nbsp;5.23(a)</U>&nbsp;of
the Seller Disclosure Schedule&nbsp;sets forth a true and complete list of all insurance policies under which the Sellers have been an
insured relating to any Acquired Asset, the named insured or otherwise the principal beneficiary of coverage at any time within the past
three&nbsp;(3)&nbsp;years showing each of the following: (i)&nbsp;the names of the insurer, the principal insured and each named insured;
(ii)&nbsp;the policy number; (iii)&nbsp;the period and amount of coverage; and (iv)&nbsp;a current, complete and accurate list of all
insurance claims notified during the three (3)&nbsp;years preceding the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 262.5pt">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;With
respect to such insurance policies: (i)&nbsp;each policy is legal, valid, binding and, subject to the Enforceability Exceptions, is enforceable
in accordance with its terms and, except for policies that have expired under their terms in the ordinary course, is in full force and
effect; and (ii)&nbsp;no Seller is in material breach or default (including any such breach or default with respect to the payment of
premiums or the giving of notice), and to the Sellers&rsquo; Knowledge, no event has occurred which, with notice or the lapse of time,
would constitute such a breach or default, or permit termination or modification, under such policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the Sellers&rsquo; Knowledge, there has been no circumstance or breach of any terms, conditions, or warranties under any such insurance
policies that would entitle the applicable insurers to decline to pay all or any part of any material claim made under such policies.
Each Seller has paid all premiums when due and have otherwise performed all of its respective obligations under all such insurance policies.
No insurer has threatened in writing to terminate any such insurance policies, to reduce the scope of the insurance thereunder or to materially
increase the premiums owed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.24</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Financial
Statements</U>. Attached as <U>Section&nbsp;5.24</U> of the Seller Disclosure Schedule&nbsp;are financial statements setting forth (a)&nbsp;revenues
and cost of goods sold of the CIED Business for the years ended December&nbsp;31, 2022, December&nbsp;31, 2023 and December&nbsp;31, 2024,
and for the six months ended June&nbsp;30, 2025 and (b)&nbsp;accounts receivable, inventory, prepaid expenses, deposits and property and
equipment of the CIED Business as of December&nbsp;31, 2022, December&nbsp;31, 2023, December&nbsp;31, 2024 and June&nbsp;30, 2025 (collectively,
the &ldquo;<U>Financial Statements</U>&rdquo;). The Financial Statements are complete and correct in all material respects and have been
prepared in accordance with GAAP, applied on a basis consistent with prior periods, except that the unaudited financial statements do
not contain footnotes. The Financial Statements fairly and accurately present the financial condition of the CIED Business on a consolidated
basis as of the dates and during the periods indicated therein, subject, in the case of the unaudited financial statements, to normal
year-end adjustments which are neither individually nor in the aggregate material in amount. The Financial Statements were prepared in
accordance with the books of account and other financial records of the Sellers, which books of account and other financial records are
accurate, complete and current.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.25</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Inventory</U>.
Subject to the applicable reserves therefor set forth in the Sellers&rsquo; books, records or financial statements, substantially all
of the Inventories included in the Acquired Assets are in good and marketable condition, and are saleable in the ordinary course of business
consistent with past practices, except for obsolete, excess, damaged, slow-moving or otherwise unusable inventory, which to the extent
existing at the date thereof, have been written off or written down in the Sellers&rsquo; books, records and financial statements in a
manner consistent with past practice and in accordance with GAAP consistently applied. Since January&nbsp;1, 2022, the Sellers have not
engaged in channel stuffing, sales of the Product on terms or at prices or quantities outside the ordinary course of business or other
practices not in the ordinary course of business that have, absent bona fide customer demand, materially increased levels of the Products
maintained at the wholesale, chain or institutional levels as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.26</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Customers
and Suppliers</U>. <U>Section&nbsp;5.26</U> of the Seller Disclosure Schedule&nbsp;lists (i)&nbsp;group purchasing organizations (&ldquo;<U>GPOs</U>&rdquo;)
with whom Sellers have an active Contract; (ii)&nbsp;the twenty (20) largest customers (measured by invoiced dollars) with respect to
the Acquired Assets for the fiscal years ended December&nbsp;31, 2023, and December&nbsp;31, 2024 and the six-month period ended June&nbsp;30,
2025, respectively (the &ldquo;<U>Major Customers</U>&rdquo;) and (iii)&nbsp;the ten (10)&nbsp;largest suppliers (measured by invoiced
dollars) with respect to the Acquired Assets for the fiscal years ended December&nbsp;31, 2023, and December&nbsp;31, 2024 and the six-month
period ended June&nbsp;30, 2025, respectively (the &ldquo;<U>Major Suppliers</U>&rdquo;) and, in each case, the dollar amount of business
conducted with each Major Customer and Major Supplier in such year and such six-month period. The Sellers are not engaged in any dispute
with any Major Customer or Major Supplier, the Sellers are not in breach of or in default of any agreement with any of the Major Customers
or Major Suppliers, no Major Customer or Major Supplier intends to cancel or otherwise substantially modify its relationship with the
Sellers or to decrease materially or limit its services, supplies or materials to the Sellers or its usage or purchase of the Products,
and to the Sellers&rsquo; Knowledge, the consummation of the transactions contemplated hereby will not adversely affect the relationship
of any Buyer with any GPO, Major Customer or Major Supplier. To the Sellers&rsquo; Knowledge, there are no Pre-Closing Claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.27</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Sanctions;
Anti-Corruption</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Seller, or any of their respective Affiliates, or any director (or equivalent) or officer of a Seller or any of its Affiliates, nor, to
the Sellers&rsquo; Knowledge, any employee or agent of any Seller or any of its Affiliates, in the past five years (i)&nbsp;is or has
been a Sanctioned Person or, (ii)&nbsp;is or has engaged in any dealings or transactions with any Sanctioned Person or Sanctioned Country,
or (iii)&nbsp;has otherwise violated Sanctions or Ex-Im Laws, or (iv)&nbsp;has made a disclosure to or received any notice from a Governmental
Authority related to actual or potential noncompliance with Sanctions or the Ex-Im Laws whether a voluntary disclosure, directed disclosure
or in response to a subpoena or other request from a Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;No
Seller nor any of its Affiliates is violating or at any time has violated any applicable Law relating to anti-bribery or anti-corruption,
including the U.S. Foreign Corrupt Practices Act of 1977, as amended and the U.K. Bribery Act 2010, in each case, as in effect at the
time of such action (all such Laws, &ldquo;<U>Anti-Corruption Laws</U>&rdquo;) or Ex-Im Law, or (ii)&nbsp;no current or former director,
member, manager, officer, employee, agent, representative, consultant or other Person acting for or on behalf of any Seller or any of
its Affiliates (each a &ldquo;<U>Seller Representative</U>&rdquo;) is violating or at any time has violated any Anti-Corruption Law. Through
the date hereof, no Seller, nor any of its Affiliates, nor their respective Seller Representatives have been the subject of any actual,
suspected, or threatened allegations, investigations (internal or government), litigation, voluntary or directed disclosures to any Governmental
Authority (including the U.S. Department of Justice, U.S. Securities Exchange Commission, or U.K. Securities Fraud Office), whistleblower
reports, or other issues in any way related to Anti-Corruption Laws. Nor has any Seller, nor any of its Affiliates, nor any Seller Representative
corruptly offered, paid, promised to pay, authorized, solicited, or received the payment of money or anything of value, directly or indirectly,
to or from any Person, including any Government Official: (a)&nbsp;to influence any official act or decision of a Government Official;
(b)&nbsp;to induce a Government Official to do or omit to do any act in violation of a lawful duty; (c)&nbsp;to induce a Government Official
to influence the act or decision of a Governmental Authority; (d)&nbsp;to secure any improper business advantage; (e)&nbsp;to obtain or
retain business in any way related to any Seller or any of its Affiliates; or (f)&nbsp;that would otherwise constitute a bribe, kickback,
or other improper or illegal payment or benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Seller and its Affiliates have instituted policies and procedures designed to ensure compliance with the Anti-Corruption Law, Sanctions
and Ex-Im Law applicable to such entities, their respective businesses, and Seller Representatives, and have maintained such policies
and procedures in full force and effect for the past five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Seller and its Affiliates have provided anti-corruption training and guidance to all relevant Seller Representatives, and have informed
these Seller Representatives of their obligations under the Anti-Corruption Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
all times during the past five years, each Seller and its Affiliates have made and kept books, records, and accounts which, in reasonable
detail, accurately and fairly reflect the transactions and disposition of the assets of such Seller and its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;At
all times during the past five years, each Seller and its Affiliates have devised and maintained a system of internal accounting controls
sufficient to provide reasonable assurances that transactions are executed and access to assets is given only in accordance with management&rsquo;s
general or specific authorization, and transactions are recorded as necessary to permit preparation of financial statements to maintain
accountability for assets and accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section&nbsp;5.28</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Employees</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Section&nbsp;5.28(a)</U>&nbsp;of
the Seller Disclosure Schedule contains a complete and accurate list of all employees of the Sellers related to the CIED Business (&ldquo;<U>Business
Employees</U>&rdquo;) as of the date of this Agreement, setting forth for each Business Employee: (i)&nbsp;the employee&rsquo;s position
or title; (ii)&nbsp;whether classified as exempt or non-exempt for wage and hour purposes; (iii)&nbsp;whether paid on a salary, hourly
or commission basis and the employee&rsquo;s actual annual base salary or other rates of compensation; (iv)&nbsp;bonus potential for the
current year (and bonus paid for the previous year); (v)&nbsp;average scheduled hours per week; (vi)&nbsp;date of hire; (vii)&nbsp;business
location (city/town and state); (viii)&nbsp;employing entity; (ix)&nbsp;vacation and other paid time off eligibility for the current calendar
year (including current balance of accrued but unused vacation or other paid time off, and current accrual rate); (x)&nbsp;status (i.e.,
active or inactive and if inactive, the type of leave and estimated duration); (xi)&nbsp;any visa or work permit status and the date of
expiration, if applicable; and (xii)&nbsp;the total amount of bonus, retention, severance and other amounts to be paid to such employee
at the Closing Date or otherwise in connection with the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Section&nbsp;5.28(b)</U>&nbsp;of
the Seller Disclosure Schedule contains a complete and accurate list of all of the independent contractors, consultants, temporary employees,
leased employees or other agents currently employed or used by the Sellers, in each case related to the CIED Business, and classified
by any Seller as other than employees, or compensated other than through wages paid by any Seller through any Seller&rsquo;s payroll other
than Distributors (&ldquo;<U>Business Contingent Workers</U>&rdquo;), showing for each Business Contingent Worker such individual&rsquo;s
(i)&nbsp;role in the CIED Business, (ii)&nbsp;location (city/town and state), (iii)&nbsp;average hours worked per week or month, and (iv)&nbsp;fee
or compensation arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Seller is a government contractor or subcontractor for purposes of any law with respect to the terms and conditions of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Seller currently classifies and has properly classified each of its Business Employees as exempt or non-exempt for the purposes of the
Fair Labor Standards Act and state and local wage and hour laws, and is and has been otherwise in compliance with such laws. To the extent
that any Business Contingent Workers are or were engaged by any of the Sellers, the Seller currently classifies and has properly classified
and treated them as contingent workers (as distinguished from Form&nbsp;W-2 employees) in accordance with applicable law and for the purpose
of all employee benefit plans and perquisites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Seller is, and for the past three (3)&nbsp;years has been, in material compliance with all applicable laws and regulations respecting
labor and employment matters, including fair employment practices, harassment, discrimination, pay equity and pay transparency, restrictive
covenants, the classification of independent contractors and employees, workplace safety and health, work authorization and immigration,
unemployment compensation, workers&rsquo; compensation, affirmative action, terms and conditions of employment, employee leave and wages
and hours, including payment of minimum wages, meals and rest breaks, and overtime.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.28(f)</U>&nbsp;of the Seller Disclosure Schedule, no Seller is delinquent in any payments to any Business
Employee or Business Contingent Worker for any wages, salaries, commissions, bonuses, fees or other direct compensation due with respect
to any services performed for it or amounts required to be reimbursed to such Business Employees or Business Contingent Workers. Neither
Seller is liable for any employment taxes or any payment to any trust or other fund governed by or maintained by or on behalf of any Governmental
Authority with respect to unemployment compensation benefits, social security or other benefits or obligations for Business Employees
(other than routine payments to be made in the normal course of business and consistent with past practice).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.28(g)</U>&nbsp;of the Seller Disclosure Schedule, neither Seller is nor has been within the past three
(3)&nbsp;years, involved in any litigation, governmental audit, governmental investigation or administrative agency proceeding, private
dispute resolution proceeding, or internal or external investigation, in each case with respect to employment or labor matters in connection
with or relating to the CIED Business, Business Employees or Business Contingent Workers (including allegations of employment discrimination,
retaliation, noncompliance with wage and hour laws, the misclassification of independent contractors, violation of restrictive covenants,
sexual harassment, other unlawful harassment or unfair labor practices). At no time in the past three (3)&nbsp;years have any allegations
involving a Business Employee, Business Contingent Worker, or director or officer of the Company been made to any Seller alleging sexual
harassment or sexual misconduct, nor has any Seller received a complaint or conducted an investigation, or otherwise become aware of allegations
of sexual harassment or sexual misconduct relating to or involving any Business Employee, Business Contingent Worker, or director or officer
of the Sellers. To the Sellers&rsquo; Knowledge, there are no facts that could reasonably be expected to give rise to a claim of sexual
harassment or other unlawful harassment or unlawful discrimination or retaliation against or involving any Business Employee, Business
Contingent Worker, or director or officer of the Sellers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.28(h)</U>&nbsp;of the Seller Disclosure Schedule, all Business Employees are employed at-will and no
Business Employee is subject to any employment contract with any of the Sellers, whether oral or written. No Business Employee or Business
Contingent Worker is eligible to earn commission, incentive compensation, or other post-employment or post-engagement compensation payments
after the end of their employment or engagement with any Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.28(i)</U>&nbsp;of the Seller Disclosure Schedule<U>,</U> the consummation of the transactions contemplated
in this Agreement will not (i)&nbsp;entitle any Business Employee to severance pay, unemployment compensation, bonus payment or any other
payment, (ii)&nbsp;accelerate the time of payment for vesting of, or increase the amount of compensation due to, any such Business Employee,
or (iii)&nbsp;entitle any such Business Employee to terminate, shorten or otherwise change the terms of their employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.28(j)</U>&nbsp;of the Seller Disclosure Schedule, (i)&nbsp;there is no, and within the past three (3)&nbsp;years
there has not been, any labor strike, picketing of any nature, organizational campaigns, labor dispute, slowdown or any other concerted
interference with normal operations, stoppage&nbsp;or lockout pending or, to the Sellers&rsquo; Knowledge, threatened against or affecting
the CIED Business; (ii)&nbsp;each Seller does not have any duty to bargain with any union or labor organization or other person purporting
to act as exclusive bargaining representative (&ldquo;<U>Union</U>&rdquo;) of any Business Employees or Business Contingent Workers with
respect to the wages, hours or other terms and conditions of employment of any Business Employee or Business Contingent Worker; (iii)&nbsp;there
is no collective bargaining agreement or other contract with any Union, or work rules&nbsp;or practices agreed to with any Union, binding
on any Seller, or being negotiated, with respect to any Sellers&rsquo; operations or any Business Employee or Business Contingent Worker;
and (iv)&nbsp;no Seller has engaged in any unfair labor practice with respect to the Business or any Business Employee or Business Contingent
Worker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Section&nbsp;5.28(k)</U>&nbsp;of
the Seller Disclosure Schedule identifies each Business Employee and Business Contingent Worker who is subject to a non-competition, non-solicitation,
confidentiality or invention assignment agreement with any Seller and includes a form of each such agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as set forth in <U>Section&nbsp;5.28(l)</U>&nbsp;of the Seller Disclosure Schedule, in the past twelve (12) months (i)&nbsp;no officer,
management-level or key Business Employee&rsquo;s employment has been terminated for any reason; and (ii)&nbsp;to the Knowledge of the
Sellers, no officer, management-level or key Business Employee, or group of more than ten (10)&nbsp;Business Employees or Business Contingent
Workers, has expressed any plans to terminate his, her or its employment or service arrangement with any Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Seller has experienced a &ldquo;plant closing&rdquo; or &ldquo;mass layoff&rdquo; or similar group employment loss as defined in the WARN
Act or any similar state, local or foreign law or regulation affecting any site of employment of such Seller or one or more facilities
or operating units within any site of employment or facility of such Seller, in each case, with respect to the CIED Business. During the
ninety (90) day period preceding the date hereof, no Business Employee or Business Contingent Worker has suffered an &ldquo;employment
loss&rdquo; as defined in the WARN Act with respect to any Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.29</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Solvency</U>.
Each Seller is a going concern and is able to pay its debts and obligations as they become due in the ordinary course of business. The
fair value of the property of each Seller, not including the Acquired Assets and taking into account the transactions contemplated by
this Agreement, is greater than the amount of each Seller&rsquo;s Liabilities as such value is established and Liabilities evaluated for
purposes of Section&nbsp;101(32) of the United States Bankruptcy Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.30</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Disclosure</U>.
Each Seller has provided the Buyers with all information that any Buyer has requested for deciding whether to execute this Agreement and
all information that such Seller believes is reasonably necessary to enable the Buyers to make such decision. Neither this Agreement (including
all the exhibits and schedules hereto), the other Transaction Documents nor any other statements or certificates made or delivered in
connection herewith contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements
herein or therein not misleading in light of the circumstances under which they were made. Except as set forth in this Agreement, to the
Sellers&rsquo; Knowledge, there is no fact that the Sellers have not disclosed to the Buyers and of which any of the Buyers&rsquo; officers,
directors, members, manager or executive employees is aware and that has had or could reasonably be expected to have a Seller Material
Adverse Effect or a material adverse effect on the ability of the Buyers to purchase the Acquired Assets, operate the CIED Business or
manufacture, market or sell any Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;5.31</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Other Warranties</U>. Notwithstanding the delivery or disclosure to any Buyer, any of their respective Affiliates or any of their respective
Representatives of any documentation or other information (including any financial projections or other supplemental data) or anything
to the contrary in this Agreement, except for the representations and warranties expressly contained in this <U>Article&nbsp;V</U> (in
each case, as qualified by the Seller Disclosure Schedule) or in any Transaction Documents, neither Sellers nor any other Person has made
or is making, and Sellers expressly disclaim, any other representation or warranty of any kind or nature, whether express or implied,
at law or in equity, including any implied representation or warranty of merchantability, usage, suitability or fitness for any particular
purpose with respect to the Acquired Assets, the Assumed Liabilities or the CIED Business, or any part thereof, and the Buyers hereby
acknowledge and agree that in entering into this Agreement, they have not relied on any representations or warranties made by any Person
other than the representations and warranties expressly contained in this <U>Article&nbsp;V</U> (in each case, as qualified by the Seller
Disclosure Schedule) or in any Transaction Documents; <U>provided</U>, that nothing herein shall be deemed to limit the rights of any
party hereto in the event of Fraud.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Article&nbsp;VI</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WARRANTIES OF THE BUYERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Buyers warrant to the
Sellers that each of the following warranties of the Buyers is as of the Signing Date and as of the Closing Date will be true and accurate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;6.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization
and Qualification</U>. BSC is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware
and has the requisite power and authority to own, lease and operate its properties and to carry on its business as it is now being conducted.
CPI is a corporation duly organized, validly existing and in good standing under the laws of the State of Minnesota and has the requisite
power and authority to own, lease and operate its properties and to carry on its business as it is now being conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;6.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authority
Relative to this Agreement</U>. Each Buyer has all necessary corporate power and authority to execute and deliver this Agreement, to perform
its obligations hereunder and to consummate the Acquisition and the other transactions contemplated hereby. The execution and delivery
of this Agreement by each Buyer and the consummation by each Buyer of the Acquisition have been duly and validly authorized by all necessary
corporate action and no other corporate proceedings on the part of either Buyer are necessary to authorize this Agreement or to consummate
the Acquisition. This Agreement has been duly and validly executed and delivered by each Buyer and, assuming the due authorization, execution
and delivery by the Sellers, constitutes a legal, valid and binding obligation of each Buyer enforceable against each Buyer in accordance
with its terms, subject to the Enforceability Exceptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;6.3</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Conflict; Required Filings and Consents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
execution and delivery of this Agreement by each Buyer do not, and the performance of this Agreement by each Buyer will not, (i)&nbsp;conflict
with or violate the Organizational Documents of any Buyer, (ii)&nbsp;conflict with or violate any Order, statute, rule&nbsp;or regulation
binding on or applicable to any Buyer or their respective properties, except for such conflicts or violations which would not, individually
or in the aggregate, have a Buyer Material Adverse Effect, or (iii)&nbsp;result in any breach of or constitute a default (or an event
which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration
or cancellation of, or result in the creation of an Encumbrance (other than Permitted Encumbrances) on any property or asset of any Buyer
pursuant to, any contract, permit or other instrument or obligation to which any Buyer is a party or by which any Buyer or any property
or asset of any Buyer is bound or affected, except for any such breaches, defaults or other occurrences which would not, individually
or in the aggregate, have a Buyer Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Permit or Order of, or declaration or filing with, any Governmental Authority on the part of any Buyer is required in connection with
the execution and delivery of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated
hereby and thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;6.4</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Brokers</U>.
No broker, finder or investment banker is entitled to any brokerage, finder&rsquo;s or other fee or commission in connection with the
Acquisition based upon arrangements made by or on behalf of any Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;VII</B></FONT><B><BR>
CONDUCT OF BUSINESS PENDING THE CLOSING<BR>
AND RELATED COVENANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;7.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conduct
of Business Generally</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Seller covenants and agrees that, during the period beginning on the Signing Date and ending on the earlier of the Closing or termination
of this Agreement, unless BSC shall otherwise agree in writing, (v)&nbsp;the CIED Business shall be conducted only in, and no Seller shall
take any action, or permit any action to be taken by its Affiliates, except in the Ordinary Course of Business and in a manner consistent
with past practice, with respect to the CIED Business or the Acquired Assets; (w)&nbsp;such Seller shall maintain, or cause to be maintained,
all Acquired Assets in good working order and condition (ordinary wear and tear excepted) (including conducting all inspections and acts
of service and repair with at least the level of care and frequency required to comply with (i)&nbsp;manufacturer recommendations or guidelines
or (ii)&nbsp;customary industry practice for similar assets as the applicable Acquired Asset), (x)&nbsp;such Seller will not separate
the employment of any present officers or key employees of the CIED Business for convenience or without Cause; <U>provided</U>, <U>however</U>,
that nothing in this <U>Section&nbsp;7.1(a)</U>&nbsp;or <U>Section&nbsp;7.1(b)</U>&nbsp;shall preclude Sellers from offering employment
to or hiring individuals for the CIED Business, consistent with past practice, if the total compensation payable to any individual hired
for the CIED Business does not exceed, in the aggregate, [***] (determined on an annualized basis), (y)&nbsp;such Seller shall use best
efforts to maintain and preserve intact its current organization and the organization, operations and franchise of the CIED Business and
to preserve the rights, franchises, goodwill and relationships of its contractors, consultants, customers, suppliers, vendors, regulators
and others having relationships with the CIED Business and (z)&nbsp;such Seller shall comply with all applicable Laws and Orders applicable
to the Acquired Assets or the CIED Business and to give prompt notice to the Buyers of any notice of any material damage or any material
loss, damage or destruction to, or any material interruption in the use of, any of the Acquired Assets (whether or not covered by insurance),
other than ordinary wear and tear and any notice received or made by any Seller of any claim asserting any material tort or violation
of applicable Law or any new Action that (in each case) relates to such Acquired Assets or the CIED Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Without
limiting the foregoing, from the Signing Date until Closing, except for the actions listed on <U>Schedule&nbsp;7.1</U> hereto, the Sellers
shall not, and no Seller shall cause or permit any of its Affiliates to, directly or indirectly do, or propose to do, any of the following
without the prior written consent of BSC, with it being understood that each of the clauses below shall constitute an independent obligation
of the Sellers and is not qualified by any of the other clauses below, and shall be deemed to be cumulative:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;sell,
license, sublicense, transfer, assign, pledge, donate, gift, or otherwise dispose of any of the Acquired Assets (other than the commercial
sale of Inventory in the ordinary course of business);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;enter
into any contract, agreement or commitment (other than as required in the ordinary course of business), or terminate, renew, amend or
otherwise modify or waive (including in the context of an extension of a term or similar matters) (other than as required in the ordinary
course of business) any of the terms of any agreements, understandings, instruments or contracts which are material to the CIED Business
(including any Material Contract) or that could materially affect any Acquired Asset or grant its consent to any of the foregoing, including
any such agreement that could limit the ability of the Buyers or any of their Affiliates to operate the CIED Business in a specific area
of business or specific geographic area after the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;without
limiting the generality of the foregoing, enter into, maintain or fail to cure a condition of breach of, or amend any agreement pursuant
to which any other party is granted manufacturing, marketing or other development or distribution rights or any rights to any Seller Intellectual
Property of any type or scope with respect to any Acquired Assets, or any other agreement relating to research, clinical trial, development,
distribution, sale, supply, license, marketing, co-promotion or manufacturing by third parties of the Products;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(iv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;take
or omit to take any action or permit any action to be take or omitted that would reasonably result in a material breach, violation or
a default of such Sellers&rsquo; obligations under any contract, agreement, instrument or other commitment that relate to or affect the
CIED Business or any Acquired Asset;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(v)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;grant
or create, or allow to be granted or created, any Encumbrances over any of the Acquired Assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;allow
to lapse, cancel or fail to reasonably apply for, maintain or further prosecution of, or fail to comply with any obligation with respect
to, any Seller Intellectual Property, or fail to take or maintain adequate measures to protect the confidentiality of any nonpublic, Seller
Intellectual Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(vii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;commence
any Action related to or affecting the CIED Business or any Acquired Asset other than (A)&nbsp;for the routine collection of bills, (B)&nbsp;in
such cases where the Sellers in good faith determine that failure to commence an Action would result in the material impairment of a valuable
aspect of the CIED Business or any Acquired Asset, <U>provided</U> that such Seller consults with the Buyers prior to the filing of such
a suit, or (C)&nbsp;with respect to this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(viii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;acquire
or agree to acquire by merging or consolidating with, or by purchasing a substantial portion of the assets of, or by any other manner,
any business or any corporation, partnership, association or other business organization or division thereof that would result in such
Seller acquiring assets or liabilities that could reasonably be expected to be Acquired Assets or Assumed Liabilities hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ix)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;adopt
a plan or agreement of, or resolutions providing for or authorizing, complete or partial liquidation, dissolution, restructuring, merger,
consolidation, division, statutory conversion or domestication, share exchange, business combination, reorganization or recapitalization
of a Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(x)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
each case solely with respect to the Acquired Assets, Products, and CIED Business, (A)&nbsp;make, change, rescind or revoke any election
in respect of Taxes; (B)&nbsp;enter into any closing or similar agreement with a taxing authority in respect of Taxes; (C)&nbsp;settle
or compromise any claim, notice, audit report, or assessment in respect of Taxes; (D)&nbsp;file any amended Tax Return; (E)&nbsp;file
any Tax Return in a manner inconsistent with past practices (unless otherwise required by a change in applicable Law); (F)&nbsp;enter
into any Tax allocation agreement, Tax sharing Agreement, or Tax indemnity agreement (other than any agreement entered into in the Ordinary
Course of Business the primary purpose of which is not Tax); (G)&nbsp;surrender or allow to expire any right to claim a material refund
of Taxes; (H)&nbsp;consent to any extension or waiver of the limitation period applicable to any claim, Action or assessment in respect
of Taxes; or (I)&nbsp;make any application for, negotiate or conclude any Tax ruling with a taxing authority;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xi)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***];</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;enter
into, modify (including by extension or renewal), or terminate any collective bargaining agreement or other Contract with any Union or,
through negotiation or otherwise, make any commitment or incur any liability to any Union with respect to any Business Employee or Business
Contingent Worker;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xiii)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;[***]
(ii)&nbsp;terminate or make any change to any Employee Benefit Plan other than changes in the ordinary course and that apply generally
to employees of Sellers in addition to the Offered Employees; (iii)&nbsp;establish, adopt, amend, or enter into any plan, policy, or arrangement
for the current or future benefit of the Business Employees that would be an Employee Benefit Plan if it were in existence as of the date
hereof; (iv)&nbsp;terminate the employment of any Offered Employee without Cause or (v)&nbsp;[***]; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(xiv)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;authorize,
commit to, agree to take, or permit to occur any of the foregoing actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;7.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Clinical
Trials</U>. The Sellers shall diligently conduct and complete all research and development activities, including nonclinical, preclinical
and clinical activities, with respect to the Products in compliance with all applicable Laws. During the period beginning on the Signing
Date and ending on the earlier of the Closing or termination of this Agreement, at the reasonable request of any Buyer, the Sellers shall
provide such Buyer(s)&nbsp;with weekly updates concerning the progress of, developments related thereto and any results from any nonclinical
testing, preclinical studies or clinical trials being conducted by or on behalf of the Sellers or any of their respective Affiliates or
Representatives related to, connected with or affecting the Products or the CIED Business; provided, that updates shall be provided no
later than within twenty-four (24) hours in the case of any adverse results or developments relating to such nonclinical testing, preclinical
studies or clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;7.3</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>FDA
Approval Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Sellers shall notify the Buyers in writing of any communications with the FDA or any similar Governmental Authority in any other jurisdiction,
related to, concerning, or associated with the Products, any Acquired Asset or the CIED Business, whether written or oral, as soon as
reasonably practicable, but in no event later than three&nbsp;(3)&nbsp;Business Days after the receipt of such communication, and within
such same time period, the Sellers shall provide the Buyers with copies of any such written communications and written summaries of any
such oral communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
time to time and at the reasonable request of any Buyer, the Sellers shall provide such Buyer(s)&nbsp;with updates concerning the progress
of regulatory filings made or to be made by or on behalf of any Seller or any of its Affiliates or Representatives and the strategy for
obtaining necessary regulatory authorizations, clearances or approvals to develop, research, manufacture, market and sell the Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;7.4</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice
of Developments</U>. From the Signing Date and continuing until the earlier of the termination of this Agreement or the Closing, the Buyers
and the Sellers shall promptly advise the other party in writing of (a)&nbsp;any event or circumstance that would reasonably be expected
to result in any warranty made by such party in this Agreement becoming untrue or inaccurate in any respect, (b)&nbsp;the failure by it
to comply in any material respect with or satisfy in any material respect any covenant, condition or agreement to be complied with or
satisfied by it under this Agreement prior to the Closing, (c)&nbsp;with respect to the Sellers, any change or event having, or which
is reasonably likely to have, a Seller Material Adverse Effect or (d)&nbsp;with respect to the Sellers, any notice or other communication
from any Person alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this
Agreement; <U>provided</U>, <U>however</U>, that no such notification will be deemed to prevent or cure any breach of, or inaccuracy in,
amend or supplement any Section&nbsp;of the Seller Disclosure Schedule, or otherwise disclose an exception to, or affect in any manner,
the warranties, covenants or agreements of the parties (or remedies with respect thereto) or the conditions to the obligations of the
parties under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;7.5</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Commercially
Reasonable Efforts</U>. From the Signing Date until the Closing, each party hereto shall use commercially reasonable efforts to take,
or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other in doing, all things necessary,
proper or advisable to consummate and make effective, in the most expeditious manner practicable, the transactions contemplated hereby,
including using commercially reasonable efforts to accomplish the following: (a)&nbsp;the taking of all reasonable acts necessary to cause
the conditions precedent to the other party&rsquo;s obligations to consummate the Closing set forth in <U>Article&nbsp;X</U> hereof to
be satisfied, (b)&nbsp;the obtaining, at the earliest practicable date, of all necessary consents, authorizations, and other similar approvals
from any Governmental Authority and the making of all necessary registrations, listings, declarations and filings (including registrations,
declarations and filings with Governmental Authorities, if any) and the taking of all reasonable steps as may be necessary to avoid any
Action by any Governmental Authority, and (c)&nbsp;the execution or delivery of any additional instruments necessary to consummate the
transactions contemplated hereby and to fully carry out the purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;7.6</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Shared
Contracts</U>. Subject to <U>Schedule 7.6</U>, each Seller shall use its commercially reasonable efforts to cause the Shared Contracts
to be assigned in whole or in part or otherwise replaced with separate contracts &ldquo;mirroring&rdquo; the terms of the applicable Shared
Contracts so that (a)&nbsp;the applicable Buyer shall be entitled to the rights and benefits, and shall assume the related portion of
any Liabilities, inuring to the CIED Business or the Products to the same extent received and borne by such Seller in accordance with
such Shared Contract prior to such assignment or separation; provided, that the Buyers shall assume Liabilities under such Shared Contracts
solely to the extent that such Liabilities would constitute Assumed Liabilities if the portion of the Shared Contract inuring to the CIED
Business and Products had constituted an Assumed Contract that had been transferred to the Buyers and (b)&nbsp;the applicable Seller shall
be entitled to the rights and benefits, and shall assume the related portion of any Liabilities, inuring to the Excluded Assets or any
other businesses of such Seller (other than the CIED Business) to the same extent received and borne in accordance with such Shared Contract
prior to such separation or assignment. Subject to <U>Schedule 7.6</U>, in the event any Shared Contract cannot be so partially assigned
by its terms or otherwise, or cannot be amended or separated, then the parties shall take such other reasonable and legally permissible
actions (including by providing prompt notice to the other party with respect to any relevant claim of Liability or other relevant matters
arising in connection with a Shared Contract so as to allow such other party the ability to exercise any applicable rights under such
Shared Contract) to cause the applicable Buyer to receive the rights and benefits of that portion of each Shared Contract that relates
to the CIED Business or Products, as the case may be (in each case, to the extent so related), as if such Shared Contract had been assigned
to (or amended to allow) such Buyer pursuant to this <U>Section&nbsp;7.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section&nbsp;7.7</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Removal
of Excluded Inventory</U>. As soon as practicable following the Signing Date, but in any event prior to the Closing, the Sellers shall
have completed the removal of all Excluded Inventory from the Sellers&rsquo; facility located in Roswell, Georgia (the &ldquo;<U>Excluded
Inventory Removal</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section&nbsp;7.8</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Ongoing
Clinical Trial Agreements</U>. Notwithstanding anything in this Agreement to the contrary, nothing herein or in any Transaction Document
shall be construed as an assignment or transfer of any Ongoing Clinical Trial Agreement or Ongoing Vendor Agreement to BSC as of the Closing.
No Ongoing Clinical Trial Agreement shall be assigned or transferred to BSC until satisfaction of such Ongoing Clinical Trial Agreement&rsquo;s
Ongoing Clinical Trial Agreement Transfer Condition, immediately after which the applicable Seller or Sellers party to such Ongoing Clinical
Trial Agreement shall be deemed to have assigned and transferred such Ongoing Clinical Trial Agreement to BSC, along with all Books, Records
and Files relating to such Ongoing Clinical Trial Agreement to the extent not yet transferred to BSC. No Ongoing Vendor Agreement shall
be assigned or transferred to BSC until the written direction from BSC to the Sellers to transfer such Ongoing Vendor Agreement; provided,
that immediately after such time the applicable Seller or Sellers party to such Ongoing Vendor Agreement shall be deemed to have assigned
and transferred such Ongoing Vendor Agreement to BSC, along with all Books, Records and Files relating to such Ongoing Vendor Agreement
to the extent not yet transferred to BSC. Until such time as a particular Ongoing Clinical Trial Agreement or Ongoing Vendor Agreement
is assigned and transferred to BSC, Buyers and Sellers shall, for no additional consideration and subject in each case to the terms set
forth in the Transition Services Agreement, cooperate with one another in an arrangement whereby BSC will be provided with the rights
and benefits of, and shall assume the Liabilities (solely to the extent such Liabilities would constitute Assumed Liabilities if such
Ongoing Clinical Trial Agreement or Ongoing Vendor Agreement had been assigned and transferred to BSC as of the Closing) under, such Ongoing
Clinical Trial Agreement or Ongoing Vendor Agreement, as if such Ongoing Clinical Trial Agreement or Ongoing Vendor Agreement had been
assigned to BSC as of the Closing; <U>provided</U>, <U>however</U>, for the avoidance of doubt, that nothing contained herein shall preclude
or restrict Elutia from terminating or modifying an Ongoing Clinical Trial Agreement solely to the extent such termination or modification
(i)&nbsp;is approved prior to implementation by the applicable Governmental Authority (if applicable) and (ii)&nbsp;does not result in
any additional liabilities or obligations under the applicable Ongoing Clinical Trial Agreement being transferred to a Buyer without such
Buyer&rsquo;s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed). From and after the date
hereof, the Sellers will not amend, modify or terminate any Ongoing Clinical Trial Agreements without providing prior written notice to
BSC and will not amend, modify or terminate any Ongoing Vendor Agreements without the prior written consent of BSC. The Sellers agree
to take any further action as is reasonably necessary or desirable to carry out the purposes of this <U>Section&nbsp;7.8</U>, including
by executing a bill of sale and assignment and assumption agreement. &ldquo;<U>Ongoing Clinical Trial Agreement Transfer Condition</U>&rdquo;
means, with respect to an Ongoing Clinical Trial Agreement, the earlier of (i)&nbsp;the date that the Sellers have completed the clinical
trials or studies with respect to such Ongoing Clinical Trial Agreement if such Ongoing Clinical Trial Agreement remains in effect as
of such date, and no obligations relating to such clinical trials or studies remain outstanding, in each case, as reasonably determined
by BSC, or (ii)&nbsp;the date designated in writing by BSC to Elutia with respect to such Ongoing Clinical Trial Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;7.9</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Exclusive
Dealing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;From
and after the Signing Date until the earlier of the Closing or termination of this Agreement pursuant to <U>Article&nbsp;XI</U>, no Seller
will, nor will it authorize or permit any of its officers, directors, Affiliates or employees or any investment banker, attorney or other
advisor or representative retained by it to, directly or indirectly, (i)&nbsp;solicit, initiate or induce the making, submission or announcement
of any Acquisition Proposal, (ii)&nbsp;participate in any discussions or negotiations regarding, or furnish to any person any non-public
information with respect to, or take any other action to facilitate any inquiries or the making of any proposal that constitutes or may
reasonably be expected to lead to, any Acquisition Proposal, (iii)&nbsp;engage in discussions with any person with respect to any Acquisition
Proposal, except as to disclose the existence of these provisions, including in response to any initial unsolicited expression of an Acquisition
Proposal, <U>provided</U>, that the receipt without response of an unsolicited interest of an Acquisition Proposal shall not by itself
constitute a violation of this <U>Section&nbsp;7.9</U>, (iv)&nbsp;endorse or recommend any Acquisition Proposal, or (v)&nbsp;enter into
any letter of intent or similar document or any contract, agreement or commitment contemplating or otherwise relating to any Acquisition
Proposal. Each Seller will, and will cause its Affiliates and its and their respective officers, directors, Affiliates, employees, investment
bankers, attorneys and other advisors and representatives to, immediately cease any and all existing activities, discussions or negotiations
with any parties conducted heretofore with respect to any Acquisition Proposal. Without limiting the foregoing, it is understood that
any violation of the restrictions set forth in the preceding two sentences by any officer, director or employee of a Seller or any of
its Affiliates or any investment banker, attorney or other advisor or representative of a Seller or any of its Affiliates shall be deemed
to be a breach of this <U>Section&nbsp;7.9</U> by the Sellers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
addition to the obligations of each Seller set forth in <U>Section&nbsp;7.9(a)</U>, each Seller as promptly as practicable shall advise
the Buyers in writing of any Acquisition Proposal or of any request for non-public information or other inquiry which such Seller reasonably
believes could lead to an Acquisition Proposal, the material terms and conditions of such Acquisition Proposal (to the extent known),
and the identity of the person or group making any such request, inquiry or Acquisition Proposal. Each Seller agrees to keep the Buyers
informed on a current basis of the status and details (including any material amendments or proposed amendments) of any such request,
inquiry or Acquisition Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;VIII</B></FONT><B><BR>
ADDITIONAL AGREEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;8.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consents</U>.
Each Seller shall use commercially reasonable efforts, and take any such actions reasonably requested by any Buyer, to minimize any adverse
effect upon the Buyers and their Affiliates and their respective businesses resulting, or which could reasonably be expected to result
after the Closing, from the failure to timely and properly deliver any third party notices or obtain any third party consent or approvals
necessary for or triggered by the consummation of the transactions contemplated hereby (including from any Governmental Authority) prior
to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section&nbsp;8.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Access
to Information.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Following
the Closing, upon reasonable notice, each Seller will provide to the Buyers (and their Representatives) full access to all employees and
consultants of such Seller and all information, properties, books, records, contracts and documents which a Buyer may reasonably request
regarding the CIED Business or the Acquired Assets which remain in the possession of such Seller or any of its Affiliates, and such Seller
will furnish or cause to be furnished to the Buyers and their Representatives all such information as they may reasonably request. No
investigation pursuant to this <U>Section&nbsp;8.2(a)</U>&nbsp;shall affect any warranty in this Agreement of any party hereto or any
condition to the obligations of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Following
the Closing, the Buyers shall, and shall cause their Affiliates to, afford to the Sellers reasonable access to the Books, Records, and
Files included in the Acquired Assets and such cooperation and assistance as shall be reasonably required, in each case, to enable the
Sellers and their Affiliates to comply with applicable Law, stock exchange rules, financial and tax reporting requirements and third-party
litigation and insurance matters relating to the Acquired Assets or Excluded Liabilities solely to the extent relating to any period prior
to the Closing. No investigation pursuant to this <U>Section&nbsp;8.2(b)</U>&nbsp;shall affect any warranty in this Agreement of any party
hereto or any condition to the obligations of the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
anything to the contrary contained in this Agreement, the Buyers and Sellers acknowledge and agree that Sellers and their Affiliates shall
be entitled to (i)&nbsp;keep copies of any Books, Records, and Files included in the Acquired Assets and transferred to the Buyers in
the Acquisition (&ldquo;<U>Transferred Books and Records</U>&rdquo;), any Business Employee Records transferred to the Buyers in the Acquisition
(&ldquo;<U>Transferred Business Employee Records</U>&rdquo;), any Assumed Contracts transferred to the Buyers or any of their Affiliates
in the Acquisition (&ldquo;<U>Transferred Contracts</U>&rdquo;) or any other documents or materials transferred to the Buyers as part
of the Transferred Assets for operational, legal, Tax, regulatory or record-keeping purposes or in order to comply with applicable Laws,
Sellers&rsquo; or their Affiliates&rsquo; internal policies and procedures as in effect on the date of this Agreement or any applicable
contractual obligations under a Contract in effect on the date of this Agreement that is not a Transferred Contract, in each case, subject
to the confidentiality obligations hereunder, (ii)&nbsp;redact or remove any information in any such Transferred Books and Records or
any other documents or materials transferred to the Buyers as part of the Transferred Assets to the extent not related to the CIED Business
or (iii)&nbsp;redact or remove any information in the Transferred Business Employee Records to the extent not relating to any Transferred
Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
a period of six (6)&nbsp;years from the Closing Date or such longer time as may be required by applicable Law, the Buyers agree to hold
and not to destroy or dispose of the Transferred Books and Records. Following the expiration of such period, if a Buyer or any of its
Affiliates desires to destroy or dispose of such Books, Records, and Files, solely upon written request of Sellers delivered within thirty
(30) days prior to the expiration of such six-year period detailing the specific Transferred Books and Records, such Buyer shall offer
to surrender such books and records to Sellers; <U>provided</U>, that such Buyer does not make a reasonable determination that providing
such Transferred Books and Records would be adverse to the business of Buyers or any of their respective Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section&nbsp;8.3</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Public
Announcements; Form&nbsp;8-K Filings; Confidentiality</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Prior
to the date hereof, Elutia has prepared and the Buyers have reviewed and approved (i)&nbsp;a draft Form&nbsp;8-K announcing the parties
entry into this Agreement, together with, or incorporating by reference, such information that is or may be required to be disclosed with
respect to the transactions contemplated by this Agreement pursuant to Form&nbsp;8-K (the &ldquo;<U>Transaction Form&nbsp;8-K</U>&rdquo;),
and (ii)&nbsp;a press release announcing the parties&rsquo; entry into this Agreement (the &ldquo;<U>Press Release</U>&rdquo;). On or
promptly after the Signing Date, Elutia shall file the Transaction Form&nbsp;8-K with the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as provided below, from and after the Signing Date until the Closing, neither Buyers nor Sellers nor any of their Representatives or Affiliates
shall issue any press release or otherwise make any public statements with respect to this Agreement or the Acquisition and any related
transactions without the prior written consent of the other parties to this Agreement, except (i)&nbsp;the Transaction Form&nbsp;8-K and
Press Release and (ii)&nbsp;as may be required by Law or the requirements of NASDAQ or the New York Stock Exchange; provided, that before
issuing any such press release or otherwise making any such public statement as may be required by Law or the requirements of NASDAQ or
the New York Stock Exchange, the party proposing to make such statement shall consult with the other parties to this Agreement and shall
incorporate any reasonable comments from such parties with respect to such press release or public statement. Notwithstanding the foregoing,
either party may make press releases or public statements that contain information that is consistent with Transaction Form&nbsp;8-K and
Press Release or any other previous press releases or public statements issued or made in accordance with this <U>Section&nbsp;8.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the parties hereto acknowledges that the information provided to it in connection with this Agreement and the Acquisition and other
transactions contemplated hereby is subject to the terms of the Confidentiality and Nondisclosure Agreement dated [***], between BSC and
Elutia (the &ldquo;<U>Confidentiality Agreement</U>&rdquo;), the terms of which are incorporated herein by reference. The parties further
acknowledge and agree that: (i)&nbsp;the Confidentiality Agreement shall remain in full force and effect and shall not be affected by
the termination of this Agreement for any reason; and (ii)&nbsp;Section&nbsp;15 of the Confidentiality Agreement is hereby amended such
that BSC&rsquo;s non-use and non-disclosure obligations under the Confidentiality Agreement shall continue in full force and effect for
a period of two (2)&nbsp;years following any such termination of this Agreement. Effective upon, and only upon, the Closing, the Confidentiality
Agreement will terminate. From and after the Closing Date, each Seller shall, and shall cause its Affiliates to, treat all information
and Trade Secrets relating to the Products or the Acquired Assets as confidential, preserve the confidentiality thereof, not duplicate,
disclose, or divulge to any Person such information or Trade Secrets, and not use such information or Trade Secrets for any reason or
purpose whatsoever, and shall instruct their respective Representatives who have had access to or knowledge of such information or Trade
Secrets to do the same, in each case, except to the extent that (i)&nbsp;disclosure of such information is required by applicable Law,
in which case the applicable Seller shall, and shall cause its Affiliates to, disclose only such information as is so required to be disclosed
by applicable Law, use reasonable best efforts to ensure the confidential treatment of any information disclosed pursuant to such applicable
Law and, to the extent legally permissible, notify the Buyers prior to making any such required disclosure, or (ii)&nbsp;such information
shall have entered the public domain other than by breach of this Agreement by any Seller or such Persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section&nbsp;8.4</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Employee
Matters.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Prior
to the Closing, a Buyer or one of their Affiliates (the &ldquo;<U>Buyer Employer</U>&rdquo;) will offer each Business Employee set forth
in <U>Section&nbsp;8.4(a)</U>&nbsp;of the Seller Disclosure Schedule the option to apply for at-will employment with the Buyer Employer
(collectively, the &ldquo;<U>Applicants</U>&rdquo;). Applicants may apply for employment with the Buyer Employer by (i)&nbsp;[***] and,
if applicable, (ii)&nbsp;[***] required by the Buyer Employer in its sole discretion, within the time period required by the Buyers (collectively,
the &ldquo;<U>Application Requirements</U>&rdquo;). The Sellers hereby agree to use its or their best efforts to allow any Applicant to
complete the Application Requirements, including by allowing any Applicant to [***] required by the Buyer Employer at the time and place
specified by the Buyer Employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
or prior to the Closing, Buyer Employer may, in its sole discretion, offer at-will employment to each Applicant who has completed the
Application Requirements in accordance with <U>Section&nbsp;8.4(a)</U>&nbsp;(collectively, the &ldquo;<U>Offered Employees</U>&rdquo;),
with such at-will employment contingent upon the occurrence of the Closing. To avoid doubt, the Buyers and the Buyer Employer may decline
to offer employment to any Applicant in its discretion. The Offered Employees who accept employment with the Buyer Employer by executing
the offer letter, restrictive covenant agreement, and other documentation required by the Buyer Employer (the &ldquo;<U>New Hire Documents</U>&rdquo;)
within the time period required by the Buyer Employer shall be referred to herein as the &ldquo;<U>Transferred Employees</U>&rdquo;. The
Business Employees who are not offered employment with or who do not accept employment with the Buyer Employer shall be referred to herein
as &ldquo;<U>Non-Transferred Employees</U>&rdquo;. The Sellers hereby consent to the hiring of any such Transferred Employees by the Buyer
Employer and hereby waive any claims or rights any Seller may have against any Buyer, the Buyer Employer and any of their Affiliates or
any such Transferred Employee under any non-competition, non-solicitation, confidentiality or employment agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;On
or prior to the Closing, the Buyer Employer shall identify to the Sellers those Transferred Employees, if any, whom the Buyer Employer
would like the Sellers to retain on the Sellers&rsquo; payroll and benefits (the &ldquo;<U>Transitional Employees</U>&rdquo;) during a
transitional period that shall last until December&nbsp;31, 2025 unless any such Transitional Employees are earlier terminated at the
Buyer Employer&rsquo;s direction (the actual length of such transitional period, the &ldquo;<U>Employee Transition Period</U>&rdquo;).
Any Transferred Employees who are not Transitional Employees shall be terminated by the Seller on the Closing Date. Any Transitional Employees
shall be terminated by the Seller on the last day of the Employee Transition Period. Sellers agree to make Transitional Employees available
to Buyer Employer, on a full-time and exclusive basis, throughout the Employee Transition Period (or, if a Transitional Employee resigns,
the date of such Transitional Employee&rsquo;s last day of employment), to provide Buyers and their Affiliates with continued services
for and with respect to the CIED Business in substantially the same manner in which such Transitional Employee served the CIED Business,
and on substantially the same terms and conditions of employment as applied to such Transitional Employee, prior to the Closing. During
the Employee Transition Period, Buyer Employer and its Affiliates will have sole responsibility for determining the overall direction
of the Transitional Employees and will be responsible for directing the daily work of the Transitional Employees in accordance with the
Buyer Employer&rsquo;s policies. All confidentiality, invention assignment, nonsolicitation, noncompetition, and other restrictive covenant
obligations owed by the Transferred Employees to the Buyer Employer under the New Hire Documents will be in full force and effect during
the Employee Transition Period. During the Employee Transition Period, Sellers will be responsible for (i)&nbsp;maintaining all employee
benefits associated with each Transitional Employee on substantially the same terms and conditions as applied to such Transitional Employee
prior to the Closing and (ii)&nbsp;bearing all costs associated with employing the Transitional Employees, including without limitation
all salary, wages, and other compensation and benefits costs and related Taxes, which Sellers will invoice to Buyers on a monthly basis,
with a final invoice sent promptly following the last day of the Employee Transition Period. Sellers and Buyer Employer agree to promptly
provide the other with any other information that is reasonably requested for the purpose of administering the other&rsquo;s obligations
under this <U>Section&nbsp;8.4(c)</U>. For the avoidance of doubt, Buyers and their respective Affiliates will not be responsible for
any costs associated with employing any Applicants or Offered Employees who are not offered or do not accept an offer of at-will employment
by Buyer Employer prior to the Closing and such Applicants and Offered Employees will not provide services to the Buyers during the Employee
Transition Period. Sellers agree not to terminate any Transitional Employee during the Employee Transition Period without the express
written consent or direction of BSC, other than for Cause; <U>provided</U>, that the Sellers provide written notice to BSC of any termination
for Cause prior to such termination or, if prior notice is not possible, within two (2)&nbsp;calendar days of any such termination for
Cause. On December&nbsp;31, 2025 (or earlier if requested by the Buyer Employer), Sellers shall terminate the employment of each Transitional
Employee who remains employed by Sellers on such date, and Buyer Employer shall employ each such Transitional Employee as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as expressly provided in <U>Section&nbsp;8.4(c)</U>&nbsp;of this Agreement, the Transition Services Agreement or Employee Lease Agreement
(if applicable), Buyer Employer shall not have any Liability with respect to any (i)&nbsp;Transferred Employee with respect to Liability
arising during such Transferred Employee&rsquo;s employment by Sellers, whether on, prior to, or, solely with respect to the Transitional
Employees, after the Closing Date or (ii)&nbsp;Non-Transferred Employees or former employees (including any Applicants or Offered Employees
who are not Transferred Employees), consultants or retirees of the Sellers (including any Person currently covered by any Seller Employee
Plan who is not a Transferred Employee), regardless of when such Liability arose or occurred (whether on, prior to or after the Closing
Date). The Sellers shall be solely responsible for the payment of, and shall pay, all wages, salaries and other compensation and employee
benefits (including any vacation pay, severance pay or benefits, notice pay, insurance, supplemental pension, deferred compensation, &ldquo;stay&rdquo;
or other similar incentive bonuses, change-in-control bonuses (or other bonuses or compensation related in any way to the execution, delivery
or performance of this Agreement), retirement and any other benefits, premiums, claims and related costs), to the extent, if any, of its
liability for same, to any of the current employees, former employees, consultants, former consultants or retirees of the Sellers based
on or arising under their employment or engagement with the Sellers before, on, and after the Closing. Except as expressly provided in
<U>Section&nbsp;8.4(c)</U>&nbsp;of this Agreement, the Transition Services Agreement or Employee Lease Agreement (if applicable), the
Sellers shall retain and be solely responsible for all Excluded Employee Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Immediately
at the Closing, Sellers shall assign to Buyer Employer, and Buyer Employer shall assume, Sellers&rsquo; interest in all Contracts between
any Seller and the Business Contingent Workers, including without limitation any consulting, non-competition, non-solicitation, or confidentiality
agreements between any Seller and the Business Contingent Workers. Sellers hereby agree to use their commercially reasonable best efforts
to deliver to Buyer Employer prior to Closing each Business Contingent Worker&rsquo;s written consent to assign Sellers&rsquo; rights
under the Contract, in a form provided by the Buyer (the &ldquo;<U>Assignment Consent</U>&rdquo;). Immediately prior to Closing, Sellers
hereby agree to terminate any Contract with any Business Contingent Worker who does not sign an Assignment Consent, <I>provided </I>that
any post-engagement confidentiality, non-solicitation, noncompetition or other restrictive covenants shall be expressly preserved. Buyer
Employer shall not have any Liability with respect to any Business Contingent Worker who does not sign an Assignment Consent prior to
Closing, including any payments or Liabilities associated with the termination of any Contract with any such Business Contingent Worker.
The Sellers hereby consent to the engagement of any such Business Contingent Workers by the Buyer Employer and hereby waive any claims
or rights any Seller may have against any Buyer, the Buyer Employer and any of their Affiliates or any such Business Contingent Worker
under any consulting, non-competition, non-solicitation, or confidentiality agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Nothing
in this Agreement shall (i)&nbsp;confer upon any Applicant, Offered Employee, Transferred Employee, Non-Transferred Employee, Business
Contingent Worker, or upon any legal representative or such employee or Business Contingent Worker, any rights or remedies, including
any right to continue in the employ or service of the Buyer Employer or any of its Affiliates for any specified period, of any nature
or kind whatsoever under or by reason of this Agreement, or (ii)&nbsp;interfere with or restrict in any way the rights of the Buyer Employer,
which rights are hereby expressly reserved, including the right to discharge or terminate the services of any Transferred Employee at
any time for any reason whatsoever, with or without Cause. Notwithstanding any provision in this Agreement to the contrary, nothing in
this <U>Section&nbsp;8.4(f)</U>&nbsp;shall be deemed to create any third party rights in any current or former employee, director, Business
Contingent Worker, or other service provider of the Buyers, the Buyer Employer, the Sellers or any of their respective Affiliates (or
any beneficiaries or dependents thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
Buyer nor any of their Affiliates will contribute to any Employee Benefit Plan or other compensation or benefit plan or agreement of the
Sellers or any of their Affiliates. Neither Buyer nor any of their Affiliates will assume sponsorship of, nor will they adopt as a participating
company in, any Employee Benefit Plan or other compensation or benefit plan or agreement of the Sellers or any of their Affiliates or
any part thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section&nbsp;8.5</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Further
Assurances.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
case, at any time after the Closing Date, any further action is necessary or desirable to carry out the purposes of this Agreement, (i)&nbsp;each
of the parties to this Agreement will take such further action (including the execution and delivery of such further instruments and documents)
as the other party reasonably may request, at the sole cost and expense of the requesting party (unless otherwise specified herein), and
(ii)&nbsp;the proper officers and directors of each party to this Agreement shall use their commercially reasonable best efforts to take
all such action and shall refrain from taking any actions which would be contrary to, inconsistent with or against, or would frustrate
the essential purposes of, the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the extent any Assumed Contract is not capable of being assigned, transferred, subleased or sublicensed to the Buyers or their designated
Affiliates without the consent or waiver of the issuer thereof or a party thereto or any third party, including a Governmental Authority,
the applicable Seller agrees to (i)&nbsp;continue to be bound thereby pending assignment to the Buyers or their designated Affiliates,
(ii)&nbsp;at the direction and expense of the Buyers, pay, perform and discharge fully all of its obligations thereunder, (iii)&nbsp;use
commercially reasonable efforts to obtain such consents and waivers and to obtain any other consents and waivers necessary to assign,
convey, settle, deliver and transfer the Assumed Contract, and (iv)&nbsp;without further consideration therefor, pay, assign and remit
to the applicable Buyer or its designated Affiliates promptly upon receipt all monies, rights and other consideration received in respect
of such Assumed Contract, and otherwise cooperate with the Buyers in all respects to provide that the applicable Buyer or its designated
Affiliates shall otherwise receive the interest of such Seller in the benefits under any such Assumed Contract, including performance
by such Seller, acting through the employees of the Buyers or their designated Affiliates without cost to such Seller, as agent for the
Buyers or their designated Affiliates. To the extent transferable, the applicable Seller shall provide the applicable Buyer or its designated
Affiliates with all of the benefits of such Assumed Contract and such Buyer or its designated Affiliates shall assume the liabilities
and obligations thereunder (solely to the extent that such liabilities or obligations would constitute Assumed Liabilities if such Assumed
Contract had been transferred to such Buyer at the Closing) and this Agreement shall not constitute an assignment, transfer, sublease
or sublicense thereof, or an attempted assignment, transfer, sublease or sublicense thereof unless and until such consents and waivers
to the assignment, transfer, sublease or sublicense have been properly obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
at any time following the Closing, it is discovered that any Acquired Asset which should have been transferred to the Buyers or their
designated Affiliates pursuant to the terms of this Agreement was not transferred to or assumed by the Buyers or their designated Affiliates
as contemplated by this Agreement, then the Sellers shall, without further consideration therefor, promptly transfer, assign or convey
or cause their respective Affiliates to transfer, assign or convey such Acquired Asset to the Buyers or their designated Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;8.6</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Insurance
Matters</U>. Each Seller agrees that with respect to acts, omissions, events or circumstances relating to the Products or the Acquired
Assets that occurred or existed prior to the Closing and that are covered by third party occurrence-based insurance policies under which
the Acquired Assets are insured on or prior to the Closing, the Buyers may, from and after the Closing, make claims under such occurrence-based
policies subject to the terms and conditions of such policies and this Agreement; <U>provided</U>, that except as otherwise provided by
this Agreement, the Buyers shall bear, and the Sellers shall not have any obligation to repay or reimburse the Buyers for, the amount
of any deductibles, self-insured retentions and other out-of-pocket expenses incurred in connection with such claims under such occurrence-based
policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;8.7</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Intellectual
Property Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
Buyer hereby covenants and agrees that it shall use commercially reasonable efforts to as promptly as reasonably practicable after the
Closing, and in any event no later than eighteen (18) months (the &ldquo;<U>Cut-Over Period</U>&rdquo;), revise sales and product literature,
packaging and labeling to delete all references to the Seller Marks; <U>provided</U>, <U>however</U>, that during the Cut-Over Period
and for a period of three (3)&nbsp;months from the end of the Cut-Over Period (the &ldquo;<U>Transitional Period</U>&rdquo;), the Buyers
may continue to distribute sales and product literature, and market, distribute, import, export and sell any Inventory and any Products
manufactured by the Buyers that use any of the Seller Marks, addresses or phone numbers to the extent that such sales and product literature
and Inventory or Products exist on the Closing Date or are manufactured within the relevant Cut-Over Period substantially consistent with
the past practices of Sellers. Subject to the Buyers&rsquo; compliance with the terms and conditions set forth in this <U>Section&nbsp;8.7(a)</U>,
effective upon the Closing Date, Sellers, on behalf of themselves and their applicable Affiliates, hereby grant to each Buyer a limited,
non-exclusive, non-transferable, non-sublicensable (except any Buyer may grant sublicenses to any Affiliate of the Buyers, <U>provided</U>,
that the applicable Buyer notifies Sellers in advance and in writing and such Buyer remains primarily liable and responsible for all acts
and omissions of such sublicensee), royalty-free, paid up right and license, during the Cut-Over Period and Transitional Period, to use
the Seller Marks solely in connection with the manufacture, distribution, marketing and sale of the Products in the conduct of the CIED
Business in the ordinary course of business and substantially consistent with past practice of any Seller prior to the Closing Date. In
no event shall any Buyer use any Seller Marks, addresses or phone numbers after the Closing Date in any manner or for any purpose materially
different from the use of such Seller Marks, addresses or phone numbers by the CIED Business during the one hundred and eighty- (180)-day
period preceding the Closing Date. As between the Parties, Sellers are the sole and exclusive owner of all right, title and interest in
and to the Seller Marks and all rights related thereto and goodwill associated therewith, and all uses of the Seller Marks and the goodwill
arising therefrom shall inure solely to the benefit of Sellers or such Affiliate of Sellers. Any use by the Buyers or any of the Buyers&rsquo;
sublicensees of any of the Seller Marks during the time periods referred to in this <U>Section&nbsp;8.7(a)</U>&nbsp;shall be substantially
consistent with the form and manner, and standards of quality, of those in effect by Sellers and their applicable Affiliates with respect
thereto during the one hundred and eighty- (180)-day period preceding the Closing Date. Sellers shall have the right upon reasonable request,
during the Transitional Period, to appoint a third-party independent auditor reasonably acceptable to the Buyers to verify and exercise
reasonable quality control with respect to the Buyers&rsquo; and the Buyers&rsquo; sublicensees&rsquo; use of the Seller Marks as provided
in this <U>Section&nbsp;8.7(a)</U>, in a reasonable manner, during normal business hours and upon reasonable advance notice; <U>provided</U>,
<U>however</U>, that such access does not unreasonably disrupt the normal operations of the Buyers or the CIED Business. The Buyers shall
have the right to require such third-party independent auditor to execute a reasonable confidentiality agreement prior to commencing such
audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: 2 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
solely as set forth in this <U>Section&nbsp;8.7</U>, during the Transitional Period, Buyers shall cease, and shall cause their Affiliates
to cease, making any use (in any form or manner or for any purpose) of any Seller Marks, including, for the avoidance of doubt, any marks
that contain or comprise any Seller Marks, including as part of any Buyer&rsquo;s name,&nbsp;Internet domain name or social media handle.
Except as expressly provided in this <U>Section&nbsp;8.7</U>, from and after the Closing Date, the Buyers shall not, and shall cause each
of their Affiliates to not, hold themselves out as having any affiliation with Sellers or any of their Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the foregoing, Buyers shall have the right, upon provision of prior written notice to Elutia, to extend the Cut-Over Period and the Transitional
Period for an additional six (6)&nbsp;months in the event either Buyer determines in good faith that such extension is reasonably necessary
for regulatory purposes, product quality purposes or similar purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;IX</B></FONT><B><FONT STYLE="text-transform: uppercase"><BR>
Tax Matters</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;9.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Cooperation</U>.
The Buyers and the Sellers agree to use commercially reasonable efforts to furnish or cause to be furnished to the other, upon request,
as promptly as practicable, such information and assistance relating to the Acquired Assets, the Products or the CIED Business, including
access to books and records, as is reasonably necessary for the filing of all Tax Returns by the Buyers or the Sellers, the making of
any election relating to Taxes, the preparation for any audit by any taxing authority and the prosecution or defense of any claim, suit
or proceeding relating to any Tax. The Buyers and the Sellers shall retain all books and records with respect to Taxes pertaining to the
Acquired Assets, the Products or the CIED Business for a period of at least seven (7)&nbsp;years following the Closing Date. The Buyers
and the Sellers shall cooperate fully with each other in the conduct of any audit, litigation or other proceeding relating to Taxes involving
the Acquired Assets, the Products or the CIED Business or the Allocation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;9.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payment
of Property Taxes</U>. The Sellers shall be liable for and shall promptly pay when due all Property Taxes levied with respect to the Acquired
Assets, the Products and the CIED Business attributable to a Tax period (or portion of a Tax period) ending on the Closing Date, and the
Buyers shall be liable for and shall promptly pay when due all Property Taxes levied with respect to the Acquired Assets, the Products
and the CIED Business attributable to a Tax period (or portion of a Tax period) beginning after the Closing Date. Upon receipt of any
bill for Property Taxes or other Taxes, the Buyers or the Sellers, as applicable, shall present a statement to the other setting forth
the amount of reimbursement to which each is entitled under this <U>Section&nbsp;9.2</U> together with such supporting evidence as is
reasonably necessary to calculate the proration amount. The proration amount shall be paid by the party owing it to the other within ten
(10)&nbsp;days after delivery of such statement. In the event that the Buyers or any of the Sellers makes any payment for which it is
entitled to reimbursement under this <U>Section&nbsp;9.2</U>, the applicable party shall make such reimbursement promptly but in no event
later than ten (10)&nbsp;days after the presentation of a statement setting forth the amount of reimbursement to which the presenting
party is entitled along with such supporting evidence as is reasonably necessary to calculate the amount of reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;9.3</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer
Taxes</U>. All transfer, stamp, gross receipts, documentary, excise, use, registration, recordation value-added and other similar Taxes
or fees (including all applicable real estate transfer Taxes) incurred in connection with this Agreement (&ldquo;<U>Transfer Taxes</U>&rdquo;)
will be borne 50% by the Sellers, on the one hand, and 50% by the Buyers. The Sellers shall prepare and file, or cause to be prepared
and filed, any Tax Return with respect to any Transfer Tax and shall cause each such Tax Return to be delivered to the Buyers for the
Buyers&rsquo; review and comment at least ten (10)&nbsp;days prior to the due date for such Tax Return (taking into account all extensions
properly obtained). The Sellers shall make such revisions to such Tax Returns as may be reasonably requested by the Buyers, the Buyers
shall join in the execution of any such Tax Return if required by applicable Law and the parties shall, as reasonably requested, cooperate
in good faith with each other in connection with the preparation and filing of any such Tax Returns to permit any such Transfer Tax to
be assessed and paid on or prior to the Closing Date in accordance with any available pre-sale filing procedure, and to obtain any exemption
or refund of any such Transfer Tax. To the extent that any Transfer Taxes are required by applicable Law to be paid by either any Buyer
or any Seller, the non-paying party shall, upon notice from the paying party, promptly reimburse the paying party for fifty percent (50%)
of such total amount paid by the paying party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;X</B></FONT><B><BR>
CLOSING CONDITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;10.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conditions
to the Obligations of Each Party</U>. The obligations of the Sellers and the Buyers to consummate the Acquisition are subject to the satisfaction
or mutual written waiver of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
Order shall have been entered, issued or enforced by any court of competent jurisdiction which (i)&nbsp;prohibits consummation of the
Acquisition, (ii)&nbsp;imposes any criminal sanctions or Liability on any Buyer, any Seller or any of their respective Affiliates in connection
with the Acquisition or (iii)&nbsp;would result in the Acquisition being rescinded following consummation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;there
shall be no Law enacted, entered and enforced after the date hereof or deemed applicable to the Acquisition (i)&nbsp;seeking to prevent,
delay, make illegal, restrain or otherwise interfere with the consummation of the Acquisition or (ii)&nbsp;that would substantially deprive
the Buyers or the Sellers of any of the anticipated material benefits of the Acquisition, taken as a whole; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(i)&nbsp;all
actions by or in respect of or filings with any Governmental Authority set forth on <U>Schedule 10.1(c)</U>&nbsp;shall have been obtained
and (ii)&nbsp;all other actions by or in respect of or filings with any Governmental Authority required to permit the consummation of
the Acquisition in accordance with the terms hereof shall have been obtained (other than those actions or filings which, if not obtained
or made prior to the consummation of the Acquisition, would not have a Seller Material Adverse Effect prior to or after the Closing or
a Buyer Material Adverse Effect after the Closing or be reasonably likely to subject any Seller, any Buyer or any of their respective
Subsidiaries or any of their respective officers or directors to substantial penalties or criminal Liability).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;10.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conditions
to the Obligations of the Buyers</U>. The obligations of the Buyers to consummate the Acquisition are subject to the satisfaction of the
following further conditions (any one of which may be waived in whole or in part by the Buyers in their sole discretion by giving written
notice to the Sellers):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;each
of the covenants and obligations that any Seller is required to comply with or to perform at or prior to the Closing shall have been complied
with and performed in all material respects;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;there
shall be no Action pending against any Buyer, any Seller or any of their respective Affiliates by any Governmental Authority (i)&nbsp;seeking
to enjoin or make illegal, delay or otherwise restrain or prohibit the consummation of the Acquisition; (ii)&nbsp;that would result in
the Acquisition being rescinded following consummation; (iii)&nbsp;seeking material damages in connection with the Acquisition; (iv)&nbsp;seeking
to compel any Buyer or any Seller to dispose of or hold separate any Acquired Assets as a result of the Acquisition; or (v)&nbsp;seeking
to impose any criminal sanctions or Liability on any Buyer, any Seller or any of their respective Affiliates in connection with the Acquisition;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;no
Seller Material Adverse Effect shall have occurred or been discovered by the Buyers since the Signing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Sellers shall have completed the activities set forth on <U>Schedule&nbsp;10.2(d)</U>&nbsp;hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Sellers shall have executed (to the extent applicable) and delivered or caused to be executed (to the extent applicable) and delivered
to the Buyers all closing deliveries required to be delivered by the Sellers to the Buyers as set forth in <U>Section&nbsp;4.2(a)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;BSC
shall have entered into each of the Contracts set forth on <U>Schedule&nbsp;10.2(f)</U>, in each case on terms reasonably satisfactory
to the Buyers; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;[***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;10.3</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conditions
to the Obligations of the Sellers</U>. The obligations of the Sellers to consummate the Acquisition are subject to the satisfaction of
the following further conditions (any one of which may be waived in whole or in part by the Sellers in their sole discretion by giving
written notice to the Buyers):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;each
of the covenants and obligations that the Buyers are required to comply with or to perform at or prior to the Closing shall have been
complied with and performed in all material respects; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Buyers shall have executed (to the extent applicable) and delivered or caused to be executed (to the extent applicable) and delivered
to the Sellers all closing deliveries required to be delivered by the Buyers to the Sellers as set forth in <U>Section&nbsp;4.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;XI</B></FONT><B><BR>
TERMINATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;11.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.
This Agreement may be terminated and the Acquisition abandoned at any time prior to the Closing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
duly authorized mutual written consent executed by each of the Buyers and each of the Sellers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
BSC (on behalf of the Buyers) or by Elutia (on behalf of the Sellers), in either case by written notice to the other, if the Closing shall
not have occurred before the day that is four (4)&nbsp;months following the Signing Date (the &ldquo;<U>Termination Date</U>&rdquo;);
<U>provided</U>, <U>however</U>, that (i)&nbsp;in the event that a Person (including any Governmental Authority) other than any Buyer
or any Seller has sought an Order, stay, decree, judgment or temporary or permanent injunction which is intended to prevent or prohibit
consummation of the Acquisition, the Termination Date shall also be automatically delayed, without any further action of the parties,
until a date no later than ten (10)&nbsp;Business Days after such Order, stay, decree, judgment or injunction is finally issued or denied,
without appeal, and (ii)&nbsp;the right to terminate this Agreement under this <U>Section&nbsp;11.1(b)</U>&nbsp;shall not be available
to (A)&nbsp;the Buyers in the event that the failure of the Closing to occur on or before such date arises out of or is related to the
failure of the Buyers to fulfill any obligation under this Agreement, and (B)&nbsp;the Sellers in the event that the failure of the Closing
to occur on or before such date arises out of or is related to the failure by any Seller to fulfill any of its obligations under this
Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
BSC (on behalf of the Buyers) or by Elutia (on behalf of the Sellers), in either case by written notice to the other, if there shall be
any Law that makes consummation of the Acquisition illegal or otherwise prohibited or if any court of competent jurisdiction or Governmental
Authority shall have issued an Order, decree or ruling or taken any other action restraining, enjoining or otherwise prohibiting the Acquisition
and such Order, decree, ruling or other action shall have become final and non-appealable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
BSC (on behalf of the Buyers), by giving written notice to Elutia at any time prior to the Closing in the event that any Seller has given
the Buyers any notice pursuant to <U>Section&nbsp;7.4</U>, if the breach or breaches described in such notice would, individually or in
the aggregate, render any condition to the Acquisition contained in <U>Section&nbsp;10.1</U> or <U>Section&nbsp;10.2</U> hereof impossible
of being satisfied;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
Elutia, by giving written notice to BSC at any time prior to the Closing in the event that BSC has given Elutia any notice pursuant to
<U>Section&nbsp;7.4</U>, if the breach or breaches described in such notice would, individually or in the aggregate, render any condition
to the Acquisition contained in <U>Section&nbsp;10.1</U> or <U>Section&nbsp;10.3</U> hereof impossible of being satisfied;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
BSC (on behalf of the Buyers), by giving written notice to Elutia if (i)&nbsp;any warranty of the Sellers contained in this Agreement
shall be inaccurate or shall have been breached as of the Signing Date, or shall have become inaccurate or shall be breached as of a date
subsequent to the Signing Date (as if made on such subsequent date); or (ii)&nbsp;any of the covenants or obligations of any Seller contained
in this Agreement shall have been breached in any material respect; <U>provided</U>, <U>however</U>, that if an inaccuracy in or breach
of any warranty of the Sellers as of a date subsequent to the Signing Date or a breach of a covenant by any Seller is curable by the same
through the use of commercially reasonable efforts during the 30-day period after any Buyer notifies Elutia in writing of the existence
of such inaccuracy or breach (the &ldquo;<U>Seller Cure Period</U>&rdquo;), then the Buyers may not terminate this Agreement under this
<U>Section&nbsp;11.1(f)</U>&nbsp;as a result of such inaccuracy or breach prior to the expiration of the Seller Cure Period, <U>provided</U>
the applicable Seller, during the Seller Cure Period, continues to exercise commercially reasonable efforts to cure such inaccuracy or
breach (it being understood that the Buyers may not terminate this Agreement pursuant to this <U>Section&nbsp;11.1(f)</U>&nbsp;if any
Buyer is in material breach of this Agreement or if such breach by a Seller is cured such that such conditions would then be satisfied);
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;by
Elutia (on behalf of the Sellers), by giving written notice to BSC, if: (i)&nbsp;any warranty of the Buyers contained in this Agreement
shall be inaccurate or shall have been breached as of the Signing Date, or shall have become inaccurate or shall be breached as of a date
subsequent to the Signing Date (as if made on such subsequent date); or (ii)&nbsp;any of the Buyers&rsquo; covenants contained in this
Agreement shall have been breached in any material respect; <U>provided</U>, <U>however</U>, that if an inaccuracy in or breach of any
warranty of the Buyers as of a date subsequent to the Signing Date or a breach of a covenant by the Buyers is curable by the same through
the use of commercially reasonable efforts during the 30-day period after Elutia notifies BSC in writing of the existence of such inaccuracy
or breach (the &ldquo;<U>Buyer Cure Period</U>&rdquo;), then Elutia may not terminate this Agreement under this <U>Section&nbsp;11.1(g)</U>&nbsp;as
a result of such inaccuracy or breach prior to the expiration of the Buyer Cure Period, provided the applicable Buyer, during the Buyer
Cure Period, continues to exercise commercially reasonable efforts to cure such inaccuracy or breach (it being understood that the Sellers
may not terminate this Agreement pursuant to this <U>Section&nbsp;11.1(g)</U>&nbsp;if any Seller is in material breach of this Agreement
or if such breach by a Buyer is cured such that such conditions would then be satisfied).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;11.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Effect
of Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as provided in <U>Section&nbsp;11.1</U> hereof, in the event of the termination of this Agreement pursuant to <U>Section&nbsp;11.1</U>,
this Agreement shall forthwith become void, there shall be no Liability under this Agreement on the part of any Buyer or any Seller or
any of their respective officers, directors, or stockholders, and all rights and obligations of any party hereto shall cease, except for
liabilities arising from a breach of this Agreement prior to such termination; <U>provided</U>, that the provisions of this <U>Article&nbsp;XI</U>
and <U>Section&nbsp;8.3</U>, <U>Article&nbsp;XII</U> and <U>Article&nbsp;XIII</U> shall survive the termination of this Agreement for
any reason. The parties&rsquo; obligations under the Confidentiality Agreement shall survive termination of this Agreement unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
party acknowledges that the agreements contained in this <U>Section&nbsp;11.2</U> are an integral part of the Acquisition and that, without
these agreements, the parties hereto would not enter into this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;XII</B></FONT><B><BR>
INDEMNIFICATION, LIMITATIONS OF LIABILITY AND CONDUCT OF CLAIMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;12.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification
by the Sellers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
and after the Closing, the Sellers will, jointly and severally, indemnify, defend and hold harmless the Buyers and their Affiliates and
each of their respective Representatives and successors and assignees (collectively, the &ldquo;<U>Buyer Indemnified Parties</U>&rdquo;)
from and against any and all Damages actually suffered or incurred by a Buyer Indemnified Party on or after the Closing Date to the extent
that such Damages directly or indirectly relate to or arise out of, </FONT>in connection with, with respect to or by virtue of any of
the following matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
breach of any representation or warranty made by any Seller contained in this Agreement or any other Transaction Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
breach of any covenant or agreement contained in this Agreement or any other Transaction Document by any Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;regardless
of any disclosure on the Seller Disclosure Schedule, by virtue of the business or operations of any Seller or any of their Affiliates
up to and including the Closing Date, including any of the matters listed in <U>Schedule 12.1(c)&nbsp;</U>hereto (collectively, the &ldquo;<U>Known
Claims</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Excluded Liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Excluded Assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
bulk sales laws of any jurisdiction in connection with the transactions contemplated by this Agreement (in view of such indemnification
obligation the Buyers hereby waive the Sellers&rsquo; compliance with any such bulk sales laws as a condition to the Closing hereunder);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
Action initiated by a current or former shareholder of the Sellers relating to the transactions contemplated by this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
claims relating to Fraud or intentional misconduct or willful breaches of this Agreement or the other Transaction Documents (the &ldquo;<U>Bad
Actor Claims</U>&rdquo;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;(A)&nbsp;the
payment (or non-payment) of the Transitional Employees&rsquo; salaries or wages, the provision (or non-provision) of benefits to the Transitional
Employees, any termination of the Transitional Employees&rsquo; employment (other than at the direction of BSC) or tax withholding, and
any remittance to the appropriate tax authorities for services that the Transitional Employees provide to Buyer Employer or its Affiliates,
in each case during the Employee Transition Period, (B)&nbsp;any claims relating to Contracts between the Transitional Employees and Sellers,
whether or not arising out of or related to any termination of the Transitional Employees&rsquo; employment at the direction of BSC; and
(C)&nbsp;the violation by any Seller of any applicable federal, state, or local law related to the employment of the Transitional Employees
during the Employee Transition Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section&nbsp;12.2</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification
by the Buyers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">From
and after the Closing, the Buyers will, jointly and severally, indemnify, defend and hold harmless the Sellers and their Affiliates and
each of their respective Representatives and successors and assignees (collectively, the &ldquo;<U>Seller Indemnified Parties</U>&rdquo;
and each, a &ldquo;<U>Seller Indemnified Party</U>&rdquo;) from and against any and all Damages actually suffered or incurred by a Seller
Indemnified Party on or after the Closing Date to the extent that such Damages directly or indirectly relate to or arise out of, </FONT>in
connection with, with respect to or by virtue of any of the following matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
breach of any representation or warranty made by any Buyer contained in this Agreement or any other Transaction Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;a
breach of any covenant or agreement contained in this Agreement or any other Transaction Document by any Buyer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Acquired Assets to the extent arising out of or related to the operation of the CIED Business on or after the Effective Time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
violation by any Buyer Employer or its Affiliates of any applicable federal, state, or local law related to the leased employment of the
Transferred Employees during the Employee Transition Period; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Assumed Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;12.3</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Claim
Procedures</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event that a Buyer Indemnified Party or a Seller Indemnified Party (each, an &ldquo;<U>Indemnified Party</U>&rdquo;) desires to make
a claim against another party hereto (the &ldquo;<U>Indemnifying Party</U>&rdquo;, which term includes all Indemnifying Parties if more
than one, in connection with any third-party Action at any time instituted against or made upon it for which it may seek to bring a claim
hereunder (a &ldquo;<U>Third-Party Claim</U>&rdquo;)), the Indemnified Party will promptly notify the Indemnifying Party of such Third-Party
Claim and of its claims with respect thereto; <U>provided</U>, that failure to promptly give such notice will not relieve the Indemnifying
Party of its obligations under this <U>Section&nbsp;12.3</U>, except to the extent, if any, that the Indemnifying Party has actually and
materially been prejudiced thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to paragraph (e)&nbsp;below, the Indemnifying Party will, upon its written confirmation of its obligation to indemnify the Indemnified
Party in full on a dollar-for-dollar (and, for the avoidance of doubt, without regard to any limitation in <U>Section&nbsp;12.5</U> hereof)
with respect to such Third-Party Claim, have the right to assume the defense of the Third-Party Claim with counsel of its choice reasonably
satisfactory to the Indemnified Party by written notice to the Indemnified Party within twenty (20) days after the Indemnifying Party
has received notice of the Third-Party Claim; <U>provided</U>, <U>however</U>, that the Indemnifying Party must conduct the defense of
the Third-Party Claim actively and diligently thereafter in order to preserve its rights in this regard; and, <U>provided further</U>,
that the Indemnified Party may retain separate co-counsel at its sole cost and expense and participate in the defense of the Third-Party
Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Indemnifying Party will not consent to the entry of any judgment or enter into any settlement with respect to the Third-Party Claim without
the prior written consent of the Indemnified Party unless the judgment or proposed settlement (i)&nbsp;includes an unconditional release
of all Liability of each Indemnified Party with respect to such Third-Party Claim, (ii)&nbsp;involves only the payment of money damages
that are fully covered by the Indemnifying Party (including amounts deemed to be paid by the Sellers pursuant to <U>Section&nbsp;12.4</U>
by distribution of amounts to any Buyer from the Escrowed Funds or by set-off against any Post-Closing Adjustment Amount payable to the
Sellers which are due and payable by the Buyers), and (iii)&nbsp;does not enjoin or otherwise restrain the Indemnified Party or impose
an injunction or other equitable relief upon the Indemnified Party or subject the Indemnified Party to criminal Liability. So long as
the Indemnifying Party has assumed and is conducting the defense of the Third-Party Claim in accordance with <U>Section&nbsp;12.3(b)</U>&nbsp;above
the Indemnified Party will not consent to the entry of any judgment or enter into any settlement with respect to the Third-Party Claim
without the prior written consent of the Indemnifying Party (which consent will not be unreasonably conditioned, withheld or delayed by
the Indemnifying Party).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event that the Indemnifying Party fails to assume or has no further right to conduct the defense of a Third-Party Claim in accordance
with <U>Section&nbsp;12.3(b)</U>&nbsp;above, (i)&nbsp;the Indemnified Party may defend against the Third-Party Claim in any manner it
reasonably may deem appropriate and consent to the entry of any judgment or enter into any settlement with respect to, such Third-Party
Claim (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith); <U>provided</U>,
<U>however</U>, that, subject to the rights of the Indemnified Party above, the Indemnifying Party may retain separate co-counsel at its
sole cost and expense and participate in the defense of the Third-Party Claim, (ii)&nbsp;the Indemnifying Party will remain responsible
for any Damages the Indemnified Party may suffer as a result of such Third-Party Claim to the extent subject to indemnification under
this <U>Article&nbsp;XII</U>, and (iii)&nbsp;the Buyer Indemnified Parties shall retain all remedies to which they are entitled under
this <U>Article&nbsp;XII</U> (including recovery against the Escrowed Funds and set-off against any Post-Closing Adjustment Amount payable
to the Sellers).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the foregoing, the Buyers shall have the right, at their discretion, to be responsible for the prosecution, defense and settlement of
(i)&nbsp;all matters relating to the Known Claims, any Product Liability Claims, and any other claims for which Buyers are entitled to
indemnity under <U>Section&nbsp;12.1</U> based upon or relating to Intellectual Property of any Person, (ii)&nbsp;any Third-Party Claim
in which the Indemnifying Party has a conflict of interest, (iii)&nbsp;any Third-Party Claim made by a Governmental Authority, (iv)&nbsp;any
Third-Party Claim that involves a customer of the CIED Business and the final determination of such Third-Party Claim could, in the reasonable
discretion of the Buyers, have an adverse impact on the CIED Business, and (v)&nbsp;any Third-Party Claim if such Third-Party Claim seeks
injunctive relief, specific performance, or other equitable relief from, or seeks to impose any criminal penalty, fine or other sanction
on, the Indemnified Party (the matters described in clauses (i), (ii), (iii), (iv)&nbsp;and (v), collectively, the &ldquo;<U>Buyer-Handled
Claims</U>&rdquo;). The Buyers shall pursue in good faith the prosecution, defense or settlement of all Buyer-Handled Claims, through
counsel of its selection, until such time, if any, that the Buyers shall elect not to pursue indemnification with respect to such Third-Party
Claim. The Buyers shall permit Elutia (on behalf of the Sellers), upon its reasonable request, to participate in the process of any settlement
or other resolution of any Buyer-Handled Claims until such time, if any, that the applicable Buyer Indemnified Party shall elect not to
pursue indemnification with respect to such Third-Party Claim; <U>provided</U>, <U>however</U>, that the Buyers shall be entitled to settle,
control, compromise or otherwise dispose of Buyer-Handled Claims in their sole discretion and without obtaining the consent of the Sellers.
The Sellers will remain responsible for any Damages of the Buyer Indemnified Parties as a result of such Buyer-Handled Claims to the extent
subject to indemnification under this <U>Article&nbsp;XII</U>, and the Buyer Indemnified Parties shall retain all remedies to which they
are entitled under this <U>Article&nbsp;XII</U> (including recovery against the Escrowed Funds and set-off against any Post-Closing Adjustment
Amount payable to the Sellers).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;12.4</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Payment
of Claims</U>. In the event of any bona fide claim hereunder, the Indemnified Party will notify the Indemnifying Party of such claim in
writing as soon as reasonably practicable. With respect to liquidated claims for Damages, if within thirty (30) days the Indemnifying
Party has not contested such claim in writing, the Indemnifying Party will pay the full amount thereof, subject to the limitations set
forth in <U>Section&nbsp;12.5</U> and except as set forth in the following sentence of this <U>Section&nbsp;12.4</U>, within ten (10)&nbsp;days
after the expiration of such period. In order to satisfy any payment obligations of the Sellers with respect to any claim pursuant to
this <U>Article&nbsp;XII</U>, the Buyer Indemnified Parties shall have the right to recover Damages: (a)&nbsp;first (i)&nbsp;from the
Escrowed Funds subject to the terms of the Escrow Agreement, to the extent available, and (ii)&nbsp;by offsetting against any Post-Closing
Adjustment Amount payable to the Sellers (whether or not then required to be paid), or through a combination of the methods specified
in the foregoing clauses (i)&nbsp;and (ii); and (b)&nbsp;subject to the limitations herein, if the amount of such Damages exceeds the
amounts available pursuant to clause (a)&nbsp;above, directly against the Sellers, subject to any applicable limitations set forth herein
on the amount of any such recoverable Damages. Without limiting the foregoing, in addition to the individual obligations of each Seller
set forth herein, the ability of the Buyers to recover any Damages under this <U>Article&nbsp;XII</U> shall represent an express contract
right to recover against the Escrowed Funds and to offset against any payments owed by the Buyers to the Sellers pursuant to this Agreement,
if any, and nothing in this <U>Article&nbsp;XII</U> shall be deemed to require any Buyer to obtain jurisdiction over any Seller, or pursue
any process in connection therewith beyond that expressly required by the terms of this <U>Article&nbsp;XII</U>. The Buyer Indemnified
Parties&rsquo; rights of recovery hereunder are severable and distinct; <U>provided</U>, that in no event shall any Buyer Indemnified
Party be entitled to recover the same Damages more than once under all of such sections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;12.5</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Limitations
of Liability and Calculation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Threshold</U>.
No Indemnifying Party shall be liable for any Warranty Claim unless and until the applicable Indemnified Parties have incurred, as to
all Warranty Claims by such Indemnified Parties, Damages in excess of [***] (the &ldquo;<U>Basket Amount</U>&rdquo;), in which case such
Indemnified Parties shall have the right to payment of all such Losses that are in excess of the Basket Amount. Notwithstanding anything
to the contrary in this <U>Section&nbsp;12.5</U>, the threshold limits imposed by this <U>Section&nbsp;12.5(a)</U>&nbsp;shall not apply
to any Damages arising out of or in connection with any Claim other than a Warranty Claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Maximum
Liability</U>. The parties specifically agree that, notwithstanding any provision of this Agreement to the contrary, (i)&nbsp;the maximum
aggregate Liability of the Sellers or the Buyers (as applicable) for any Warranty Claim (other than Bad Actor Claims) under this Agreement
will not exceed the Escrow Amount; (ii)&nbsp;the maximum aggregate Liability of the Sellers or the Buyers (as applicable) for any Special
Claims and any claims for breaches of any Fundamental Warranties (other than claims for Fraud) will not exceed the Base Purchase Price;
and (iii)&nbsp;the maximum aggregate Liability of the Sellers or the Buyers (as applicable) for any Fundamental Excluded Claims and Fraud
claims, in each case, shall be uncapped.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Time
Limit</U>. All warranties of the Buyers or the Sellers in this Agreement or in any document, certificate or other instrument delivered
by any such parties under this Agreement, and the obligations of the parties with respect thereto, shall survive the Closing and shall
expire on, and no Indemnifying Party will be liable for any Damages hereunder with respect to a breach of such warranties unless a written
notice of a Warranty Claim is given by the Indemnified Party to the Indemnifying Party with respect thereto prior to, the twelve (12)
anniversary of the Closing Date. All Fundamental Warranties shall survive for six (6)&nbsp;years, except Fundamental Warranties relating
to <U>Section&nbsp;5.9</U> (<I>Taxes</I>), shall survive for the statute of limitations with respect to the applicable underlying subject
matter. Subject to the foregoing, all other covenants, agreements and indemnities of the parties contained in this Agreement will survive
the Closing indefinitely in accordance with their terms. Notwithstanding the foregoing, if at any time prior to the applicable expiration
date set forth above any Indemnified Party delivers a written notice to the Indemnifying Party, then such Claim asserted by such Indemnified
Party shall survive until such time as such Claim is fully and finally resolved. Notwithstanding the foregoing, nothing contained herein
shall be deemed to limit any Buyer Indemnified Party&rsquo;s ability to make a claim for Fraud or any intentional misconduct or willful
breach against any Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Materiality</U>.
Notwithstanding anything in this Agreement to the contrary, for purposes of determining whether any representation or warranty has been
breached, or is otherwise not true, and the amount of Damages arising therefrom, each representation and warranty in this Agreement (and
Schedules and Exhibits hereto or certificates delivered herewith) and in any Transaction Document shall be read without regard and without
giving effect to the terms or phrases &ldquo;material,&rdquo; &ldquo;in all material respects,&rdquo; &ldquo;Material Adverse Effect,&rdquo;
or similar words or phrases contained in such representation or warranty (as if such words or phrases were deleted from such representation
and warranty), except in the case of the use of the defined terms &ldquo;Seller Material Adverse Effect&rdquo; and &ldquo;Material Contract&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Insurance</U>.
Notwithstanding anything to the contrary set forth herein, nothing in this Agreement, including any periods of survival with respect to
the representations, warranties and covenants set forth herein, shall in any way require any Buyer Indemnified Party to be first paid
for a claim under any insurance policy before seeking recourse against any Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exclusive
Remedy</U>. Except (i)&nbsp;with respect to claims for Fraud or any intentional misconduct or willful breach of this Agreement, (ii)&nbsp;as
set forth in <U>Section&nbsp;3.2</U>, and (iii)&nbsp;equitable remedies pursuant to <U>Section&nbsp;13.5</U>, from and after the Closing,
the rights of the Buyer Indemnified Parties under this <U>Article&nbsp;XII</U> shall be the sole and exclusive remedies of the Buyer Indemnified
Parties for monetary damages with respect to Claims arising under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;12.6</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Tax
Treatment</U>. Any payment made pursuant to this <U>Article&nbsp;XII</U> shall be treated as an adjustment to the Purchase Price for U.S.
federal (and applicable state and local) income Tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;XIII</B></FONT><B><BR>
GENERAL PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.1</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">. All notices, requests, claims,
demands and other communications hereunder shall be in writing and shall be deemed to have been duly made or given when personally delivered,
mailed by first class mail, return receipt requested, or delivered by express courier service or via electronic mail (without the sender
receiving evidence of non-delivery) to the respective parties at the following addresses (or at such other address for a party as shall
be specified in a notice given in accordance with this <U>Section&nbsp;13.1</U>):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">if to the Buyers:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Boston Scientific Corporation</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">300 Boston Scientific Way</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Marlborough, Massachusetts 01752</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Chief Corporate Counsel</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: legalnotices@bsci.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">with a copy to (which shall not constitute notice):</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Goodwin Procter LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">100 Northern Avenue</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Boston, Massachusetts 02210</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">E-mail: MMcGrail@goodwinlaw.com; TOCallaghan@goodwinlaw.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Michael McGrail; Trey O&rsquo;Callaghan</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">if to the Sellers:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 1in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Elutia Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">20 Firstfield Road</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Gaithersburg, Maryland 20878</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Jeff Hamet</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: JHamet@elutia.com</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">with a copy to:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Kilpatrick Townsend&nbsp;&amp; Stockton LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">1100 Peachtree Street N.E., Suite&nbsp;2800</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Atlanta, Georgia 30309</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Attention: Mick Cochran</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Email: MCochran@ktslaw.com</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.2</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule&nbsp;of applicable law,
or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as
the economic or legal substance of the Acquisition is not affected in any manner materially adverse to any party. Upon such determination
that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in
order that the Acquisition be consummated as originally contemplated to the fullest extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.3</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Entire
Agreement; Assignment</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">. This Agreement and each
of the exhibits and schedules hereto, together with the Transaction Documents, constitutes the entire agreement among the parties with
respect to the subject matter hereof and supersede all prior agreements and undertakings, both written and oral, among the parties, or
any of them, with respect to the subject matter hereof. Except for an assignment by a Buyer to any of its Affiliates, this Agreement shall
not be assigned without the prior written consent of the other parties hereto. Upon any such permitted assignment and assumption by a
Buyer, such Buyer shall have no further Liability hereunder with respect to any obligations assumed by the assignee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.4</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Parties
in Interest</U>. Nothing in this Agreement, express or implied, is intended to confer on any person other than the parties and their respective
successors and assigns any rights or remedies under or by virtue of this Agreement; provided that the Indemnified Parties are express
third party beneficiaries hereof for purposes of <U>Article&nbsp;XII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.5</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Specific
Performance</U>. Each party agrees and acknowledges that (i)&nbsp;irreparable damage would occur in the event that the provisions of this
Agreement or the other Transaction Documents or obligations, undertakings, covenants or agreements of the parties were not performed in
accordance with their specific terms or were otherwise breached, and (ii)&nbsp;money damages, even if available, would be an inadequate
remedy for any such failure to perform or any breach of this Agreement and the other Transaction Documents. Accordingly, it is agreed
that the Buyers may have no adequate remedy at law and each party agrees that the Buyers shall have the right, in addition to any other
rights and remedies existing in their favor, to enforce their rights and the other party&rsquo;s obligations hereunder not only by an
action or actions for damages but also by an action or actions for equitable relief, including to an injunction to enforce specifically
the terms and provisions in this Agreement and the other Transaction Documents without proof of actual damages. If any such action is
brought by a Buyer, each Seller hereby waives the defense that there is an adequate remedy at law or the requirement for the posting of
any bond or similar security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.6</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
law of the State of Delaware, including its statutes of limitations, shall govern this Agreement and the other Transaction Documents,
the interpretation and enforcement of their terms and any claim or cause of action (in law or equity), controversy or dispute arising
out of or related to this Agreement and the other Transaction Documents or their negotiation, execution or performance, whether based
on contract, tort, statutory or other law, in each case without giving effect to any conflicts-of-law or other principle requiring the
application of the Law of any other jurisdiction, including any borrowing statute that would result in the application of the statute
of limitations of any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the parties hereby irrevocably and unconditionally consents to submit to the sole and exclusive jurisdiction of the courts of the State
of Delaware and of the United States District Court for the District of Delaware, in each case, located in the State of Delaware (the
 &ldquo;<U>Chosen Courts</U>&rdquo;) for any litigation, claim, dispute, proceeding, or cause of action arising out of or relating to the
this Agreement and the other Transaction Documents, or the negotiation, validity or performance of this Agreement and the other Transaction
Documents, or the transactions contemplated hereby and thereby (and agrees not to commence any litigation relating thereto except in such
Delaware courts), waives any objection to the laying of venue of any such litigation in the Chosen Courts and agrees not to plead or claim
in any Chosen Court that such litigation brought therein has been brought in any inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Each
of the parties agrees that service of process may also be made on such parties in any suit, action, dispute or proceeding in the manner
provided in <U>Section&nbsp;13.1</U> and agrees not to assert (by way of motion, as a defense, or otherwise) in any suit, action, dispute
or proceeding that service of process made in accordance with <U>Section&nbsp;13.1</U> does not constitute good and valid service of process.
Service made pursuant to the preceding sentence above shall have the same legal force and effect as if served upon such party personally
within the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.7</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>WAIVER
OF JURY TRIAL</U>. EACH OF THE PARTIES HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, DISPUTE, ACTION, PROCEEDING OR
COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE OTHER TRANSACTION DOCUMENTS
OR THE ACTIONS OF ANY PARTY HERETO IN NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.8</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Headings</U>.
The descriptive headings contained in this Agreement are included for convenience of reference only and shall not affect in any way the
meaning or interpretation of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.9</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts</U>.
This Agreement may be executed and delivered (including by facsimile transmission or.pdf) in one or more counterparts, and by the different
parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which
taken together shall constitute one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.10</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fees
and Expenses</U>. Except as otherwise expressly set forth herein, (a)&nbsp;all costs and expenses incurred in connection with this Agreement
and the Acquisition by the Sellers shall be paid by the Sellers, and (b)&nbsp;all costs and expenses incurred in connection with this
Agreement and the Acquisition by the Buyers shall be paid by the Buyers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.11</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment</U>.
This Agreement may not be amended except by an instrument in writing signed by BSC and Elutia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.12</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Waiver</U>.
At any time prior to the Closing, any party hereto may (a)&nbsp;extend the time for the performance of any obligation or other act of
any other party hereto, (b)&nbsp;waive any inaccuracy in the warranties contained herein or in any document delivered pursuant hereto,
and (c)&nbsp;waive compliance with any agreement of the other party or condition to such party&rsquo;s obligations contained herein. Any
such extension or waiver shall be valid if set forth in an instrument in writing signed by the party or parties to be bound thereby. The
failure of any party hereto to assert any of its rights hereunder shall not constitute a waiver of any of such rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.13</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Construction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Unless
the context of this Agreement otherwise requires, (i)&nbsp;words of any gender include each other gender; (ii)&nbsp;words using the singular
or plural number also include the plural or singular number, respectively; (iii)&nbsp;the terms &ldquo;hereof,&rdquo; &ldquo;herein,&rdquo;
 &ldquo;hereby&rdquo; and derivative or similar words refer to this entire Agreement; (iv)&nbsp;the terms &ldquo;Section&rdquo;, &ldquo;Schedule&rdquo;
and &ldquo;Exhibit&rdquo; refer to the specified section&nbsp;of, or schedule or exhibit to, this Agreement; (v)&nbsp;the words &ldquo;including,&rdquo;
 &ldquo;include&rdquo; and &ldquo;includes&rdquo; shall be deemed to be followed by the words &ldquo;without limitation&rdquo;; and (vi)&nbsp;the
word &ldquo;or&rdquo; shall be disjunctive but not exclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
words &ldquo;provided&rdquo; or &ldquo;made available&rdquo; or words of similar import (regardless of whether capitalized or not) when
used with reference to documents or other materials or information required to be provided or made available to the Buyers shall mean,
any documents or other materials or information posted to the VDR as of the Disclosure Cut Off Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;References
to agreements and other documents shall be deemed to include all subsequent amendments and other modifications thereto. References to
statutes shall include all regulations promulgated thereunder and references to statutes or regulations shall be construed as including
all statutory and regulatory provisions consolidating, amending or replacing the statute or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
language used in this Agreement shall be deemed to be the language chosen by the parties to express their mutual intent, and no rule&nbsp;of
strict construction shall be applied against either party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Whenever
this Agreement refers to a number of days, such number shall refer to calendar days unless Business Days are specified and shall be counted
from the day immediately following the date from which such number of days are to be counted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
accounting terms used herein and not expressly defined herein shall have the meanings given to them under GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.14</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Actions;
Privileged Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to <U>Article&nbsp;XII</U>, from and after the Closing (i)&nbsp;the Buyers shall have exclusive authority and control over the investigation,
prosecution, defense and appeal of all Actions with respect to Assumed Liabilities, and may settle or compromise, or consent to the entry
of any judgment with respect to, any such Action, without the consent of Sellers; (ii)&nbsp;the Sellers shall have exclusive authority
and control over the investigation, prosecution, defense and appeal of all Actions with respect to Excluded Liabilities, and may settle
or compromise, or consent to the entry of any judgment with respect to, any such Action, without the consent of the Buyers; and (iii)&nbsp;the
Sellers and the Buyers shall use reasonable efforts to cooperate in good faith with respect to the investigation, prosecution, defense
and appeal of all Actions that relate to both Excluded Liabilities and Assumed Liabilities; provided, that nothing in the foregoing portion
of this subsection (iii)&nbsp;will restrict the right of any party to engage its own counsel in connection with the investigation, prosecution,
defense or appeal of any Action that relate to both Excluded Liabilities and Assumed Liabilities; <U>provided</U> that if any Indemnified
Party seeks to assert a claim for indemnification with respect to any such matter, the parties hereto shall comply with the provisions
of <U>Article&nbsp;XII</U> instead of this <U>Section&nbsp;13.14(a)</U>&nbsp;with respect to such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
parties hereto hereby agree that their respective rights and obligations to maintain, preserve, assert or waive any attorney-client and
work product privileges belonging to any such party with respect to the CIED Business, the Acquired Assets, the Excluded Assets, the Assumed
Liabilities, the Excluded Liabilities and the Products (collectively, &ldquo;<U>Privileges</U>&rdquo;), shall be governed by the provisions
of this <U>Section&nbsp;13.14(b)</U>. With respect to matters relating to the Excluded Assets or the Excluded Liabilities, and with respect
to all files, books, records, work papers, documents, communications or other information of a Seller or any of its Affiliates prepared
in connection with the Transaction Documents or the transactions contemplated thereby, the Sellers shall have sole authority to determine
whether to assert or waive any Privileges, including the right to assert any Privilege against the Buyers and their Affiliates. The Buyers
and their Affiliates shall take no action without the prior written consent of the Sellers that would reasonably be expected to result
in any waiver of any such Privileges of a Seller or any of its Affiliates. After the Closing, the Buyers and their Affiliates shall have
sole authority to determine whether to assert or waive any Privileges with respect to matters relating to the Products, the Acquired Assets
or the Assumed Liabilities, including the right to assert any Privilege against the Sellers or their Affiliates. The Sellers shall not,
and shall cause their respective Affiliates not to, take any action after the Closing without the prior written consent of the Buyers
that would reasonably be expected to result in any waiver of any such Privileges of the Buyers. The rights and obligations created by
this <U>Section&nbsp;13.14(b)</U>&nbsp;shall apply to all files, books, records, work papers, documents, communications and other information
as to which the Sellers or their Affiliates would be entitled to assert or has asserted a Privilege without regard to the effect, if any,
of the transactions contemplated hereby (the &ldquo;<U>Privileged Information</U>&rdquo;). Upon receipt by a Seller or its Affiliates,
or by a Buyer or its Affiliates, as the case may be, of any subpoena, discovery or other request from any third party that actually or
arguably calls for the production or disclosure of Privileged Information of the other party or if a Seller or its Affiliates or a Buyer
or its Affiliates, as the case may be, obtains knowledge that any current or former employee of a Seller or its Affiliates, or of a Buyer
or its Affiliates, as the case may be, has received any subpoena, discovery or other request from any third party that actually or arguably
calls for the production or disclosure of Privileged Information of the other party, such party shall promptly notify the other party
of the existence of the request and shall provide such other party a reasonable opportunity to review the Privileged Information and to
assert any rights it may have under this <U>Section&nbsp;13.14(b)</U>&nbsp;or otherwise (at its sole cost) to prevent the production or
disclosure of Privileged Information. A Seller&rsquo;s transfer of any files, books, records, work papers, documents, communications or
other Privileged Information to a Buyer in accordance with this Agreement and such Seller&rsquo;s agreement to permit a Buyer to obtain
Privileged Information existing prior to the Closing are made in reliance on the parties&rsquo; respective agreements, as set forth in
this <U>Section&nbsp;13.14(b)</U>, to maintain the confidentiality of such Privileged Information and to take the steps provided herein
for the preservation of all Privileges that may belong to or be asserted by the Sellers or the Buyers, as the case may be. The access
to files, books, records, work papers, documents, communications or other Privileged Information being granted pursuant to this Agreement,
and the disclosure to the Buyers and the Sellers of Privileged Information relating to the CIED Business, the Acquired Assets, the Excluded
Assets, the Assumed Liabilities, the Excluded Liabilities or the Products pursuant to this Agreement in connection with the transactions
contemplated hereby shall not be asserted by the Sellers or the Buyers to constitute, or otherwise be deemed, a waiver of any Privilege
that has been or may be asserted under this <U>Section&nbsp;13.14(b)</U>&nbsp;or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; ">Section&nbsp;13.15</FONT><FONT STYLE="">&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Tax Advice</U>. Each party hereto acknowledges and agrees that it has not received and is not relying upon Tax advice from any other party
hereto, and that it has and will continue to consult its own advisors with respect to Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Article&nbsp;XIV</B></FONT><B><BR>
CERTAIN DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used herein the following
terms not otherwise defined have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Accountants</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.2(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquired Assets</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquired Equipment
and Tools</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;1.1(b)(iii)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquired Inventory</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.1(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquisition</U>&rdquo;
shall have the meaning set forth in the recitals hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquisition Proposal</U>&rdquo;
means any bona fide offer or proposal (other than an offer or proposal by a Buyer or any of its Affiliates) relating to any of the following:
(a)&nbsp;sale, lease, license, contribution or other disposition, directly or indirectly, by merger, consolidation, share exchange, business
combination, asset sale, or otherwise, of the CIED Business or any of the Acquired Assets, other than sales of Inventory or supplies in
the ordinary course of business, or (b)&nbsp;transaction which is similar in form, substance or purpose to any of the foregoing transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
means any pending or threatened action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative
or appellate proceeding and any informal proceeding), prosecution, contest, hearing, inquiry, inquest, inspection, audit, warning or untitled
letters, demand, examination or investigation issued, commenced, brought, conducted or heard by or before, or otherwise involving, any
Governmental Authority or any arbitrator or arbitration panel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Activities to Date</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.12(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means, with respect to any Person, any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled
by, or is under common control with, such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Agreement</U>&rdquo;
shall have the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Allocation</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.3</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Anti-Corruption
Laws</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;5.27(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Applicants</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;8.4(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Application Requirements</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;8.4(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Appraiser</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.2(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Assignment
Consent</U>&rdquo; </FONT>shall have the meaning set forth in <U>Section&nbsp;8.4(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Assumed Contracts</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.1(b)(vi)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Assumed Lease Contracts</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.1(b)(viii)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Assumed Liabilities</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;2.2</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bad Actor Claims</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;12.1(h)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Base Purchase Price</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.1(a)(i)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Basket Amount</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;12.5(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bill of Sale</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;4.2(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Books, Records and
Files</U>&rdquo; means any and all information, including proprietary and confidential information, including all business and personnel
records, books, documents, budgets, projections, sales data, studies, ledgers, journals, models, price lists, plans, equipment maintenance
records, technical documentation (including designs, design history files, specifications, functional requirements, operating instructions,
logic manuals, blueprints, schematic drawings, engineering data,&nbsp;etc.), user documentation (installation guides, user manuals, training
materials, release notes, working papers,&nbsp;etc.), clinical studies, data and documentation, customer, supplier, distributor and vendor
lists and files, regulatory filings, correspondence and documentation, other correspondence, account histories, sales literature and promotional
materials, information relating to the purchase of materials, supplies and services, pricing and cost information, research and commercial
data, credit information, catalogs, brochures and training and other manuals, complaint history, all documentation used in and data from
the development, design, research, testing and manufacture of products (including manufacturing processes and procedures, device manufacturing
records, process validation records and manufacturing records), and all other similar rights, property and information, and including
all documents, data or information that are reasonably related to or necessary for the continued design, development, manufacture, use,
testing, marketing, promotion, commercialization, sale or distribution of the Products or are useful to support the filing or prosecution
of the Seller Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>BSC</U>&rdquo; shall
have the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>BSC Acquired Assets</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.1(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Contingent
Workers</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;5.28(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Employee</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.28(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day on which banks are not required or authorized to close in the City of Boston, Massachusetts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer</U>&rdquo;
shall have the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer Cure Period</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;11.1(f)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer Employer</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;8.4(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer-Handled Claims</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;12.3(e)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer Indemnified
Parties</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;12.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyer Material Adverse
Effect</U>&rdquo; means any change or effect that, when taken individually or together with all other adverse changes and effects, has
had or could reasonably be expected to have a material adverse effect on the business, financial condition, assets, prospects, operations,
Liabilities or properties of the Buyers and their Affiliates, taken as a whole, or otherwise affect the ability of the Buyers to consummate
the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buyers</U>&rdquo;
shall have the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>CAPA Documentation</U>&rdquo;
means all documentation related to corrective and preventive actions. These documents detail the processes and actions undertaken to identify,
investigate, track and resolve issues (corrective actions) related to product quality, manufacturing processes, or other areas and to
prevent those issues from recurring (preventive actions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>CanGaroo&reg; Product</U>&rdquo;
means the family of products commonly known as CanGaroo&reg; offered for sale by one or more Sellers as of the date prior to the Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>CanGaroo&reg; RM
Product</U>&rdquo; means the family of products commonly known as CanGaroo&reg; RM offered for sale by one or more Sellers as of the date
prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Cause</U>&rdquo;
means the applicable employee&rsquo;s (i)&nbsp;dishonest statements or acts with respect to his or her employer or any Affiliate of his
or her employer, or any current or prospective customers, suppliers vendors or other third parties with which such entity does business;
(ii)&nbsp;commission of (A)&nbsp;a felony or (B)&nbsp;any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; or (iii)&nbsp;material
violation of the policies of his or her employer or the Buyer Employer, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>CE Mark</U>&rdquo;
means the &ldquo;CE&rdquo; marking (or such other successor marking to the &ldquo;CE&rdquo; marking) required under applicable Laws for
sale of a product in the European Economic Area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Chosen Courts</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;13.6(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>CIED
Business</U>&rdquo; </FONT>shall have the meaning set forth in the Recitals hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>CIED Envelope Products</U>&rdquo;
means bioenvelopes for use in securing a cardiac implantable electronic device (&ldquo;<U>CIED</U>&rdquo;) or neurostimulator or other
implantable medical devices having mechanical or electrical components, including Next Generation CIED Envelope Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Claim</U>&rdquo;
means a claim for indemnification pursuant to <U>Article&nbsp;XII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;4.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Date</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;4.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Inventory
Statement</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;3.2(b)(i)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Inventory
Value</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;3.2(b)(i)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Payment</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.1(a)(i)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>COBRA</U>&rdquo;
means Title X of the Consolidated Omnibus Budget Reconciliation Act of 1985</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>COBRA Liabilities</U>&rdquo;
means any and all Liabilities under COBRA<FONT STYLE="background-color: white">, and any other similar and applicable statute, </FONT>arising
out of events in connection with the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Code</U>&rdquo;
means the United States Internal Revenue Code of 1986.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Contract</U>&rdquo;
means any agreement, contract, instrument, certificate, note, indenture, purchase order, license, lease, commitment, understanding or
other arrangement, in each case whether written or unwritten.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Confidentiality
Agreement</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;8.3(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Covenant Claim</U>&rdquo;
means any claims by the Buyers the basis of which is that any covenants made by or on behalf of any Seller in this Agreement is, or is
alleged to be, breached.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>CPI</U>&rdquo; shall
have the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>CPI Acquired Assets</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.1(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Cut-Over Period</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;8.7(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Damages</U>&rdquo;
means all damages, interest, losses, costs, Taxes, payments, royalties, penalties, fines, obligations, judgments, awards, and expenses
that are incurred or suffered or that are claimed in good faith by a third party to have been incurred or suffered by such party with
respect to or relating to an event, circumstance or state of facts; <U>provided</U>, <U>however</U>, that in no event shall Damages include
punitive damages except to the extent such punitive damages are actually awarded to a third party in connection with a Third-Party Claim.
Damages shall specifically include court costs and the reasonable fees and expenses of legal counsel arising out of or relating to any
direct or third-party claims, demands, actions, causes of action, suits, litigations, arbitrations or Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Design History Files</U>&rdquo;
means the documentation relating to the development and regulatory approval of the Products, including (a)&nbsp;project plans, (b)&nbsp;specifications,
(c)&nbsp;requirement specifications, (d)&nbsp;risk management documentation, (e)&nbsp;clinical evaluation, (f)&nbsp;assessment of applied
standards, (g)&nbsp;verification and validation documentation, and (h)&nbsp;regulatory (including the FDA and any Notified Body) certification
documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Device Master Records</U>&rdquo;
means the necessary documentation for the manufacturing, distribution and service of the Products, including (a)&nbsp;specifications and
data sheets, (b)&nbsp;software requirement specifications, (c)&nbsp;software design specifications, (d)&nbsp;labeling information, (e)&nbsp;user
manuals and (f)&nbsp;manufacturing process information consisting of manufacturing process description, work instructions<I>,</I> test
procedures, manufacturing protocol<I>,</I> acceptance test protocol, list of materials and service documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure Cut Off
Time</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;4.2(a)(xv)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dispute Notice</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.2(b)(iii)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dispute Period</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.2(b)(iii)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disputed Inventory
Items</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;3.2(b)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Distributors</U>&rdquo;
shall mean sales agents engaged and classified by any Seller as other than employees, or compensated other than through wages paid by
any Seller through any Seller&rsquo;s payroll.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effective Time</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;4.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>EluPro&trade; Product</U>&rdquo;
means the drug-eluting product commonly known as EluPro&trade; offered for sale by one or more Sellers as of the date prior to the Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Employee Benefit
Plan</U>&rdquo; means (a)&nbsp;each employee benefit plan within the meaning of Section&nbsp;3(3)&nbsp;of ERISA (whether or not subject
to ERISA); and (b)&nbsp;stock option plans, stock purchase plans, equity-based plans, retention plans, profit sharing plans, bonus or
incentive plans, programs or arrangements, severance pay plans, programs or arrangements, deferred compensation arrangements or agreements,
employment agreements, executive compensation plans, programs, agreements or arrangements, change in control plans, programs or arrangements,
supplemental income arrangements, vacation plans, and all other employee benefit plans, agreements, and arrangements, not described in
(a)&nbsp;above; and (c)&nbsp;plans or arrangements providing compensation to employee and non-employee directors, in each case, that the
Seller sponsors, contributes to, or provides benefits under or through, or has any obligation to contribute to or provide benefits under
or through, if such plan provides benefits to or otherwise covers any current or former Business Employee or Business Contingent Worker
(or any of their spouses, dependents, or beneficiaries).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Employee Lease Agreement</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;4.2(a)(x)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Employee Transition
Period</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;8.4(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Encumbrances</U>&rdquo;
means any lien, pledge, hypothecation, charge, royalty, mortgage, security interest, encumbrance, equity, trust, equitable interest, claim,
preference, right of possession, lease, tenancy, license, encroachment, covenant, infringement, interference, Order, proxy, option, right
of first refusal, preemptive right, community property interest, legend, defect, impediment, exception, reservation, limitation, impairment,
imperfection of title, condition or restriction of any nature (including any restriction on the transfer of any asset, any restriction
on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise
or transfer of any other attribute of ownership of any asset), and includes any agreement to give any of the foregoing in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Enforceability Exceptions</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.2(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Environmental Laws</U>&rdquo;
means all Laws relating to protection of human health, safety, and the environment, including surface or ground water, drinking water
supply, soil, surface or subsurface strata or medium, ambient air, pollution control and Hazardous Materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Environmental Permits</U>&rdquo;
means all Permits applicable to the ownership, operation and use of the Acquired Assets issued pursuant to Environmental Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>ERISA</U>&rdquo;
means the Employee Retirement Income Security Act of 1974.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>ERISA Affiliate</U>&rdquo;
means the Sellers and each other Person that, together with the Sellers, is or at the relevant time was treated as a single employer under
Section&nbsp;414 of the Code or under Section&nbsp;4001(a)(14) of ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Escrow Agent</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.1(a)(i)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Escrow Agreement</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.1(a)(i)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Escrow Amount</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.1(a)(i)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Escrowed Funds</U>&rdquo;
means the amounts delivered to the Escrow Agent pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Estimated Inventory
Excess</U>&rdquo; means the amount by which the Estimated Inventory Value exceeds the Target Inventory Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Estimated Inventory
Shortfall</U>&rdquo; means the amount by which the Target Inventory Value exceeds the Estimated Inventory Value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Estimated Inventory
Statement</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;3.2(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Estimated Inventory
Value</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;3.2(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Ex-Im
Laws</U></FONT>&rdquo; means all Laws relating to sanctions, export, reexport, transfer, and import controls, anti-boycott, and similar
Laws, including the Export Administration Regulations, the International Traffic in Arms Regulations, U.S. sanctions Laws administered
by the U.S. Department of the Treasury&rsquo;s Office of Foreign Assets Control, Section&nbsp;999 of the Code, U.S. customs regulations
and the Foreign Trade Regulations and the customs and import Laws administered by U.S. Customs and Border Protection and other jurisdictions
in which any Seller or any of its Affiliates conducts business, or has been conducted, or is otherwise subject to, except to the extent
inconsistent with U.S. law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excess Adjustment
Amount</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;3.2(b)(ii)(2)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excluded Assets</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.2</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excluded Contracts</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.2(j)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excluded Employee
Liabilities</U>&rdquo; shall have the meaning set for the in <U>Section&nbsp;2.1(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;&ldquo;<U>Excluded
Inventory</U>&rdquo; shall have the meaning in <U>Section&nbsp;1.2(h)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excluded Inventory
Removal</U>&rdquo; shall have the meaning in <U>Section&nbsp;7.7</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excluded Liabilities</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;2.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excluded Patents</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.2(m)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Excluded Product
Liabilities</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;2.1(i)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo; means
the United States Food and Drug Administration, or any successor agency thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA Fraud Policy</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.12(h)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>FDCA</U>&rdquo;
means the Federal Food, Drug, and Cosmetic Act, as amended, at 21 U.S.C. &sect;&sect;&nbsp;301 <I>et seq.</I>, </FONT>as amended from
time to time, and the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fraud</U>&rdquo;
means with respect to any party to this Agreement, Delaware common law fraud in the making of the representations and warranties expressly
set forth in <U>Article&nbsp;V</U> or <U>Article&nbsp;VI</U> (as applicable) of the Agreement or any representation or warranty in any
Transaction Document or certificates delivered in connection with the Agreement made by such party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fundamental Excluded
Claims</U>&rdquo; means any claim described in <U>Section&nbsp;12.1(d)</U>, <U>Section&nbsp;12.1(e)</U>&nbsp;or <U>Section&nbsp;12.1(g)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fundamental Warranties</U>&rdquo;
means the warranties set forth in <U>Section&nbsp;5.1</U> (<I>Organization, Good Standing and Qualification; No Ownership Interests</I>),
<U>Section&nbsp;5.2</U> (<I>Authorization; Binding Obligations; Governmental Consents</I>), <U>Section&nbsp;5.4</U> (<I>Title to Assets;
Conveyance; Sufficiency</I>), <U>Section&nbsp;5.5</U> (<I>Intellectual Property</I>), <U>Section&nbsp;5.9</U> (<I>Taxes</I>), <U>Section&nbsp;5.12</U>
(<I>Clinical and Regulatory Matters</I>), <U>Section&nbsp;5.13</U> (<I>Brokers; Expenses</I>), <U>Section&nbsp;5.22</U> (<I>Related Party
Transactions</I>), Section&nbsp;5.29 (<I>Solvency</I>), <U>Section&nbsp;6.1</U> (<I>Organization and Qualification</I>) and <U>Section&nbsp;6.2</U>
(<I>Authority Relative to this Agreement</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fundamental Warranty
Claim</U>&rdquo; means any claims by the Buyers (or Sellers, as applicable) the basis of which is that any Fundamental Warranty made by
or on behalf of Sellers (or the Buyers, as applicable) is, or is alleged to be, untrue or inaccurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles in effect from time to time, consistently applied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Government Healthcare
Program</U>&rdquo; means the Medicare, Medicaid, and CHAMPUS/TRICARE programs, any other similar or successor federal healthcare programs
(as defined in 42 U.S.C. &sect; 1320a-7b(f)) and any similar state or local healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Government
Official</U>&rdquo;</FONT> means any (i)&nbsp;full- or part-time officer or employee of any Governmental Authority, whether elected or
appointed; (ii)&nbsp;person acting in an official capacity or exercising a public function for or on behalf of any Governmental Authority;
or (iii)&nbsp;political parties, political party officials, or candidates for political office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Governmental Authority</U>&rdquo;
means any (a)&nbsp;nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction
of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or quasi-governmental authority
of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board,
instrumentality, officer, official, representative, organization, unit, body or Person and any court or other tribunal); (d)&nbsp;multi-national
organization or body; or (e)&nbsp;individual, entity or body exercising, or entitled to exercise, any executive, legislative, judicial,
administrative, regulatory, police, military or taxing authority or power of any nature. For the avoidance of doubt, &ldquo;Governmental
Authority&rdquo; shall include the FDA and any applicable Notified Body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>GPO</U>&rdquo; shall
have the meaning set forth in <U>Section&nbsp;5.26</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Hazardous Materials</U>&rdquo;
means any waste, pollutant, contaminant, hazardous substance, toxic or corrosive substance, hazardous waste, special waste, industrial
substance, by-product, process-intermediate product or waste, petroleum or petroleum-derived substance or waste, chemical liquids or solids,
liquid or gaseous products, or any constituent of any such substance or waste, the use, handling or disposal of which, or exposure to,
is governed by or subject to applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Healthcare
Laws</U>&rdquo; means the FDCA, Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act),
the federal Anti-Kickback Statute (42 U.S.C. &sect;&nbsp;1320a-7b(b)), the Stark Anti-Self-Referral Law (42 U.S.C. &sect;&nbsp;1395nn),
</FONT>the Civil Monetary Penalties Law (42&nbsp;U.S.C. &sect;&nbsp;1320a-7a), the Physician Payments Sunshine Act (42 U.S.C. &sect;&nbsp;1320a-7h),
the Anti-Inducement Law (42 U.S.C. &sect;&nbsp;1320a-7a(a)(5)), the Civil False Claims Act (31 U.S.C. &sect;&sect;&nbsp;3729 <I>et seq.</I>),
the Criminal Penalties for Acts Involving Federal Health Care Programs Provision (42 U.S.C. &sect;&nbsp;1320a-7b(a)), the exclusion laws
(42 U.S.C. &sect;&nbsp;1320a-7), HIPAA, the European Medical Device Directives (Directive 93/42/EEC, 90/385/EEC, and 98/79/EC as amended)
(the &ldquo;<U>Medical Device Directives</U>&rdquo;) and any European Economic Area Member State laws implementing the provisions of these
directives, the Misleading and Comparative Advertising Directive (2006/114/EC), the Unfair Commercial Practices Directive (2005/29/EC),
and any European Economic Area Member State laws implementing the provisions of these directives, all regulations or guidance promulgated
pursuant to such Laws, and any other foreign, federal, or state Law that regulates the design, development, research, testing, manufacturing,
processing, storing, importing or exporting, licensing, labeling or packaging, advertising, distributing or marketing of tissue, pharmaceutical
or medical device products, or any other Law that is related to health care fraud and abuse, kickbacks, marketing federally reimbursed
products, professional fee splitting prohibitions, patient or program charges, recordkeeping, claims process, documentation requirements,
medical necessity, referrals, the hiring of employees or acquisition of services or supplies from those who have been excluded from government
health care programs, quality, safety, privacy, security, licensure, accreditation or any other aspect of providing health care services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>HIPAA</U>&rdquo;
means the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &sect; 1320d et seq.), as amended by the Health Information
Technology for Economic and Clinical Health Act (42 U.S.C. &sect; 17921 et seq.).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
means, with respect to any Person, whether or not contingent, all (a)&nbsp;indebtedness or other obligations of such Person for borrowed
money, whether current, short-term or long-term, (b)&nbsp;obligations of such Person evidenced by bonds, notes, debentures, letters of
credit or similar instruments, (c)&nbsp;obligations of such Person under conditional sale, title retention or other agreements or arrangements
creating an obligation of such Person with respect to the deferred purchase price of property, goods or services, (d)&nbsp;interest rate
and currency obligation swaps, hedges or similar arrangements (including any breakage costs), (e)&nbsp;obligations of such Person under
or in respect of any lease that has been or should be accounted for as a capital lease in accordance with GAAP, (f)&nbsp;any obligations
for earnouts or other similar payments owed in connection with any acquisitions, (g)&nbsp;any commitment by which such Person assures
a creditor against loss (including contingent reimbursement liabilities with respect to letters of credit), (h)&nbsp;interest, fees, prepayment
penalties or premiums and other expenses owed with respect to any indebtedness or Liabilities of the type referred to in clauses (a)&nbsp;through
(g)&nbsp;above, and (i)&nbsp;all obligations of such Person to guarantee any of the foregoing types of obligations on behalf of any other
Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indemnified Party</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;12.3(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indemnifying Party</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;12.3(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Information Security
Measures</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;5.18(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual Property</U>&rdquo;
means intellectual property or proprietary rights of any description including (a)&nbsp;rights in any United States and foreign (i)&nbsp;patent,
patent application (including any utility models, provisionals, continuations, divisions, continuations-in-part, extensions, renewals,
reissues, revivals and reexaminations, any national phase PCT applications, any PCT international applications, and all foreign counterparts),
or industrial design, (ii)&nbsp;trademark, service mark, logo, trade dress or trade name, URL or domain name and (iii)&nbsp;related registrations
and applications for registration for any of the foregoing; (b)&nbsp;rights in works of authorship including any United States and foreign
copyrights and rights under copyrights, whether registered or unregistered, including moral rights, and any registrations and applications
for registration thereof and mask works; (c)&nbsp;Trade Secrets; (d)&nbsp;inventions, discoveries, or improvements, modifications, Know-How,
techniques, methodologies, writings, work of authorship, designs or data, whether or not patented, patentable, copyrightable or reduced
to writing or practice, including any inventions, discoveries, improvements, modification, know-how, technique, methodology, writing,
work of authorship, design or data embodied or disclosed in any: (i)&nbsp;computer source codes (human readable format) and object codes
(machine readable format), (ii)&nbsp;specifications, (iii)&nbsp;manufacturing, assembly, test, installation, service and inspection instructions
and procedures, (iv)&nbsp;engineering, programming, service and maintenance notes and logs, (v)&nbsp;technical, operating and service
and maintenance manuals and data, (vi)&nbsp;hardware reference manuals, (vii)&nbsp;user documentation, help files or training materials,
and (viii)&nbsp;schematics; (e)&nbsp;publicity rights; (f)&nbsp;rights in databases and data collections (including knowledge databases,
customer lists and customer databases) under the laws of the United States or any other jurisdiction, whether registered or unregistered,
and any applications for registration therefor; (g)&nbsp;any other proprietary or intellectual property rights now known or hereafter
recognized in any jurisdiction worldwide; and (h)&nbsp;goodwill related to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual Property
Assignment</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;4.2(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Inventory</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.1(b)(ii)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Inventory Adjustment
Cap</U>&rdquo; means [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Inventory Value</U>&rdquo;
means, as of any particular time, the value of the Acquired Inventory as determined in accordance GAAP applied on a consistent basis with
the determinations in the Sellers&rsquo; Financial Statements for prior periods (to the extent such determinations are consistent with
GAAP);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>IRS</U>&rdquo; means
the United States Internal Revenue Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Know-How</U>&rdquo;
(whether or not capitalized) means all factual knowledge and information that gives a Person the ability to develop, produce, manufacture
or market something that it otherwise would not have known how to develop, produce, manufacture or market with the same accuracy or precision,
including all inventions (whether or not patentable), invention disclosures, processes, procedures, writings, methods, algorithms and
formulae, know-how, Trade Secrets, technology, software code, protocols, information, knowledge, practices, formulas, instructions, skills,
techniques, proposals, technical data, designs, drawings (including engineering and auto-cad drawings), blue prints, computer programs,
apparatus, ideas, concepts, research and development information, results of experiments, test data, including pre-clinical and clinical
data, pre-clinical and clinical trial results, analytical and quality control data, manufacturing data and descriptions, market data,
devices, assays, chemical formulations, notes of experiments, specifications, compositions of matter, whether in intangible, tangible,
written, electronic or other form, and all documentation related to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Knowledge</U>&rdquo;
means, when used with respect to the Sellers, the actual knowledge of Dr.&nbsp;C. Randal Mills, Matthew Ferguson, Dr.&nbsp;Michelle Williams,
Jeffrey Hamet, Dr.&nbsp;Sonali Fonseca, Kimberly Mulligan, Erica Elchin, Courtney Guyer and Tamara Grossett; provided, that the Sellers
shall be deemed to have actual knowledge of a particular fact or other matter if any of such individuals is actually aware of that fact
or matter, or should be aware of such fact or matter after exercise of reasonable diligence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Known Claims</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;12.1(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Law</U>&rdquo; means
any national, supranational, state, provincial, municipal or local statute, law, constitution, ordinance, code, regulation, rule, notice,
court decision, interpretation, agency guidance, Order, resolution, corporate integrity agreement, stipulation, determination, requirement
or rule&nbsp;of law (including common law), code or edict issued, enacted, adopted, promulgated, implemented or otherwise put into effect
by or under the authority of any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liability</U>&rdquo;
means any Indebtedness, obligation, duty, commitment or liability of any nature (including any unknown, undisclosed, unmatured, unaccrued,
unasserted, contingent, indirect, conditional, implied, vicarious, derivative, joint, several or secondary liability), regardless of whether
such debt, obligation, duty, commitment or liability would be required to be disclosed on a balance sheet prepared in accordance with
GAAP and regardless of whether such Indebtedness, obligation, duty or liability is immediately due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>License Agreement</U>&rdquo;
shall have the meaning set forth in Section&nbsp;4.2(a)(xvii)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Major Customer</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.26</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Major Supplier</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.26</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Contract</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.3(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Negotiation Period</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.2(b)(iii)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>New Hire Document</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;8.4(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Next Generation
CIED Envelope Products</U>&rdquo; means, regardless of their development-stage, any planned or next generation CIED Envelope Products,
including their related Intellectual Property rights, developed for or by the Sellers as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Non-Transferred
Employee</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;8.4(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Notified Body</U>&rdquo;
shall mean an entity licensed, authorized or approved by the applicable government agency, department or other authority to assess and
certify the conformity of a medical device with the requirements of Council Directive 93/42/EEC of 14&nbsp;June&nbsp;1993 concerning medical
devices, as amended from time to time, and applicable harmonized standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Offered Employees</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;8.4(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ongoing Clinical
Trial Agreements</U>&rdquo; has the meaning set forth in <U>Section&nbsp;1.1(b)(xvii)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ongoing Vendor Agreements</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;1.1(b)(xvii)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Open-Source Software</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.5(l)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Operations Employees</U>&rdquo;
means the employees set forth on <U>Schedule 14(a)</U>&nbsp;who become Offered Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Order</U>&rdquo;
means any (a)&nbsp;order, judgment, injunction, edict, decree, ruling, pronouncement, requirement, determination, decision, opinion, verdict,
sentence, subpoena, writ or award issued, made, entered, rendered or otherwise put into effect by or under the authority of any court,
administrative agency or other Governmental Authority or any arbitrator or arbitration panel; or (b)&nbsp;contract with any Governmental
Authority entered into in connection with any Action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary Course
of Business</U>&rdquo; means an action taken by or on behalf of any Seller in the normal and ordinary course of operating the CIED Business;
<U>provided</U>, that an action shall not be deemed to have been taken in the &ldquo;ordinary course of business&rdquo; unless such action
is: (a)&nbsp;consistent with the past practices of such Seller and is taken in the ordinary course of the normal day-to-day operations
of such Seller; and (b)&nbsp;not required to be authorized by the direct or indirect equityholders of the Seller, the board of directors
or managers (or similar governing body) of such Seller or any committee of the board of directors or managers (or similar governing body)
of such Seller and does not require any other separate or special authorization of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Organizational Documents</U>&rdquo;
means the articles of incorporation, certificate of incorporation, charter, by-laws, articles of formation, certificate of formation,
regulations, operating agreement, certificate of limited partnership, partnership agreement and all other similar documents, instruments
or certificates executed, adopted or filed in connection with the creation, formation or organization of a Person, including any amendments
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permit</U>&rdquo;
means any (a)&nbsp;permit, license, certificate, franchise, concession, approval, consent, ratification, permission, clearance, confirmation,
endorsement, waiver, certification, designation, rating, registration, listing, qualification or authorization issued, granted, given
or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law; or (b)&nbsp;right under any
contract with any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted Encumbrances</U>&rdquo;
means (i)&nbsp;liens for Taxes not yet due and payable or liens for Taxes that are being contested in good faith through appropriate proceedings
and for which adequate reserves have been set aside, and (ii)&nbsp;statutory liens of landlords, liens of carriers, warehouse persons,
mechanics and material persons and other liens imposed by law, in each case incurred in the ordinary course of business consistent for
sums not yet due and payable, if a reserve or other appropriate provision, if any, as shall be required by GAAP shall have been made therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual, corporation, partnership, limited partnership, limited liability company, syndicate, person (including a &ldquo;person&rdquo;
as defined in Section&nbsp;13(d)(3)&nbsp;of the Securities Exchange Act of 1934, as amended), trust, association or entity or government,
political subdivision, agency or instrumentality of a government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Personal Information</U>&rdquo;
means, in addition to all information defined or described in Privacy Laws or by the Sellers as &ldquo;personal data,&rdquo; &ldquo;personal
information,&rdquo; &ldquo;personally identifiable information,&rdquo; &ldquo;PII,&rdquo; &ldquo;protected health information,&rdquo;
 &ldquo;PHI,&rdquo; or any similar term in the Sellers&rsquo; privacy policies or other public-facing statement, any information that regarding
or capable of being associated with an individual Person or device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Post-Closing Adjustment
Amount</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;3.2(b)(ii)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Closing Claims</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;1.1(b)(xvi)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Press Release</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;8.3(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Privacy Laws</U>&rdquo;
shall mean any Laws, statutes, rules, regulations, ordinances, orders, judgements, decisions, rulings or other applicable requirement
that govern the receipt, collection, compilation, use, storage, processing, sharing, safeguarding, security, disposal, destruction, disclosure
or transfer of Personal Information, and any such legal requirement governing privacy, data security, data or security breach notification,
any penalties and compliance with any order, including (i)&nbsp;HIPAA, amendments, and associated regulations; (ii)&nbsp;all state and
local data privacy and security laws dealing with data security and the protection of personal information, including Chapters 93H and
93I of the Massachusetts General Laws; (iii)&nbsp;the Sarbanes-Oxley Act of 2002; (iv)&nbsp;the information collection, reporting, and
safeguarding requirements of the FDA regulations; (v)&nbsp;Section&nbsp;5 of the Federal Trade Commission Act; (vi)&nbsp;the Electronic
Communications Privacy Act of 1986; (vii)&nbsp;the California Consumer Privacy Act; (viii)&nbsp;the Children&rsquo;s Online Privacy Protection
Act (COPPA); (ix)&nbsp;the CAN-SPAM Act; (x)&nbsp;the Telephone Consumer Protection Act; and (xi)&nbsp;any analogous legislation in any
jurisdiction in which the Sellers carry on the CIED Business and / or from which the Sellers collect Personal Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Privacy Requirements</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.18(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Privileged Information</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;13.14(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Privileges</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;13.14(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Product Liability
Claims</U>&rdquo; means any claims involving actual or alleged Liability for death or injury to person or property as a result of any
actual or alleged defect in any product manufactured or sold by or for a Seller at or prior to the Closing Date, or any actual or alleged
warranty, recall or similar Liability for any product used, manufactured or sold by or for a Seller at or prior to the Closing Date, or
any statutory Liability of a Seller or any Liability of a Seller assessed with respect to any failure to warn arising out of products
used, manufactured or sold prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Products</U>&rdquo;
means, collectively, the CanGaroo&reg; Product, CanGaroo&reg; RM Product, EluPro&trade; Product and CIED Envelope Products (including,
for the avoidance of doubt, Next Generation CIED Envelope Products), all related sizes, replacements, modifications, improvements and
line extensions, if any, and all related accessories and components, if any, in each case, as developed by or on behalf of the Sellers
as of prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Property Taxes</U>&rdquo;
means all real property Taxes, personal property Taxes and similar ad valorem Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Protected Health
Information</U>&rdquo; shall have the meaning as that term is defined in 45 C.F.R. &sect; 160.103.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase Price</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;3.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Real Property Contracts</U>&rdquo;
means any contract, lease or other agreement related primarily to any real property interests to which a Seller is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Release</U>&rdquo;
means any releasing, disposing, depositing, discharging, injecting, spilling, leaking, pumping, dumping, emitting, leaching, migrating,
escaping or emptying of a Hazardous Material at, into or onto the environment, the soil, surface waters, groundwater, land, stream sediments,
surface or subsurface strata and ambient air and biota living in or on such media including movement or migration through or in the environment,
whether sudden or non-sudden and whether accidental or non-accidental, or any release, emission or discharge as those terms are defined
in any applicable Environmental Law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Representatives</U>&rdquo;
means, in respect of any Person, the officers, directors, managers, employees, agents, attorneys, accountants, advisors, contracted parties
and other representatives of such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Retained Business</U>&rdquo;
means any and all businesses of the Sellers or their Affiliates other than the CIED Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Sales Agency Contracts</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;2.1(h)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Sales Employees</U>&rdquo;
means the Business Employees set forth on <U>Schedule 14(b)</U>&nbsp;who become Offered Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Sanctioned
Person</U>&rdquo; means a Person that is (a)&nbsp;the subject of Sanctions</FONT>, including any Person listed in any Sanctions-related
list of designated Persons, (b)&nbsp;operating, resident in or organized under the laws of a country or territory that is the subject
of country or territory-wide Sanctions (currently, Cuba,&nbsp;Iran, North Korea, Syria, the Crimea region of Ukraine, the so-called Donetsk
People&rsquo;s Republic, and the so-called Luhansk People&rsquo;s Republic (each a &ldquo;<U>Sanctioned Country</U>&rdquo;), the government
of any of these jurisdictions, or the Government of Venezuela), or (c)&nbsp;50% or more owned or controlled (as such term is used in the
definition of &ldquo;Affiliate&rdquo;) by any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<U>Sanctions</U>&rdquo;
means those trade, economic and financial sanctions laws, regulations, embargoes and restrictive measures (in each case having the force
of law) administered, enacted or enforced from time to time by (a)&nbsp;the United States (including the Department of Treasury, Office
of Foreign Assets Control</FONT> and the United States Department of State); (b)&nbsp;the United Nations Security Council, the European
Union, any European Union member state and His Majesty&rsquo;s Treasury of the United Kingdom; and (c)&nbsp;other similar governmental
bodies with regulatory authority over any Seller or any of its Affiliates, except to the extent inconsistent with U.S. law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller</U>&rdquo;
shall have the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Disclosure
Schedule</U>&rdquo; shall have the meaning set forth in <U>Article&nbsp;V</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Indemnified
Parties</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;12.2</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Intellectual
Property</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;1.1(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller IT Assets</U>&rdquo;
means any and all software (including object code, binary code, source code, libraries, routines, subroutines or other code, and including
commercial, open-source and freeware software), systems, servers, computers, hardware, firmware, middleware, networks, data communications
lines, routers, hubs, switches and all other information technology equipment, and all associated documentation used or held for use in
connection with the operation of the CIED Business of the Sellers as previously conducted, as currently conducted, or as currently proposed
to be conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Licenses</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.12(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Marks</U>&rdquo;
shall mean &ldquo;Aziyo&rdquo;, &ldquo;Elutia&rdquo; and any mark or domain set forth on <U>Schedule 14(c)</U>, in each case, that is
related to or used in the CIED Business, and any associated logos and any variations or other derivatives thereof; and, in each case,
whether in block letters or otherwise, whether alone or in combination with other words or elements, and including all translations, adaptations,
and other derivations and combinations thereof, and any marks confusingly similar thereto or embodying any of the foregoing either alone
or in combination with other words or elements, and all common law rights, registrations, applications for registration thereof and social
media handles and domain names associated therewith, together with any extensions and renewals thereof, and together with the goodwill
associated with any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Material
Adverse Effect</U>&rdquo; means any change, effect, development, event or occurrence that, individually or in the aggregate, has had,
or could reasonably be expected to have, a material adverse effect on or material adverse change with respect to (a)&nbsp;the business,
operations, condition (financial or otherwise), assets, prospects, operations, liabilities or properties of a Seller relating to the Acquired
Assets, or (b)&nbsp;the ability of a Seller to timely perform its obligations under this Agreement or consummate the transactions contemplated
by any Transaction Document, <U>except</U>, in the case of the preceding clause (a), for any such change, effect, development, event or
occurrence resulting from (i)&nbsp;the announcement of the Acquisition, (ii)&nbsp;changes in general economic or political conditions,
or (iii)&nbsp;changes, after the date of this Agreement, generally affecting businesses operating in the industry of the CIED Business,
including changes in Laws applicable to such industry; <U>provided</U>, <U>however</U>, that the effects resulting from changes, effects,
developments, events or occurrences described in clauses (ii)&nbsp;or (iii)&nbsp;may be deemed to constitute, and shall be taken into
account in determining whether there has been or could reasonably be expected to occur, a Seller Material Adverse Effect if such changes,
effects, developments, events or occurrences, individually or in the aggregate, disproportionately impact the CIED Business relative to
other businesses operating in the industry of the CIED Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Seller Non-Competition
Agreement</U>&rdquo; shall have the meaning set forth in <U>Section&nbsp;4.2(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Sellers</U>&rdquo;
shall have the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Service Provider</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;2.1(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shared Contract</U>&rdquo;
means any legally binding written or oral agreement, contract, lease, license instrument or other understanding to which a Seller is a
party with any non-Seller party that is not an Assumed Contract and which contract benefits or burdens both the CIED Business or a Product,
on the one hand, and the Retained Business or any Excluded Assets, on the other hand. For the avoidance of doubt, for purposes of this
Agreement the definition of &ldquo;Shared Contract&rdquo; shall exclude any collective bargaining agreements, employment agreements and
employment related benefit plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Special Claims</U>&rdquo;
means any claims for any of the matters indemnifiable under <U>Section&nbsp;12.1</U> or <U>Section&nbsp;12.2</U>, except for Fraud claims,
Fundamental Excluded Claims, Warranty Claims and Fundamental Warranty Claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
or &ldquo;<U>Subsidiaries</U>&rdquo; (whether or not capitalized) of any person means any corporation, partnership, limited liability
company, joint venture or other legal entity of which such person (either above or through or together with any other subsidiary), owns,
directly or indirectly, more than 50% of the shares or other equity interests the holders of which are generally entitled to vote for
the election of the board of directors or other governing body of such corporation or other legal entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Target Inventory
Value</U>&rdquo; means [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Tax</U>&rdquo; or
 &ldquo;<U>Taxes</U>&rdquo; (and with correlative meaning, &ldquo;<U>Taxing</U>&rdquo; and &ldquo;<U>Taxation</U>&rdquo;) means all income,
gross receipts, franchise, profits, estimated, alternative minimum, add-on minimum, sales, use, transfer, registration, value added, ad
valorem, excise, export, natural resources, severance, margin, escheat, stamp, withholding, occupation, premium, windfall profit, environmental,
customs, duties, real property, personal property, capital stock, capital gains, net worth, intangibles, social security, pension insurance
contributions, employment, unemployment, disability, payroll, license, employee or other tax or similar levy, of any kind whatsoever,
including any interest, penalties, or additions to tax in respect of the foregoing, whether disputed or not and including any obligation
to indemnify or otherwise assume or succeed to the Tax Liability of any other Person by law, contract or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Tax Return</U>&rdquo;
means any return, declaration, report, claim for refund, information return, or other document (including any related or supporting schedule,
attachment or amendment) filed or required to be filed with a taxing authority in connection with the determination, assessment, or collection
of any Tax or the administration of any laws, regulations, or administrative requirements relating to any Tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Technical Information</U>&rdquo;
means all Know-How, data, technology, and other information of any Seller or its Affiliates that is used or useful in the evaluation,
design, development, research, testing, registration, manufacture, processing, packaging, labeling, distribution, use or sale of each
Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Termination Date</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;11.1(b)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Third-Party Claim</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;12.3(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trade Secrets</U>&rdquo;
means trade secrets, Know-How and confidential and proprietary information, information, designs, formulae, compositions, algorithms,
procedures, methods, techniques, ideas, research and development, data, specifications, processes, inventions (whether patentable or not
and whether reduced to practice or not) and improvements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction Documents</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.1</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction Form&nbsp;8-K</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;8.3(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Taxes</U>&rdquo;
shall have the meaning given in <U>Section&nbsp;9.3</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transferred Business
Employee Records</U>&rdquo; shall have the meaning given in <U>Section&nbsp;8.2(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transferred Contracts</U>&rdquo;
shall have the meaning given in <U>Section&nbsp;8.2(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transferred Employee</U>&rdquo;
shall have the meaning given in <U>Section&nbsp;8.4(a)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transitional Employees</U>&rdquo;
shall have the meaning given in <U>Section&nbsp;8.4(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transitional Period</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;8.7</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Treasury Regulations</U>&rdquo;
means the regulations promulgated by the U.S.&nbsp;Department of the Treasury under the Code, as such regulations may be amended from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Union</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;5.28(j)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>VDR</U>&rdquo; shall
have the meaning set forth in <U>Section&nbsp;4.2(a)(xv)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>WARN Act</U>&rdquo;
shall have the meaning set forth in <U>Section&nbsp;2.1(c)</U>&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warranty Claim</U>&rdquo;
means any claim by a Buyer or a Seller, the basis of which is that a warranty made by or on behalf of a Seller or a Buyer (as the case
may be) is, or is alleged to be, untrue or inaccurate (but always excluding Fundamental Warranty Claims).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Pages&nbsp;Follow</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, and intending
to be legally bound hereby, the parties hereto have caused this Asset Purchase Agreement to be duly executed and delivered as a sealed
instrument as of the date and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">BOSTON SCIENTIFIC CORPORATION</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ Jonathan Monson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Jonathan Monson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Executive Vice President and Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">CARDIAC PACEMAKERS INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Jonathan Monson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Jonathan Monson</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Vice President and Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ELUTIA INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ C. Randal Mills</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">C. Randal Mills, Ph.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ELUTIA MED LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ C. Randal Mills</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">C. Randal Mills, Ph.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>tm2525591d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2525591d1_ex99-1img001.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Elutia Announces Sale of BioEnvelope Business
to Boston Scientific Corporation for $88 Million</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Transaction affirms the strength of Elutia&rsquo;s
proprietary drug-eluting biologics platform and fully funds advancement of NXT-41 in breast reconstruction </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Company to provide update at the H.C. Wainwright
27th Annual Global Investment Conference on Wednesday, September 10 at 9:30 a.m. ET -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">GAITHERSBURG, Md., September 9, 2025 &mdash; Elutia
Inc. (Nasdaq: ELUT) (&ldquo;Elutia&rdquo; or the &ldquo;Company&rdquo;), a pioneer in drug-eluting biomatrix technologies, today announced
it has entered into a definitive agreement to sell its EluPro&trade; and CanGaroo&reg; bioenvelopes, designed to protect patients receiving
implantable medical devices, to Boston Scientific Corporation (NYSE: BSX) for $88 million in cash. The transaction underscores the value
of Elutia&rsquo;s proprietary drug-eluting biologic technology platform and enables the Company to complete development and commercialization
of its near-term blockbuster pipeline without the need for shareholder dilution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;EluPro has clearly demonstrated that our
proprietary drug-eluting biologics platform works at scale,&rdquo; said Dr. Randy Mills, CEO of Elutia. &ldquo;With the successful launch
of EluPro, seven national group purchasing organization contracts secured and more than 160 value analysis committee approvals, we have
shown that we can develop, manufacture and commercialize these highly regulated breakthrough products, and that they are valued by physicians.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;Now, with a transformed balance sheet,
an established commercial engine and a proven team, we are ready to repeat our success with NXT-41x. This novel technology is designed
to transform the $1.5 billion breast reconstruction market and help women recovering from breast cancer to thrive without compromise,&rdquo;
added Dr. Mills.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The deal is expected to close in the fourth quarter
of 2025, subject to customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transformative Impact for Shareholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transaction marks a pivotal advance for Elutia,
strengthening the Company&rsquo;s financial position and unlocking long-term shareholder value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Balance Sheet Transformation</B> &ndash; Positions Elutia to eliminate outstanding debt, substantially
resolve litigation from the Company&rsquo;s previously divested Orthobiologics business, and leaves the Company with a significantly reduced
burn rate.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Non-Dilutive Funding</B> &ndash; Fully funds advancement and commercialization of NXT-41 and NXT-41x,
creating a clear path to cash-flow positive operations without shareholder dilution.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>Focus</B> &ndash; Enables Elutia to dedicate its resources toward advancing its SimpliDerm franchise
and first-in-class drug-eluting pipeline in the $1.5 billion U.S. breast reconstruction market. Elutia will directly leverage its considerable
experience developing EluPro to address this even larger unmet clinical need and market opportunity.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BofA Securities is acting as financial advisor
to Elutia in the sale of its BioEnvelope business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Company Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Members of the Company&rsquo;s management
team will provide a company update at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will begin on
Wednesday, September 10 at 9:30 a.m. Eastern Time / 6:30 a.m. Pacific Time. A webcast of the presentation can be accessed by
clicking here.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please log in approximately 10 minutes prior to
the scheduled start time. A live and archived webcast of the event will be available on the &ldquo;Investors&rdquo; section of the Elutia
website at&nbsp;http://investors.elutia.com/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Elutia</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Elutia develops and commercializes drug-eluting
biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need
of implantable technologies, Elutia&rsquo;s mission is humanizing medicine so patients can thrive without compromise. For more information,
visit www.Elutia.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains &ldquo;forward-looking
statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. Forward-looking statements can be identified by words such as &ldquo;projects,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
&ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;believes,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;promise&rdquo; or similar references
to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered
forward-looking statements, including any statements and information concerning the market reception of EluPro, including the timing and
anticipated success thereof. These forward-looking statements are based on our management&rsquo;s beliefs and assumptions and on information
currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements
are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking
statements, including, but not limited to the following: our ability to successfully commercialize, market and sell our EluPro product;
our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and
our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims
related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits
and claims; our ability to prevail in lawsuits and claims seeking indemnity, contribution and insurance coverage for FiberCel and other
viable bone matrix product liabilities; the continued and future acceptance of our products by the medical community; our ability to enhance
our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our
commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number
of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our
ability to successfully realize the anticipated benefits of the November 2023 sale of our Orthobiologics business; physician awareness
of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete
against other companies, most of which have longer operating histories, more established products and/or greater resources than we do;
pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations
that could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by
the FDA and comparable foreign authorities for our products and product candidates; our ability to obtain, maintain and adequately protect
our intellectual property rights; and other important factors which can be found in the &ldquo;Risk Factors&rdquo; section of Elutia&rsquo;s
public filings with the Securities and Exchange Commission (&ldquo;SEC&rdquo;), including Elutia&rsquo;s Annual Report on Form 10-K for
the year ended December 31, 2024, as such factors may be updated from time to time in Elutia&rsquo;s other filings with the SEC, including
Elutia&rsquo;s Quarterly Reports on Form 10-Q, accessible on the SEC&rsquo;s website at www.sec.gov and the Investor Relations page of
Elutia&rsquo;s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties,
you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia
in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required
by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new information, future developments or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investors:</B><BR>
Matt Steinberg<BR>
FINN Partners<BR>
matt.steinberg@finnpartners.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>elut-20250908.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaeKObOdzZR+aYkxtmBybSmqnyUjsIQkECT/K7qmgTkB -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:elut="http://aziyo.com/20250908" elementFormDefault="qualified" targetNamespace="http://aziyo.com/20250908">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aziyo.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="elut-20250908_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="elut-20250908_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>elut-20250908_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>elut-20250908_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="elut-20250908.xsd#Cover" roleURI="http://aziyo.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aziyo.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2525591d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2525591d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> 5 # 2(  A$! Q$!_\0
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MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)J!MH[:)1/MC1MTAY_B!Z K^M>B?#O0?^$?\%6%HZ;;B1?/G'?>_.#]!A?\
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M_P! V+_P)C_QKZ9HKH^L3,O9H^9O^%0>,_\ H&Q?^!,?^-1O\)/&J=-(5_\
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MVR/E7ZY/TKWW%&*IXB;\A*FBII>EVFCZ?#8V,*PVL*[4C4=/\3WS5RBBN<T
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-%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ELUTIA INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001708527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-4790334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">20
Firstfield Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">247-1170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class&#160;A
    Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELUT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2525591d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aziyo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>elut-20250908.xsd</File>
    <File>elut-20250908_lab.xml</File>
    <File>elut-20250908_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2525591d1_8k.htm">tm2525591d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2525591d1_8k.htm": {
   "nsprefix": "elut",
   "nsuri": "http://aziyo.com/20250908",
   "dts": {
    "schema": {
     "local": [
      "elut-20250908.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "elut-20250908_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "elut-20250908_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2525591d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://aziyo.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2525591d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2525591d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aziyo.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-25-088481-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-088481-xbrl.zip
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MH2),YYT#7S=V@WLS;?&-^^7>OFJW_ ]02P,$%     @ $$@I6W3Y14[C)
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MLV#CKO#!C8^*OME,L571H@ZC-5UA9<QM378V+_6Y3+ H'@6^$1\+3)9JEJ[
M?U/:1H\^\'OJLX'<LQQ7HO"+0PHE.2)981:7X$8'MI*&)DZ.M!.Z\EK[0PO!
MQ=!7%YRBR$)B!L6E[TEA<V BH,*(5*TTWCM:T^@?**QEW;6T)@K&ROHIF4""
M"7AJB.F6& ,B"G['Q3..)E,%:\UT)N=95\LR'>M@^5A'C;7]&UA&$"I([VC.
MY(#"#LB:(9*2#@_>P1I6)AJIKK[)RD9R(7"#J+ 35PF(^)J/&^C-HD\0X#.%
MVR#CE$PM[!0$,4Q+-U(EX@$@ :D3^L8Y-;NAMBV]K6=13L=-U:5I:7#N+H8D
MZ8KL(\F<CW+R"T<DRV/"M Y%B4TB4]?K@4P9Q4!V-LO2?3<7GWQ.9?K+5+=L
ME52W7(I^[*F=.3YDAPG"G[V6Y3GLEW.?37U&*BG!,&8T0]X@TU*@U8"F7NS;
MAJ%*,_W ,",R-A.[ MA-&[^I:;&SLY!I\8O8B5F>)RL!%IU0(6B,1/EI]%B(
MGI6D!'Z.Z05OE<+LQ2#HY$#[/G* N6LM4QS<&\<DR<G*,W4P11O$A!8:VPM^
MZ:U"^=2ALMNR]1?9QFGUA?%KQJ[,:4?LF$U]T\I!XVEX*I8?A'I1;G9-RE#.
M&9Y9BU-7JI'CJ"YKRVNXF7=&Z?,.V=4A\%94J$^NZ.@SMA.WQ"QX2UP21P1@
M=$3;SD&EO#D%U"] XW>'L-:>,EKUZ$&E7SIF!(H.Q =8.4[U) BND2WH(FJ*
M2S_9G9;9Z<TJGWJJ*Q2>ZA[+-*UNQ*!&@:=1(!,4:&EEZ7@5LOQ0<%^+#R,A
MFUL'\\]*Y64'"N6D:^.HI.LLZ6KI,6KL>";(&(0A06B^K4YB<!R@NT&2AB?K
M!L<:A:ZL&!6@GX,-6GR$>5SSS-+/;'0)IAJ6/53>0_%I5WBN ">D^%QG (J/
MT0['&ZNCM(>!!!P9=YA]8?JH,,+48ZR!FWX81,JMG'H!/I:;U VBWI+@XWH\
M3,6X1)>K%T=@(.K"&%EC!YZ7VY=\<" E1^7/!<:YHJ!KP(Q#"=L/;<%10[.6
M_!_CC%%8R)>PT1AK*Q"QE<Z<NYH7?;D4)HK69 R2@I=4+%\DO"5.MHD[:OK%
MK'=ILKYB)>;?@CG+N?2-0<<NQP-'Y#7Y((A-J2T!:7+^5$^7208KLE*>'48V
M]791V%JUB$(B%FVM<I5LTSZ9^2L.DQ*E"L-#59'H3RIIN0(YI\E)J&RQGJX%
MT-$'(6,ODA8.K5UY$PC 0$WJU6M+ E<;4O6FCO$1*V>P@E5Q@%4?S_P$L:3P
MAEI5[.LHORH#FHU9"S'K^NB54UEC9K-FC 88"-1G+!7*TO@O (W?FU)@?\%R
M0!)%E4S6'A8#U(\1;B1J#$00(P!&+)OCH;0\JBKYPL<07@]0?*CE XQST9BM
M&BY@DE@QY]MD&*9B=>.(.)/B6F1F[AIT2!G8JM2$,K)RX/8H4-,+@+@I:0G4
MXH1QORK0E<* E@LD'X7N+5HU<5+T1D$Y,%'HJF4J00UC72."5VEC)(6/N5X0
M#IKCKST-#Y9KAHZ*0'M\0B/KN+%A:+P!.4!B<EP)O^0#*/D,LBJO&0H*[9L[
MBW655TG&01ONR029FFWD4\Y 0F/@"#C75=&@""-S>[0<9>Q3X@3H&L2I5+$/
M78&?V6W-Q5CZK8*8,BW6!D--4/%N2"19@J?"7$@4KH_EI%@'JH+W6@).M37S
MH_0'R85),U@K *#;[%D44*0O*U!M<N+#H(#CKBZ1+XRJJB^4C'%]74H+AC*5
MW4Z- R9+'"+Y3T'G@")*B^[(-;GAH(9B5884(YXR!5;'+CCZ+:&R9W^].E62
MZ29PT<V?JCI(I1E5A"@S?@J$D*,?UP,WRI"TI26LJ5\:XIE0'6)7D?J([#I?
M"+!II@94HIV>4@80P\P4,W-$%]:1E"PHDLS4'%42.P?[7J* CX75QOPT?G'[
M/+VD&V8Y@=]AD(L!!\EBBYBB1W20(G$CL_JS *,O^@%5F^DZ!QU,U>8!'H,=
M#@/'1,.3I5HFM(O4I[QTC2OH BZDJ>W&V9)2=QWH&Z)@5:4K>&\<4%X1*.$/
MU "9WNB<C@P!ZH>6/C6<:$A]" %KZ:C:2\<\TS,' B^*)X9'U:;I,T"QBV=L
M%2".&*&-2@#X]"0=@4+8OD$3[J1J&UFJ9 [V6PMS7?D/$V;K\!EJ#"VR<&0?
MA!/U+)N:)R);?:% AU! ]:GDI8PQ8&Z 24]28%)(62P5DJ F1<XQ+D*9=*R0
ME)A"2H>@X(G9*=37"EZM [JS)%!.VH&H)QP3LR3&;D;2F7P-'KA&UC86%PYZ
M'H*B _7B!7W7EAF9-QI,) R%%?UXC,B</E$"$\2EK[)A:00>GME +V96X";>
M$]&D8MF>ZQ/I"?Q.#*:1%7W(J)KDU\WP6=HKD;M8_RV2&F%39H3&)ED5PT!&
MJ55!=<=> /Y0F!Z&L;11K)KCKIB<#!9"FIT  %=A9_J 6@S2 _\#*+;*H?AL
MC.G6/3K6H&[A!^")"5$=*+.#2KAPA=IZITP0K!;H$-=I$7V3)4NY1'U40A_1
MCT>RDB.Y$9^8A$L?4Q0T'" T"$$():D/\JN,]/5RIJ=F$]\I*I]RO1*J('80
M3M37#VYH+HWO]( 0CX%VTM2+%C3O:AVT%@,EGP[!C&$'^F22KLS5X@'61ID
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M3W1&1R\51E:[@3/!GX-HZ.W_/U!+ P04    "  02"E;M\B__^&" 0!$S@D
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M7@%-\$E8E&B5JH)$ 0R9*<I;X,XA?CR."[*$P10+M1!%<3+5D]B\$;6C1F]
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M_?4#V*:TH_'OAC=+D&W>PRE0784/RF.T/:=3Z0O.]6ZFW'U<FCGOSFAC+(Y
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M<K0(D(,F6(P%"8O.QULB,/9/^FLN2G>7)!<H$8[1XV:LG1<ME)0E1154I*&
M591I-1P1I\64*I@T]DU#"IU?1WDV-G#:.(_(;.4*5\_8ZC1$B\7PCLD<IQM9
MJQ@$"^QTSG3KP$= J0V8\'%JLAIU.]4'L%)J,4NN)/KJ!C<:3-RF]$RUUMMX
M(*#0<T$B<+%'1Y=DF+(0[6N@=6H->7IPO:A</]VK**(RB<<3IO@66^7NJ6;0
M@6I2&B"TF%R1I2/3$ZX#5=?9%%S! 27>J*^K;!EK"%)\'@YU1'IBU-,!ZB;A
M-<.!-5#2^1K,17P51Z!8Y; OJ :RH-0;A0+!#L#=D@1NT(SBJ952O4;DY;E5
MO):&;]WEYJ[A!UB848QCB"7@[93IFY,;_<L\9MR8KNUWK[3X9H+'.!V1)2A>
M4/!7D"?VB]OFH-_<:%Q5CJ#JXQ_-- 0EP\/_S/+/%)VNZB]TGS$R 9^/D(BF
M(E"U7!/7OR(HW*LE<.(.!NB[]B)V:T\3VS0707_GIT[0V_D#;S2KH)"VXI&C
M.K8-&DIRBI0>"*>@9G*=[?>__ZP?EER\VZ3E*G')@2JO$3[O1*5LR??<K;GF
M$WX7_ &&/L_#+\&I*J<YWA-^IATP"2=HP>+O;J(3M!M^Q(>H-?] V6(]Z2U2
M7 ]XK9;+#;U;M]S0Z^?<T&-2!K<^.1OJTW3E&KK!*M>_ZGH[="9'5/S7<;F8
M@HMI2*6 Q%ZA1M,T*CK&AB/["5W.V*6W<"O>&%SF%+HQ>065NI'I=!GB(:%J
MT*@&OY4^OHEO3/+[B3 %BD.ZN4&N2W56R.L5.P[I-,%GA?4"W:>^($2P0)MB
MB;+_F%WMPXP1]PUA*&,#;FY<*\S 4-P('@2&[S07CH50GXZ37.T86@3X>LJ.
ME]Q?>%_ * 8;>5JJ*HU 0%Q;L5D#?7..EAO_&TYH0V9#=T1/#HD4J)#/#[K2
MBS")#46Y7K_<MD?"03C32ZYBV!$#89'@YVVERN23"+SNED-RA&5S0X;&1D'L
M)@>VJZF<$SLWIB. R_W6M%BC:8Y"X' T"*<D86KTU&QN*(SG%8258,H]+&_D
MN H<C/ S?62R4>0,ZS0:\_ X^ZTY*<)3326%)H<B%'F:IX82+)*ZQ;%@!0D,
M&:/E):;^@JU7+R58XJ\!)D*B*XI)Z0I'(X#B/U.P":NRMG@_R*?RQB !TQ04
M/#C7,.89!STQX>OPS'"&$\8:SE2TW7$F:N%\!%L, ^*K:-X73]%GI28.*Q#B
M8_2X"+ 84ZZ5Y0K3"5/+<C)W#.*Z9=<NW9"5NE,EA;,A.JI<6HP!NV$\P72%
M#!Y3J8AL$I0O? _M)99MXJC],D$URC2$RXEC!^\E4JA#'K!)X$PN&IFBB/$)
M'XVS8@JRS 0IP^T);Z#0WALJ&Y(>J%2-XM+,EDFBL?W'E1V8L3-4/K:DF@9J
MO^6&9_RW[]@<LYP\3>M!6Y'#2!;GZD?& U-23BBJF'<G,SR1=GZXEN>W,0R6
M3\D97&%)7=D1YU!.HUDSX5]S3LPVF9^3%ENB [Q5UBB]3C6+?-4?9J''V02]
MK2-'\-,K[GV^?*;/-F[7;Z4?9**A_I/FO'1#TW7W9-)ZP+($58C*M-B;K5F=
M30QR^=-)WYO[?'NP:[JZ*D*PGBA_AX-^ A2J]["S%F\MAD)0>+-JJZ**,O89
M+6"]:GZM"4L;:!UW5TSKJ(UDG];Q*"O1Q@$#(M4H(S1T+S05O&Q_UB7Y;#$!
MZO!SFET3=#<P1*J\V?D *PU19#9"\+'';>S<F'=MEB86L=68M>8!A W?I3-2
MOEI]MD-IHKD4\?(!UBN@+TC9OQN_.]/D+H:5T N2^[ WN:@10DBI]X+*^R@K
MBK<Y5<(X8S4N$62B3ESP6)=?S=#&$WMZK#.&HK0K4VG:$S!='!D>I/IU0X J
MLUJM7?LMF-5J:0$6JJH3YY$R/7*BA'M@P5H%GP87*1(LP$M!$7)5Z$6#DQS\
MKVWQC)'<9D86MJ1XM,..'A#FM$A?>/M:H^!(;"FS(,:O+O07;B%SC<0C!,@Y
M'.;L@S(@A7_U'VXW:=/M'W)L]A%SL9#>/%4N]L=!GU8HU.: Q1X[K.>KEV:X
MNJ7QRXJL17P#HGS-%R1:W8+40,.-&JS:G7D! -@[^9?' *_[$JO5+7&A<J2[
M$5HZPNB$"R Z2J?6.8DP4?2*QF_/<A=!8B$_%9NO2OYH0\>;&]>7&9>=@%WX
M%)/Z7RT,HY4(@RL3UE GPF.9^&!/@I G29BN^R)<K&Y'2IFI1V_IJUZB%2<_
MK58#1CZL %#1GY$_.PA,1IQ.YQ0,-?-\D^/'W"X6YDRE_Z(\3)C,D)0[WW[
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MQTR$5\=;4 H04POF99P)0?)@QO"5>LO3D?@I<'863MR8&Y55'K&Y$9*A\!P
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M2CI024HG7>9%%D\-^JO9>%(FDF^4YA;LP($GA] FI\G3*![A"?RVO-QV:A?
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MO?GE[-/)K^7E+]_COY82*Z@S8L&A$!<C[IGI#'[+SV-/T%$@%+D)T&WK-TM
M3>O&*GPW:LHCMXH:)J#J#=8GH()"R0KO^Z3R. 8!]H+T#J-*6HI3VD%4VX6A
MWU?I/';W]^^XO4IE:-AS)1AJ@6EF\/0*VG3!GX5>4A:;>8CM&S <G_3S;UD6
MP>HA/]H0UYT0ZTA&THCC]R&WBI@^;=&E^@)F<LI(<O5%#0G,25I*)L0@(_ ;
M,$ODV8'O1CCE/$OC(2B .'&<Z^#%R<$'4Z&W;;/UMH+-"4>Y]^%&NKDI=.2O
M62<CTKD H@,5J' ]D 4#FE5PT$ZE'(>W(_(X,&9HRI.U'8'0SJ%\F=H$T?:[
M&:GLVB$>6/DH*_'H0WB  ;,8'#>BN3CPYMDQW"_6&ILD#FYY;E(WC7S>;[&$
M3 D^-2_J:)M/O@YZ X[TK5=OMPVNA\A4ZU__UQ0L;:'%26^H \7Y!WG@^@Z?
M%6>;%]R"5+RW=D(?DR0<*D,CSSZXI\1J%2GR@L6*-3,X+Y\J,19='UP/BAHL
MJLE-22"G6C:N# ,OL_*^VOWYY:L@?#%^(0'TD+M>$2^PABE[<U?MI^!1^GKY
MG8=K/2P)*OAA[4 %KYY!!8_90%UUSR!IC!NK>L/5A[O9GT33H&J+'*.2>470
MQ"E,ZR#/$G7S935TACU&'CN+[,-H-%"Z;4EM>"Z:8CVI-GMU:0ZOR@.F_GP4
M_.7AYL9>S#;669BPW=XU/9?UK]/QI ZO$0-Y;#MAHLU-I/JUU.%^4T],]\&5
M]I_/2[X*NC*L%7,6%Z;^/ \C!:_PN;CMBA[LO*(U%49S_[8G8:DT_)Y_QL(8
MC(ZR_1ZG4B^V],,8YULOX/::%96*_HI,?.!U3Q0F'>S ?!XR[%<;(H0!@WOS
M=(P3NW^6O:\BF0B1TBK=&3I8/4I&PF=HQP^E;M=!^-]2'GM-&D:R)!64(&R"
MYC:\SUIG9<6%L/[G&*_BI1>T1G'W ^5#TW(O?,)M3IA&:  &0_@7+V^G(QC2
M&GKQ6YHWF_=* N_"A"G2=N@)&'Y.L^M$11?*,IT%?A\-BL4M?OJ6@< @J?K$
M10;K5NL,(F%PK;G#%O'ZCBC@4G)@;7L; VY4=>TTRK:T46.G;]$9R*5M_&3X
MZ=SWI/"J$SWW,W088,(7YTBCV_'-O;7!MWD!%Y@]&E3\;R70UH4SY!>S+9H5
M:=N]M>^\CN\I&)B+B%)=<&C-Z@\Q(^-&AH4>I]OQQR.3+.N91KJU^28%JSDQ
M*&*-(N\D/FG>^KT#&[V;G[WE0BKG]IJG(1B&$VY!.8*'40F6\S1W@BKP1DJ,
M"':'8VP&<F>#W!SV4^-)$IK0>%Q9O,T-VL9XIF/\C5&2)!><?"@J$>?(DZ8Y
M.$D/^[KM=EFJU=&3',M+@Y-/[)P,3%O0N$D_U\7,9H-2B"].**511]3ZJT5C
M%G9IVW]+ODM9'\VOX$NXOGL5-&V$4E "3$2QYH?@W2WOT90R*N:\F82S;#0*
M$H7D.4*9@#)#3#$W%BR:7)CT\[0R1+DN+,$-!25 VZ&7#J?C04ZWV9*R6LK8
MG9ATF7-)L:TY.)K*-'I?4'R4MNOAB38HKE%H6%LOU%!5>N.*_(&[[SRXEG#4
M4N@!5J[B9UF$2;B#,%+) 2)W1MH3ZQ! UOAJNGRH^$HA-*4.V-?09&GFK*;+
MZ8 DR;8>H4(XP#J1<];((9TR[HM/*0(77L9Y)& S 5\1J"HM,1F/%[+ XWB&
M6,X^- 4)U=3/VDO7;<1+JRX!S#+.F">]")82 5<&=*I=@YX5P=;QZ".DX$03
M!''J72@_7".%26%\K43F49@G,:<5C8#J[U0:4Z M-8EMDT?3W5+X!@VU$N/@
MJ.41%9_8$C42P&1&  ,]&U^UK=9;).,O7^N"FC4/P5J,I &Z-J9N(:[Q%T=8
M7;?5-7;G]+KRRJU2>%GS8$3$L"4:.L45G/>>8NJ2U9IHNK-+*O"[\[#9.L^5
M*%2J.>!!,J&.L:([HGN=S+=0&^ILO$:?W[@G;R?[9FF>A?_7K:^6?2< W ,'
M*IN!8WJ(1J+K/E6@"7.NJX1123?>7J]Y[JN'P:@%9IP-]("E8$E0Q(]K!XK8
M?09%/")%<Q\)1=K!N*<GE(1)9H9&*1)R0-G<]7H%,NB?H^YF-;XBU[>Y,52Y
MN'J*49D1%5..L7R+ ;N$*GRY5,V&*.:X**96+3OYL8OL2N649\,*V NN !M)
MCNVO:1X742SN%D:0C;T1<#^9,;MU6+?,U,98%)(9N&,GD&XF)NK&H5-S"QVC
M,_!---"EO!'K&*><=*1ON:-9>P&[2QBA4;1LO-\7&\-Q@MC2,#=2H1>/;S4C
M?FZO,Z#)E922!:$&D%J5L)<WS,#<!-=^F$T,UO0XOPC3^-^A5&,?&&BTAH&+
MH4L5K.@*B+1Q=B)>/ :$K[M#"&0$.)1)S#$WRQ(+#X@RI\\0G-MA3DC[*,9O
M(9_ZEB.IO(FHB">+9MOU$7/9Y+\-J3UI4D9="Y*;"Z&$2CL42]S69/LU0T([
M*1/'Z95S!U9NYTZ\ ,<L\P=F?)6TF(XUB:#<=WX,W[*(R WD5WU#O<_=&:54
M!I.3H[,D"Y@A=#IBU2$]R"7/PA,B"0HT4Z<)9:B&O'[LV'2T:^:M/F6HJ':J
M"-)P;+-?) 9LJ#(1>,?17$R=6')%-I8#$ &BZ!Y_PO#]3,A3WYO$'!3H%$FR
MN9GFE(D$RAQ9G36ZG[^ !=O(/(PKS'!\?N:Z*[;;9*Q]A4:@^-LP!CJ@^IN4
MH; >BC8X 1&-([T3]R]C!6+2XST-0G[,*[E 8?H98(=Y(;@.\QRSLI:"V?!1
MU\K8JQ6WN,,P'(%9L5QX?D/T['%R8N*50MI_F&KJ^$"[K- 5,!0E QUU(:0*
M1/.!"62[03R?#LG)L1 '1=R/6W@EEMP3I(;U_P.]T6WI!&$"?%2!$HONE)F8
M<75(@8$]&#/V)J=8BO<EWI=.^67][3FKU_#ZM16_Y4MO=VP@N@!E4]-15&/F
MOQ1!B2_#B'4A3;6$9VK#,8@G*85"GUYS)]0RKZ@^9>@:LL5-7/1[2VL0<CN=
MW/A'/2W=",XB> +7-S@R9Q0HJEO33MX$RA84GU68JRBH]9P'^G('9 XVMVXJ
MVAXE87$91#F1M'($D->-V2^T>>-8#+;LS!+M:A$IF(#;< HC/8HPUI+I8BK*
ML)2I#(,\ ]=/6DVC%%]?7[^(1@71N[P D\MP!!#_#14/X9FL(U8G\MGQM!R
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MOX4M5HJ++FTE!)P"^R,734:^-^_<#G?6)5\\+DH'$.V!EC8W;([C,+RF;78
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M,9=@%RNHK6EC42]BVYCCCOU0-U;BDLSZC9$T2K1C4<$=;/\$FH!^4N.!(0F
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MP3 ZI)6CQ.S,',E,P@MZ0K$_9_2A?K2W%5G@//5HVMI)_%-6S170BFPB8MR
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M!$-_[8:)5(X(\==S? _QF O'0F*B?%O4?NC&=J\L>&1L>9LDET4?,#;[/!-
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MTI/@XB]K]W;N9Z5(/8)<N8+^ZH#/4M?W!P_2##;+XX=/?GST\X/'Q[F!NGB
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M6;:3*V[@%8%@(<X02=$/W7Q(Q1M<[W@TH[X/AD<DD @NA-M+P%/T%^\B!N,
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M7"PQ(VY0^\#OI9O+?L)%/T1\4W<^U$#E4];215DO)L95PDTM.O,@V-L4#?U
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M*=E1;U&1+5KT;H4$13LLWW[B"%9-IK&8*=,:V35J'HFM 9&LK=MN8 PDDZ>
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M:AJ\G$:/YTCC,F<:8\1K,'(.$7Z4 $EU\(8Z!(-U\@T[)7=?;83_\[9!.K@
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MX!PV.L.KEUUQ29Y)5YV[ *XB8W99H+BR(F!+Z"PO6SCPA"UW60%FTD;*FG\
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M]2:&-O,DC*@[4FZ8N:"?M^=5X$073&K ^!5.KLC@ 0VWLV =,K:2KRV6Z/+
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M7A1UQSR[$N,O(<%<H20;)C+T:WHVIN<?WPO>""+% E&N]):%YCM* H0V08*
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MF)'^\> RTD_O,])WR3SM5:7K9.V.#V=+UO@0%NX9GA%Y9OE%QNP8,YZ6V6?
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M6@)Q[D:.PCS^ M$80V\:A^/P !M< Q;G/GBS(T_>B)L!?!,N>+J#@ 2>C_,
M+#MRMN!9X=]3>6BAT]>@;Z4-F(:!F%3!+'?:0ZROY-;'.DCWDZ9.,),R#HWS
MZT[FOO,J -\>L^A=K[3RNTSPH3O$>TVH_IW.-;?. 8PL/B]$_=@AF]/!,O!W
M0:9\*4[MH*U!$I4@Q4C&&DXU!E2;2.OW_V"0L]6; LUS-!U:H8L<57;30N>4
M+:'I&(&K4D_5DDE2]*>2]BW4'%IR^,HVV)T*1"1/% Y^# 5<)*"TJFAHV==P
MOCK[I_6:P4M8)W+&MRV'.$>WVT#7 5H1VTLUE+YZU00DWK[ $C,M2]\R&(P
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M!]E+!D/T+HHA'D0ZG!-GH1A>.WFL)G?.F&3M5O"M<L%4XFWY3TAUUODO\H/
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MIG\A'@S6BJ>34.%V67\&- 1+?^9#[<]L*/UY5.[Z-)Y/V4/S]>R>3C2.98E
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MX9Z,#X>O&L([DX7X\^C0OS\X5-KC>U3:G<FD)4KZSV^UI(_ISKZ^<"?OJZH
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MWB>N]VSZ0#%V!J4/HUE1-?CR\7*D+6$!//9)?/K"9A\(LV_*S>!*%\#+%<Y
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M-&B%B20Q;?#F0JN;ZMD8;GZO:;^^_S)T-!E2)'<G*X[%QP',_Y7=>;Z_*#M
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M;7[!#P%2Y0&A(H)'*OCV($4XL'^%H<XY-5]2%-*XHB$&G].,@YYL(<(XRS+
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M&Y)'@<GG#6G$6?*9L-7/+2?7)+K,"^*3$*])1:;]M:_S+7:8JVFM3L8=DL_
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M4ZZ%(S= Z@;3P/A#+_$R'Q-M(8<<34Y(H_PEG0MB 1XAV*_&#]O 5#Y[U$0
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M4T+2+C>A@(I<+EU77> TM'49VV<).!GEXQ9VCJQ72VO4QRZ.O@GU1L@R=E6
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ML:+Q,HT-%HHA46:N/N/81OPXN:/0WM(]2P)G02<E9N3=Y8!,M*:1B728&\L
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MH"5<O9\A6#^(^#*TGXVCHDBIBASC/1=YC5XI*4X&U 7K8Y:.2X$QD%RW7.#
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MR5W&]).RKFG*J-2$4QFXH5H#$J"6&"A/+H$4K'23=$3 $Z6_8OQMJA@H$N9
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MN(8O,0.B\EK,W0C/G#VO)%3W%?<H<V\P1)T[]ML"QZ1EV) 6?3 D'CWP5#G
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M./GH3K8P=(Z&RI3D&7.=\ M%P6AE +1 AS:_-K1;\J3'G,9/34DRO1F!3%G
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G-34Y,60Q7V5X.3DM,2YH=&U02P4&      8 !@"- 0  =<\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tm2525591d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="elut-20250908.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001708527</identifier>
        </entity>
        <period>
            <startDate>2025-09-08</startDate>
            <endDate>2025-09-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-08" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-08" id="Fact000004">0001708527</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-08" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-08" id="Fact000010">2025-09-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-08" id="Fact000011">ELUTIA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-08" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-08" id="Fact000013">001-39577</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-08" id="Fact000014">47-4790334</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-08" id="Fact000015">20 Firstfield Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-08" id="Fact000016">Gaithersburg</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-08" id="Fact000017">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-08" id="Fact000018">20878</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-08" id="Fact000019">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-08" id="Fact000020">247-1170</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-08" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-08" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-08" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-08" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-08" id="Fact000025">Class&#160;A     Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-08" id="Fact000026">ELUT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-08" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-08" id="Fact000028">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2025-09-08" id="Fact000029">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
